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Thesis abstract
Group B Streptococcus: molecular epidemiology, pathogenic profiling and
control strategies
Kate Hayes, B.Sc.
Group B Streptococcus (GBS) are frequent colonisers of the gastrointestinal tract of
healthy adults with worldwide rates of 18% colonisation; however, they are also
opportunistic pathogens capable of causing invasive disease, particularly in neonates
and adults with underlying conditions. Indeed, GBS is the leading cause of invasive
neonatal disease worldwide with a global incidence of 0.49 per 1000 live births and
GBS disease in adults is increasing globally, with estimated rates of 10.9 cases per
100,000 people. While GBS remain largely susceptible to penicillin, there have been
reports of reduced beta-lactam susceptibility in certain countries and resistance to
other antibiotic classes continues to rise. GBS strains are distinguished by their
serotype, defined by an expressed capsular polysaccharide, and vaccine efforts have
primarily focused on this capsule as a target; however, as of yet, there is no vaccine
licensed for use. The aims of this thesis were to identify the predominant serotypes
and antimicrobial resistance properties of circulating GBS isolates in Ireland, to
investigate pathogenic traits of these isolates and to examine novel therapeutic options
for GBS.
The molecular epidemiology of n = 253 clinical GBS strains was investigated by
determining the serotype and antimicrobial resistance traits in a collection of both
colonising (n = 202) and invasive (n = 51) isolates. High levels of erythromycin
(22.5%) and clindamycin (21.3%) resistance were observed and the emergence of the
unusual L phenotype was detected, which had not been previously reported in Ireland.
Resistance to both erythromycin and clindamycin was higher among colonising
isolates than colonising isolates (P < 0.05), with mean zones of X mm and X mm for
erythromycin and clindamycin respectively. The serotype distribution revealed that
overall serotypes Ia (28.1%), III (26.88%), II (13.44%), V (11.86%) and Ib (11.46%)
were the most common among GBS strains. Serotype distribution was differed among
invasive and colonising isolates, whereby serotype III (31.37%) predominated among
invasive isolates while serotypes Ia (29.7%) and III (25.745) were the most common
xi

in colonising strains. Serotype III predominated among resistant isolates (33.3%). To
examine novel antimicrobials for GBS, the bacteriocin nisin was explored, and some
level of susceptibility characterised by zones of inhibition was detected in 91% of
isolates. Investigation of the genetic basis for resistance to nisin in GBS revealed the
presence of a nisin resistance gene (nsr) in 98.4% of isolates, as well as the presence
of an ABC transporter, nsrFP, in 84.4% of isolates. A bioengineered derivative of
nisin, nisin PV, designed to resist cleavage by the nisin resistance protein (NSR),
displayed significantly enhanced activity against isolates (P < 0.05) compared to the
wild-type peptide, with an MIC50 of 20.1 µg/ml and 6.3 µg/ml for nisin A and nisin
PV respectively. Investigating the potential of novel alternative antimicrobial
strategies determined that erythromycin and nisin used in combination exerted a
synergistic effect in a proportion of isolates by time-kill curve assays. This
combination also reduced TNF-α production (P < 0.05) in U937 macrophages
challenged with GBS. The capacity of GBS to form biofilms and the underlying
genetic determinants associated with biofilm formation were investigated within the
collection. Reducing gastrointestinal colonisation could help limit GBS infections and
anti-biofilm agents are an interesting approach to help achieve this. Consuming food
products with antimicrobial activity could prevent biofilm formation and therefore the
potential for certain food products to inhibit and reduce GBS biofilms was assessed.
Biofilm formation was significantly inhibited and reduced by natural food products
garlic, honey, feta and goats cheese by the XTT assay for cell viability (P < 0.05). This
thesis provides a current assessment of the characteristics of clinical GBS strains
circulating in the South of Ireland and has highlighted novel antimicrobial strategies
for the control of GBS.
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1.1. Introduction
Group B Streptococcus (GBS; Streptococcus agalactiae) is a Gram positive bacterium
that frequently colonises the gastrointestinal and genitourinary tract of healthy adults
(Russell et al., 2017a). GBS is an opportunistic pathogen, meaning it can progress
from a colonisation state to causing invasive disease when the host immune response
is weakened. GBS contain an arsenal of virulence factors that can aid in this disease
progression. Maternal GBS colonisation (18% worldwide) is a major risk factor for
neonatal disease and vertical transmission from mother to neonate during labour is the
most frequent acquisition of GBS by the neonate (Russell et al., 2017b). GBS is the
leading cause of neonatal disease worldwide, with fatality rates of up to 20% (Edmond
et al., 2012; Lamagni et al., 2013). Moreover, invasive disease in non-pregnant adults
as a consequence of GBS infection is increasing globally (Lamagni et al., 2013).
Currently penicillin is the first choice antibiotic for preventing and treating GBS
infections however, reports of reduced susceptibility are emerging (Dahesh et al.,
2008; Kimura et al., 2008). Until recently, erythromycin and clindamycin were
considered as second line antibiotics in Ireland and resistance to these antibiotics has
continued to rise (Lamagni et al., 2013). Indeed, the UK guidelines which are adopted
by Irish hospitals no longer recommend clindamycin for use due to the high levels of
resistance reported and instead vancomycin is used as a second line of treatment
(Hughes et al., 2017). However, countries such as America still offer clindamycin as
therapy, once susceptibility has been confirmed. Moreover, the increased use of ‘last
resort’ antibiotics such as vancomycin is dangerous as it can promote the development
of resistant bacteria. Thus, there is a need for alternative treatments options for GBS
infections, in order to preserve the current effectiveness of penicillin as well as
preventing the spread of resistance to vancomycin.
This review provides an overview of GBS disease and epidemiology, as well as a
comprehensive analysis of the virulence mechanisms and antimicrobial resistance
determinants displayed by this pathogen. Furthermore, alternative antimicrobials are
discussed, focussing on exploring the potential of naturally occurring compounds as
antimicrobial agents against GBS.
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1.2. Classification
GBS express a sialylated capsular polysaccharide (CPS) as a defence mechanism for
evading the host immune response (Cieslewicz et al., 2005). This CPS is a
distinguishing characteristic of each of the 10 GBS serotypes (Ia, Ib, II-IX) that have
been identified to date. Each capsule type is made up of four monosaccharides
(glucose, galactose, N-acetylglucosamine and sialic acid) arranged in different repeat
patterns but always ending in sialic acid bound to galactose. This end-terminal sialic
acid is extremely important as its presence prevents complement from binding to the
surface of GBS (Marques et al., 1992). Non-typeable strains with no expressed capsule
can also occur due to various mutations (Rosini et al., 2015; Alhhazmi and Tyrrell,
2018).
The global incidence of serotype distribution across different populations is outlined
in Table 1.1. Serotype distribution varies worldwide but serotypes I-V are documented
as the most frequently found (Russell et al., 2017a). Differences are noted within
geographical areas, whereby regions in Asia and South East Asia have the
predominance of serotypes VI-IX (Russell et al., 2017a). Furthermore, certain
serotypes are associated with different disease states. Serotypes I-V are the most
common among colonising strains (Russell et al., 2017a), whereas serotype Ia is the
most common among maternal GBS disease (Hall et al., 2017). There is a strong
association between serotype and invasive infant disease (Baker and Barrett, 1974;
Tazi et al., 2010), with serotype III dominating followed by serotypes Ia, Ib, II and V
(Madrid et al., 2017). Serotypes Ia, Ib, II and V are the most common among nonpregnant adults with invasive disease (Martins et al., 2012; Camuset et al., 2015;
Francois Watkins et al., 2019). Variations noted between serotype associations with
different disease states can be attributed to different sources of infection, or indeed
due to strain variation whereby strains adapted for infection of particular hosts may
possess that enable them to progress to invasive disease. Moreover, maternal GBS
colonisation may include multiple serotypes while only certain serotypes progress to
cause invasive disease in neonates.
GBS can be further classified based on multi-locus sequence typing (MLST) (Jones et
al., 2003; Bisharat et al., 2004), and associations between MLST type and disease
have been identified. In particular, ST-17 is strongly associated with neonatal disease
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(Jones et al., 2003; Bisharat et al., 2004; Tazi et al., 2010) and serotype III ST-17
strains are referred to as the ‘hypervirulent’ clone (Tazi et al., 2010). Invasive disease
in non-pregnant adults has been associated with ST-1 (Flores et al., 2015).
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Table 1.1: Worldwide incidence of Group B Streptococcus maternal colonisation, invasive disease and serotype prevalence.
Country

GBS carriage
rate

Serotype prevalence

Algeria 2011-2012

NR

V (47.73%); II (25%); III (22.73%); Ia (4.55%).

(Bergal et al., 2015)

Argentina 2004-2010

9.38%

Ia (40%); III (21%); V (12%); II (10%); Ib (9%); IX (4%).

(Oviedo et al., 2013)

Australia 2005-2008

0.57/1000

(Ko et al., 2015)

Australia 2015-2017

24%

Belgium 2007

24%

EOD: Ia (30%); III (25%); V (20%); Ib (7%); II (7%); VI (7%); IV (3%); VII (2%).
LOD: III (65%); Ia (17%); V (13%); Ib (4%); II (2%).
Ia (27.9%); III (20.9%); II (16.3%); V (15.8%); Ib (8.4%); VI (5.1%); IV (2.8%); NT (1.9%); VIII
(0.5%); IX (0.5%).
III (20.8%); V (20.8%); IV (12.5%); Ia (10.4%); Ib (10.4%); II (10.4%).

Brazil 2008-2015

26.2%

Ia (37.3%); II (19.9%); NT (12.1%); Ib (11.1%); V (9.1%); III (6.8%); IV (3.5%).

(Botelho et al., 2018)

Canada 2009-2012

0.36/10,000

(Teatero et al., 2014)

Canada 2014

NR

EOD: III (44.1%); Ia (14.7%); IB (14.7%).
LOD: III (74.6%).
Adults: V (26%).
III (25%); Ia (23%); V (19%); II (13%); Ib (9%); IV (6%); VI (1%).

Central Africa 2008

19%

V (30.3%); III (27.5%); Ib (22.9%); Ia (6.4%); Ia (12.8%).

(Belard et al., 2015)

China 2008-2015

NR

III (45.6%); Ia (18.7%); Ib (15.5%); V (14%); II (2.6%); VI (1.6%); NT (2.07%).

(Lu et al., 2016)

China 2012-2015

6.5%

III (32.1%); Ia (17.9%); Ib (16.1%); V (14.3%); II (5.4%).

(Wang et al., 2015)

Denmark 2005-2011
England and Wales
1991-2010

2.3/100,000
Infant:
0.7/1,000
Adult:
2.99/100,000

III (34%); Ia (18%); V (15%); Ib (12%); NT (9%).
EOD: III (41%); Ia (26%); V (12%); II (9%); Ib (8%); IV (1%).
LOD: III (67%); Ia (18%); V (5%); Ib (4%); II (3%); IV (1%).
Adult: III (25%); Ia (25%); V (20%); II (14%); Ib (12%); IV (2%); VI (1%); VIII (1%), VII (<1%);
IX (<1%).

(Lambertsen et al., 2014)
(Lamagni et al., 2013)

France 2012-2015
France 2004-2007

17%
NR

III (26%); V (25.1%); Ia (19.7%); II (14.1%); IV (6.1%); Ib (5.2%).
Bone and joint infections: III (29%); V (25%); Ia (16%).

(Tazi et al., 2019)
(Kernéis et al., 2017)

Germany 2004

21.1%

III (28%); Ib (19%); Ia (16%); V (15%); II (12%); IV (6%); NT (4%).

(Kunze et al., 2011)

Ghana 2013

19.1%

Ia (28.1%); V (27.1%); III (21.9%); II (9.4%); Ib (8.3%).

(Vinnemeier et al., 2015)
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Reference

(Furfaro et al., 2019)
(El Aila et al., 2009)

(Teatero et al., 2017)

Iceland 1975-2014

2.17/100,000

Adults: Ia (23%); Ib, II, III and V (14-17%).

(Björnsdóttir et al., 2019)

Iceland 1976-2014

0.7/1000

Infants: III (48.98%); Ia (22.45%).

(Björnsdóttir et al., 2016)

India 2015-2016
Iran 2013-2014
Ireland 2010-2016

15%
15.4%
NR

(Chaudhary et al., 2017)
(Sadeh et al., 2016)
(Hayes et al., 2017)

Italy 2011

13.7%

III (22.2%); V (20%); II (20%); Ia (13.3%); VII (6.7%); Ib (4.4%); NT (13.3%).
III (50%); II (25%); Ia (12%); V (11%); Ib (2%).
Overall: Ia (28.1%); III (26.88%); II (13.4%); V (11.86%); IV (3.95%); VII (1.58%); VI (1.19%);
VIII (0.79%); IX (0.4%).
Invasive: III (31.37%); Ia (21.57%); Ib (17.65%); V (13.73%); II (5.88%).
Colonising: Ia (29.7%); III (25.74%); II (15.3%); V (11.39%); Ib (9.9%).
III (33.8%); V (24.15); II (13.8%).

Italy 2005-2008

NR

EOD: III (54%); Ia (16.2%); II/V (10.8%); Ib (5.4%); IV (2.7%).
LOD: III (89.5%); Ib (5.3%); Ia/II (2.63%).

(Imperi et al., 2011)

Japan 2010-2013

NR

(Morozumi et al., 2016)

Japan 2007-2008

NR

Japan 2004-2010

0.18/1000

Adults: Ib (39.5%); V (16%); III (13.8%); VI (9.5%); Ia (8.6%); II (7.4%); VIII (3.8%);
IV (0.9%); VII (0.2%).
V (15%); VI (13%); Ib (12%); II (11%); III (10%); VIII (9%); Ia (7%); VII (1%); NT: 22%
Note: decrease in serotypes VI and VIII compared to previous study.
EOD: III (42.1%); Ia (36.84%); Ib/V/VI/VIII (5.3%).
LOD: III (53.3%); Ia (28.8%); Ib (13.3%); IV/V (2.2%).

Kenya 2011-2013

11.7%

III (38.3%); Ia (21.2%); VI (175); Ib (12.5%); II (8.7%); IV (2%); VII (0.3%).

(Seale et al., 2016)

Korea 2006-2007

NR

(Seo et al., 2010)

Lithuania 2006-2007
Malaysia 2010-2011

15.3%
NR

V (29.9%); III (26.4%); Ia (17%).
VI and VIII noted as emerging serotypes within invasive isolates.
III (34.5%); Ia (29.7%); II (10.8%); IV (8.8%); V (7.4%); Ib (4.7%); VI (2%); NT (2%).
VI (22.3%); VII (21.4%); III (20.4%); Ia (17.5%); V (9.7%); II (7.7%); IV (1%).

Morocco 2013

24%

V (36%); II (25%); III (18%); Ia (9%); IV (7%); IX (5%).

(Moraleda et al., 2018)

Netherlands 1987-2011

0.32/1000

Neonates: III (60%); Ia (16%).

(Bekker et al., 2014)

Norway 2009-2011

26%

III (24.9%); V (16.9%); Ia (15.7%).

(Brigtsen et al., 2015)

Poland 2007-2009

30%

III (35%); Ia (20%); V (17%); II (15%); Ib (8%); IV (5%).

(Brzychczy-Wloch et al., 2012)

Poland 2006-2010

NR

Infants: III (50%); II (27%); V (14%); Ia (9%).

(Brzychczy-Wloch et al., 2014)

Portugal 2009-2015

NR

(Lopes et al., 2018)

Portugal 2002-2004
Portugal 2005-2012
Romania 2009

NR
NR
NR

Adults: Ia (30.5%); Ib (24%); V (18.4%); III (12.6%); II (6.7%); IV (1.6%); IX (1.4%);
VI (0.4%); VIII (0.4%); NT (4.1%).
Infants: III (40.6%); Ia (28.13%); II (12.5%); V (10.9%); Ib/IV (3%).
III (23%); Ia (21%); V (20%); II (14%); IV (9%); Ib (8%); NT (4%).
II (26%); III (26%); Ia (19%).
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(Rojo-Bezares et al., 2016)

(Kimura et al., 2013b)
(Matsubara et al., 2013)

(Barcaite et al., 2012)
(Eskandarian et al., 2015)

(Martins et al., 2007)
(Florindo et al., 2014)
(Usein et al., 2009)

Senegal 2008
Serbia 2009-2016

NR
15%

V (33.7%); Ia (22.7%); III (19.02%); II (17.8%); Ib (6.75%).
Overall: III (32.2%); Ia (13.7%); V (11.8%).
Invasive: III (58.8%); Ia (13.7%); V (11.8%).
Non-invasive: III (29%); V (27%).
V (66.67%); III (21.05%); Ia (1.75%); II (1.75%); IV (1.75%); IX (1.75%); NT (5.3%).
III (43.8%); V (20.3%); Ia (12.1%); Ib (9.5%).
Overall: III (33.9%); II (22.7%); Ia (14.9%); V (10.7%); IV (8.7%); Ib (8.3%); VII (0.8%).
Colonisers: II (31.6%); III (26.3%); Ia (17.9%).
Invasive: III (38.2%); II (22.1%); IV (13.2%).
Neonatal: III (39.2%); Ia (22.8%); II (12.7%).
Infant: III (48%); Ia (18%); V (16%); Ib (6%), II (6%); IV (2%); IX (2%); VIII (1%).
Adults: V (39%); III (20%); Ib (14%); Ia (11%); II (9%); IV (4%); IX (2%); VII (1%); VIII (1%).
III (29.4%); V (25.5%); Ia (19.2%).

(Brochet et al., 2009)
(Gajic et al., 2019)

South Africa
South Korea 2006-2008
Spain 2010-2016

16.6%
8%
NR

Sweden 2004-2009

NR

Switzerland 2009-2010

21%

Taiwan 2006-2015

0.34/1000

(Tsai et al., 2019)

0.94/1000

Overall: III (34.2%); VI (22.8%); Ia (12.6%); Ib (12.6%); V (12.6%).
Invasive neonatal: III (60.6%); Ia (17.3%)
Invasive adult: VI (32.6%); Ib (19.4%); V (19.4%).
Colonising: VI (35%), III (25%); V (16%); Ib (10%).
Neonates: III (60%); Ia (17%).

UK and Ireland
2014-2015
USA
2008-2016

10.9/100,000

Adults: Ia, Ib, II, III and V (86.4%).

(Francois Watkins et al., 2019)

USA 2006-2015

0.54/1000

Worldwide
2000-2017

18%

Worldwide
2000-2017

0.49/1000

Increase in serotype IV for these infections.
EOD: Ia (27.3%); III (27.3%); II (15.6%); V (14.2%); Ib (8.8%).
LOD: III (56.2%); Ia (20%); V (8.3%); IV (6.2%); Ib (6.1%).
Overall: Ia, Ib, II, III and V are the most common and account for 98% of serotypes globally.
Central America, South-east Asia, and Bangladesh had lower incidences of III than the global
estimate of 25%.
Greater prevalence of serotype V in Western Africa.
VI, VII, VIII and IX are more frequently reported in south, south-east and eastern Asia.
Infants: III (61.5%); Ia, Ib, II, III and V causing 97% of cases.

(Africa and Kaambo, 2018)
(Lee et al., 2010)
(López et al., 2018)

(Gudjónsdóttir et al., 2015)
(Fröhlicher et al., 2014)

(O’Sullivan et al., 2019)

(Nanduri et al., 2019)
(Russell et al., 2017a)

(Madrid et al., 2017)

Highest incidence in Africa (1.12/1000); lowest in Asia (0.30/1000).

Incidence of maternal colonisation, invasive GBS disease and serotype distribution of Group B Streptococcus worldwide. Studies of maternal colonisation rates
are highlighted in yellow; studies of invasive GBS strains are highlighted in orange and studies reporting on both colonising and invasive isolates are highlighted
in green. Maternal GBS carriage is reported as a percentage of the population tested, invasive infant GBS disease is reported as incidence per 1000 live births
and invasive adult disease is reported incidence per 100,000 people. NR indicates studies that did not report the incidence of GBS carriage or disease.;
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1.3. Group B Streptococcal disease
1.3.1. Neonatal disease
Invasive neonatal GBS disease is characterised as either early-onset (EOD) or lateonset (LOD) disease. EOD typically presents within the first week of life as
pneumonia or sepsis, while LOD can occur up to three months after birth and usually
presents as meningitis (Heath et al., 2004). EOD accounts for 60-70% of all invasive
GBS disease and is usually associated with serotypes Ia, II, III and V. Mortality rates
for EOD range from 3-20% with a mean case fatality rate of 9.6% (Heath et al., 2004;
Edmond et al., 2012). LOD is mostly associated with serotype III and results in
meningitis in 50% of cases, with significant mortality and morbidity associated with
LOD (Libster et al., 2012). The most recent HPSC Irish study identified that serotype
III was the most common serotype detected amongst all invasive GBS disease (HPSC,
2018).
The transmission of GBS from mother to infant is summarised in Figure 1.1. Maternal
rectovaginal colonisation with GBS is the most frequent pathway for neonatal
colonisation and a significant risk factor for EOD, where GBS is acquired vertically
by the neonate during delivery (Russell et al., 2017b). In the event of maternal
colonisation, 50% of babies born will become colonised themselves and
approximately 1% will go on to suffer invasive disease (Heath et al., 2009; Russell et
al., 2017b). Maternal colonisation with GBS is also associated with pre-term births
(Bianchi-Jassir et al., 2017). The route of transmission for LOD remains less clear,
although is associated with nosocomial, community or maternally acquired infections
(Morinis et al., 2011; Le Doare et al., 2016; Tazi et al., 2019).
The first global study of the burden of invasive GBS disease was carried out in 2015,
with worldwide estimates of 205, 000 infants presented with EOD and 114, 000 with
LOD (Seale et al., 2017). The study reported 90, 000 GBS-related infant deaths and
10, 000 cases of children with disabilities were reported. Furthermore, 57, 000
stillbirths and up to 3.5 million preterm births were considered to be attributable to
GBS. Moreover, GBS associated stillbirths account for 1% of worldwide stillbirths
and 4% of stillbirths in Africa (Seale et al., 2017). Infants with invasive GBS disease
may develop neurological complications (Tann et al., 2017), with 32% of children
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diagnosed with GBS-associated meningitis having lasting neurodevelopmental
impairment (Kohli-Lynch et al., 2017).

Figure 1.1: Transmission of Group B Streptococcus from mother to neonate.
Maternal colonisation occurs in approximately 18% of all pregnant women worldwide and
half of their neonates become colonised with GBS. Invasive GBS disease in infants manifests
itself as either early onset (EOD) or late onset (LOD) disease, both presenting with different
clinical symptoms.
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1.3.2. Maternal disease (also referred to as pregnancy-related disease)
GBS colonisation during pregnancy is transient and can potentially develop into
invasive disease. The exact route of transmission of GBS infections in maternal
patients is largely unknown; however, GBS colonisation in the gastrointestinal tract
has been recognised as a risk factor for vaginal colonisation (Meyn et al., 2009).
Maternal disease may occur during pregnancy as a result of GBS infection and is a
major risk factor for transmission to the neonate. Maternal GBS disease is associated
with sepsis, intra-amniotic infection, bacteraemia and early post-partum endometritis
(Phares et al., 2008; Hall et al., 2017). A recent meta-analysis review also implicated
GBS in a substantial number of surgical-site infections post caesarean section (Collin
et al., 2019). However, large scale studies monitoring the prevalence of invasive
maternal disease due to GBS infections are somewhat lacking and deserve further
investigation.
1.3.3. Disease in non-pregnant adults
GBS can also cause invasive disease in non-pregnant adults. The acquisition of
invasive GBS disease in adults is currently unknown and data are lacking regarding
information pertaining to the source, pathway and incidence of infection. While the
direct route of acquisition for GBS in adults is largely unknown, gastrointestinal
colonisation likely contributes to many of the infections as a crucial first step. GBS
frequently colonise the gastrointestinal tract of healthy adults (Manning et al., 2004;
Meyn et al., 2009). Of interest, the frequency of adult invasive disease has tripled in
the US since 1990 and now stands at 10.9 per 100, 000 people and remains highest in
males >80 years old (Francois Watkins et al., 2019). Moreover, invasive GBS disease
in adults currently causes 60% more infections than Group A Streptococcus and 20%
more infections than Streptococcus pneumoniae (Francois Watkins et al., 2019).
Currently, there are no studies reporting on the incidence of invasive disease in nonpregnant adults in Ireland.
Invasive GBS disease in adults usually manifests itself as pneumonia, osteomyelitis
and skin and/or soft tissue infections (Farley and Strasbaugh, 2001; Camuset et al.,
2015), as well as bone and joint infections (Smith et al., 2015; Kernéis et al., 2017).
Invasive GBS disease in non-pregnant adults is primarily associated with underlying
conditions, diabetes and obesity (Sendi et al., 2008; Pitts et al., 2018; Francois
Watkins et al., 2019).
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Furthermore, urinary tract infections (UTIs) are becoming more prevalent among
adults as a consequence of GBS colonisation and infection. UTIs caused by GBS
include an initial binding to bladder cells with progression to cytotoxicity to urothelial
cells and the eventual production of an inflammatory response that facilitates disease
progression (Tan et al., 2012; Ulet et al., 2010; Kline et al., 2011; Leclercq et al.,
2016).
Infective endocarditis (IE) has also been reported in GBS disease, and while ultimately
rare, it is life threatening. Indeed, IE as a consequence of GBS is often linked to other
debilitating diseases such as cirrhosis, diabetes or meningitis (van Kassel et al., 2019).
A study reported that 16% of all IE cases were associated with GBS (Kim et al., 2018)
and GBS related IE is more serious than other Streptococcal IE owing to the increase
in mortality observed (Ivánova-Georgiva et al., 2010; 2018).

1.4. Epidemiology
Recently, a collaborative initiative was tasked with estimating the global burden of
GBS disease through extensive reviews and meta-analyses (Lawn et al., 2017). The
outcomes of these analyses are published in 11 different reports, each targeting
different aspects of GBS related disease. Maternal colonisation was estimated
worldwide at 18%, with the lowest incidence observed in Asia and the highest
observed in the Caribbean (Russell et al., 2017a). Data for maternal disease studies
are limited, particularly in developing countries, but was estimated at 0.38 per 1000
pregnancies (Hall et al., 2017).
The incidence of invasive GBS disease in infants (including neonates) is estimated at
0.49 per 1000 live births, with the highest rates observed in Africa and the lowest rates
observed in Asia. The incidence of EOD was reported as 0.41 per 1000 live births
while the incidence of LOD was 0.26 per 1000 live births (Madrid et al., 2017). Of
note, a separate study limited to the UK and Ireland in 2014-2015 identified a higher
incidence of invasive GBS infant disease of 0.94 per 1000 births (0.57 and 0.37 per
1000 births for EOD and LOD respectively) and a case fatality rate of 6.2%
(O’Sullivan et al., 2019). They also noted an overall increase from their previous study
in 2000-2001 despite the implementation of guidelines for the prevention of EOD.
Furthermore, the most recent HPSC study identified the incidence of EOD in Ireland
as 0.61 per 1000 births and the incidence of LOD as 0.21 per 1000 births (HPSC,
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2018). The incidence of maternal colonisation and invasive GBS disease reported
worldwide are detailed in Table 1.1.
Studies investigating the global prevalence of invasive disease among non-pregnant
adults are lacking; however, the most recent US study reports an incidence of 10.9
cases per 100, 000 people (Francois-Watkins et al., 2019). Studies reporting the rates
of invasive GBS disease in adults are also included in Table 1.1.

1.5. Virulence
For EOD and LOD, certain risk factors are associated with invasive disease. For EOD,
maternal colonisation, prematurity, bacteriuria are all associated with an increased risk
of disease (Russell et al., 2017a). The risk factors for LOD are less clear but are
associated with prematurity and gut colonisation and acquisition is either through
vertical, nosocomial or environmental transmission (Pintye et al.,., 2016). In healthy
hosts, GBS can progress from an innocuous coloniser to a dangerous pathogen that
causes invasive infections. This progression involves a number of stages, including
the initial colonisation and adherence to host cells, followed by translocation across
cell membranes and invasion of the host, and finally, evasion of the host immune
response. Throughout each of these stages, GBS employ a number of virulence factors
that facilitate disease progression. Several GBS virulence factors have been identified
and their role in disease progression has been extensively elucidated (Rajagopal, 2009;
Armistead et al., 2019). Table 1.2 and Figure 1.2 summarise the major virulence
factors that have been identified to date.
1.5.1. Adherence to host cells
The first step in GBS pathogenesis is colonisation of the host, in particular the vaginal
or genitourinary tract. Despite the low pH of the vaginal environment, GBS can still
bind to the epithelium in this environment. This occurs via interactions with
lipoteichoic acid (LTA) and GBS surface proteins through binding to extracellular
matrix (ECM) proteins such as fibronectin (Fn) and fibrinogen (Fng). GBS can also
adhere to other cell types including lung epithelial and endothelial cells,
gastrointestinal epithelial cells and the blood-brain barrier (BBB) microvascular
endothelial cells (Maisey et al., 2007). Surface anchored proteins involved in GBS
adherence include FbsA, Srr1, Pili and ScpB (Beckmann et al., 2002; Dramsi et al.,
2006; Schubert et al., 2004; Sheen et al., 2011).
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1.5.2. Invasion of host cells
Following adhesion, GBS can invade and persist within the host environment. GBS
have the potential to penetrate epithelial, endothelial and mucosal barriers using a
number of mechanisms including transcytosis, cell injury and inflammatory
mechanisms (Gibson et al., 1993; Nizet et al., 1996; Doran et al., 2003). To achieve
this, GBS employ secreted invasins or toxins, including fibrinogen binding proteins,
(FbsB) and beta-haemolysin cytolysin (β-h/c) (Table 1.2; Figure 1.2). A distinct
feature of GBS is the ability to cross the blood brain barrier (BBB). The BBB is a layer
of capillary endothelial cells, connected by tight junctions that separate the brain and
the central nervous system from the rest of the body’s bloodstream (Hawkins et al.,
2006). Penetration of the BBB leads to progression of invasive GBS infection and
ultimately meningitis (Doran et al., 2003). This occurs via attachment and invasion of
human brain microvascular endothelial cells (hBMECs), direct cell injury with
cytotoxins, and most importantly, the activation of inflammatory pathways which
compromise the integrity of the BBB (Nizet et al., 1996; Doran et al., 2003).
1.5.3. Evasion of the host immune response
Subsequent to successful invasion by GBS, the host immune response is activated in
an attempt to clear the pathogen. Effective removal of GBS involves the recruitment
of phagocytic cells, such as neutrophils and macrophages, as well as the opsonisation
of GBS by antibodies in the presence of complement. GBS evades the host immune
response by disguising itself to prevent recognition by the host or by producing
enzymes or proteins to resist defence mechanisms used by the host. For instance, the
capsule expressed by GBS contains an outer sialic acid that shares high similarity to
host moieties and therefore GBS avoids recognition by the host via molecular mimicry
and thus limits complement deposition (Marques et al., 1992; Carlin et al., 2009). GBS
further protect themselves by binding factor H, a regulator of host complement, to
protect themselves from opsonisation (Maruvada et al., 2009). GBS can also evade
the rapid release of toxic reactive oxygen species (ROS). Although they don’t produce
catalase, they still resist ROS through the use of glutathione (Wilson and Weaver,
1985; Cornacchione et al., 1998), SodA (Poyart et al., 2001a) and orange carotenoid
pigment (Spellerberg et al., 2000). SodA is a superoxide dismutase that converts
singlet oxygen or superoxide oxygen to molecular O2 and H202 which are then
metabolized, thus preventing oxidative stress during infection (Poyart et al., 2001a).
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GBS can also evade host antimicrobial peptides by incorporating D-alanine into their
cell wall teichoic acids, which increases the positive charge on their surface, thereby
reducing the affinity for cationic peptides (Poyart et al., 2001b).
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Table 1.2: The major virulence factors associated with the pathogenesis of Group B Streptococcus.
Virulence Factor

Pathogenesis process
Adherence

Betahemolysin/cytolysin
(β-H/C)
C5a peptidase
(ScpB)

Binds fibronectin.

Invasion

Evasion

Direct injury to cells via
pore-formation.
Triggers host cell lysis.

Resists reactive oxygen species
(ROS).

(Nizet et al., 1996; Doran et al., 2002; Liu et al., 2004;
Whidbey et al., 2013)

Binds fibronectin.

Serine protease – cleaves C5a
preventing neutrophil recruitment.

(Bohnsack et al., 1991; Beckmann et al., 2002; Cheng et al.,
2002; Tamura et al., 2006)

Interferes with complement to
prevent phagocytosis.
Mimics host moieties to prevent
recognition by the host.
Increases positive charge of
membrane to repel antimicrobial
peptides.

( Marques et al., 1992; Cieslewicz et al., 2005; Xia et al.,
2015)

Capsular polysaccharide
(Cps)

D-alanylation of LTA

Fibrinogen binding
protein A
(FbsA)

Binds fibrinogen.

Fibrinogen binding
protein B
(FbsB)
Fibrinogen binding
protein C
(FbsC)

Binds fibrinogen.
Biofilm formation.

Binds fibrinogen and
promotes entry into host
cells.

(Gutekunst et al., 2004; Al Safadi et al., 2011)

Binds fibrinogen.
Facilitates crossing the
blood-brain barrier.

(Buscetta et al., 2014; Jiang and Wessels, 2014)

Secreted protease that degrades
host hyaluronic acid and interferes
with host immune response.
Adherence to cells of
BBB.

(Poyart et al., 2001b; Poyart et al., 2003; Saar-Dover et al.,
2012)
(Schubert et al., 2004; Al Safadi et al., 2011)

Hyaluronate Lyase
(HylB)
Hyper-virulent GBS
adhesin
(HvgA)

Reference (s)

Particular role in
crossing the BBB.

(Baker and Pritchard, 2000; Kolar et al., 2015; Vornhagen et
al., 2016)
(Tazi et al., 2010, 2012)
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Invasion-associated
gene A
(iagA)

Anchors LTA to
bacterial cell membrane.
Plays a role in BBB
barrier.
Binds laminin.

Laminin-binding protein
(Lmb)

Binds laminin.

Pilus islands
(PI-1; PI-2a and PI-2b)

PI-1a – attachment
and biofilm
development.
PI-2b – adherence.
PI-2a – adherence
and biofilm
formation.

PI-2b – facilitates
crossing the BBB.
Invasion of lung cells
and BBB.

Plasminogen binding
protein
(PbsP)

Binds plasminogen.

Facilitates crossing the
BBB.

Serine-rich
repeat protein 1
(Srr-1)

Binds fibrinogen and
human keratin 4.
Biofilm formation.

Serine-rich
repeat protein 2
(Srr-2)

Binds fibrinogen,
plasmin and
plasminogen
Biofilm formation.

Streptococcal
fibronectin-binding
protein A
(SfbA)
Superoxide dismutase
(SodA)

(Doran et al., 2005)

(Spellerberg et al., 1999; Moulin et al., 2016)
Resistance to antimicrobial
peptides and macrophages.

( Dramsi et al., 2006; Maisey et al., 2007, 2008; Pezzicoli et
al., 2008; Konto-Ghiorghi et al., 2009; Rinaudo et al., 2010;
Sheen et al., 2011; Sharma et al., 2013; Lazzarin et al., 2017;
Périchon et al., 2018)

(Buscetta et al., 2016; Lentini et al., 2018)

( Sheen et al., 2011; Seo et al., 2012, 2013; Wang et al., 2014)

Enhances invasion and
virulence.

(Seifert et al., 2006; Seo et al., 2013; Six et al., 2015)

Binds fibronectin.
Facilitates BBB crossing.

( Stoner et al., 2015; Mu et al., 2016)

Resists ROS.
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(Poyart et al., 2001a)

Figure 1.2: Major virulence factors involved in Group B Streptococcus virulence.
GBS virulence factors facilitate in the pathogenesis of GBS through adherence, invasion and
evasion of the immune response. Adherence and invasion occur via interactions with the host
extracellular matrix (ECM). Surface proteins (highlighted in purple) such as fibrinogenbinding proteins (FbsA and C) and serine rich repeat proteins (Srr1 and 2) bind to fibrinogen,
the serine protease ScpB and SfbA binds to fibronectin as well as cleaving the chemoattractant
C5a, the plasminogen-binding protein PbsP and FbsC both bind plasminogen, while the
laminin binding protein (Lmb) interacts with laminin. The surface protein HvgA is associated
with hypervirulence and promotes adherence, invasion and crossing the blood-brain barrier.
Lipoteichoic acid (LTA) is anchored to the bacterial membrane by the glycosyltransferase
encoded by the iagA gene facilitating invasion, while the secreted toxin β-h/c (blue) promotes
invasion by forming pores in the host cell membrane. Evasion of the host immune response
occurs through a number of mechanisms, including host mimicry by the CPS (yellow),
cleavage of C5a chemoattractant by ScpB and degradation of hyaluronic acid by HylB (blue).
Furthermore, some expressed proteins are involved in biofilm formation including pili (green),
Srr1, Srr2 (purple) and FbsC (purple).
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1.5.4. Biofilm formation
Attachment and adherence to the host is one of the most critical steps in infection, and
persistent colonisation by bacteria usually involves biofilm formation (Ward et al.,
1992). Many bacteria commonly form biofilms, conferring phenotypes that are
different from the planktonic state cells (Costerton, 1999). Biofilms are microbial
communities where bacteria are enclosed in a self-produced extracellular polymer
substance matrix (EPS), a complex mix of proteins, polysaccharides, nucleic acids and
lipids (Donlan, 2002). Biofilm formation involves many stages, including the initial
loose attachment of the bacterial cells to the host, followed by stronger adhesion
through recruitment of additional cells and production of an EPS. The biofilm
continues to mature and develop before finally dispersing and facilitating the spread
of planktonic bacteria (Costerton, 1999; Hall-Stoodley and Stoodley, 2009). Biofilms
are also associated with increased antimicrobial resistance and survival during
stressful conditions, such as nutrient deprivation, production of oxygen radicals and
extreme pH, as well as being associated with persistent colonisation and infection
(Donlan and Costerton, 2002).
Biofilm formation by GBS has been observed in many studies (Kaur et al., 2009;
Konto-Ghiorghi et al., 2009; Rinaudo et al., 2010; Borges et al., 2012; D’Urzo et al.,
2014) and promotes colonisation as it enables the bacteria to withstand harsh
environments and host defence systems (D'Urzo et al., 2014; Rosini and Margarit,
2015). Studies have examined the enhanced adherence of GBS to vaginal epithelium
at acidic pH (Tamura et al., 1994) and subsequent studies highlighted the role of an
acidic pH in biofilm production (D’Urzo et al., 2014). Despite this, extensive studies
examining the role of biofilm production in vaginal colonisation and persistent
infection are still needed.
GBS express several surface proteins that are involved in biofilm formation, the most
significant being the surface appendages pili, particularly the pilus protein 2a, PI-2a
(Rinaudo et al., 2010). Other factors associated with biofilm formation include
fibrinogen-binding proteins (FbsC) and serine-rich repeat proteins (Srr1and 2).
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1.6. Prevention of GBS disease
Some countries have established guidelines whereby as a preventative measure against
EOD, intrapartum antibiotic prophylaxis (IAP) is given to mothers during labour. In
such countries, IAP is administered in conjunction with a microbiological screening
process or based on risk factors for GBS (Verani et al., 2010; ACOG, 2019).
According to the screening approach recommended by the CDC and ACOG,
rectovaginal swabs are taken at 36-37 weeks gestation as well as from women at risk
of pre-term delivery and in the case of positive GBS colonisation, a high dose of
penicillin is administered (Verani et al., 2010; ACOG, 2019). According to these
guidelines, if a patient presents with severe penicillin allergies, clindamycin is
administered but only if the GBS isolate is confirmed to be susceptible to clindamycin.
In the case of non-susceptibility to clindamycin, vancomycin is administered (ACOG,
2019).
Currently, Ireland does not have any established guidelines regarding preventative
and/or screening measures for GBS infections; instead, guidelines for the UK
published by the Royal College of Obstetricians and Gynaecologists (RCOG) are
adhered to. Universal microbiological screening is not currently recommended by the
RCOG. Instead, a risk factor approach is advised. Risk factors include preterm labour
(<37 weeks), premature rupture of the membranes, GBS bacteriuria, having a previous
baby with GBS disease, intrapartum fever of >380C and if GBS disease is detected at
the onset of labour (Hughes et al., 2017). For IAP, a high dose of benzyl-penicillin is
given and in the cases of severe allergies, vancomycin is administered. Clindamycin
is no longer recommended due to the high resistance rates (Hughes et al., 2017). If a
baby is suspected of having EOD, penicillin and gentamicin are administered as soon
as possible.
Currently, there is no international consensus on which IAP strategy is better (Le
Doare et al., 2017). A recent study suggested that the accuracy in predicting GBS
positivity based on risk factors is low and can result in unnecessary administration of
IAP in some cases, as well as a lack of IAP in other cases. The authors recommended
intrapartum testing in conjunction with a point-of-care assay such as PCR
identification of GBS at the onset of labour for optimal IAP (Johansen et al., 2019).
Arguments favouring a risk-based approach rather than routine screening include it
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being a more cost-effective strategy, with potentially less women being exposed to
unnecessary IAP. There are also issues associated with IAP such as a lack of
compliance due to lack of resources. Furthermore, while the introduction of IAP has
seen the incidence of EOD fall, it has had no effect on the incidence of LOD, stillbirth
or premature delivery associated with GBS. In fact, in some cases the incidence of
LOD has increased (Madrid et al., 2017; Romain et al., 2018). Moreover, studies
suggest that the unnecessary use of IAP can affect the neonatal gut microbiome and
potentially encourage the development of antibiotic resistant strains (Mazzola et al.,
2016; Zimmermann and Curtis, 2019).
The World Health Organisation (WHO) recommends that IAP programs should be
implemented according to local policies and guidelines (WHO, 2015). In the first
extensive review of global IAP regimens, the authors concluded that there were
variable policies, reporting and implementation of IAP guidelines and concluded that
a vaccine would be more beneficial (Le Doare et al., 2017).

1.7. GBS vaccine efforts
The development of a GBS vaccine for immunization of pregnant women has been
identified as a priority by the WHO (Kobayashi et al., 2016). The GBS serotypes Ia,
Ib, II, III and V comprise up to 97% of invasive infections worldwide (Madrid et al.,
2017), and thus vaccine efforts have focused on CPS conjugate vaccines. The first in
vivo trial was conducted in pregnant women and involved a monovalent vaccine, the
III-tetanus toxoid conjugate vaccine, which was well tolerated (Baker et al., 2003).
Novartis has since developed a trivalent (Ia, Ib, III) CRM197 vaccine and have
conducted a phase Ib/2 clinical trial with infants born to vaccinated women (LerouxRoels et al., 2016; Madhi et al., 2017). In 2017, Pfizer began development of a
pentavalent (Ia, Ib, II, III and V) vaccine which is in phase I of clinical trials. However,
issues with the efficiency of CPS-based vaccines have been highlighted, due to the
emergence of other dominant serotypes, capsular switching of virulent strains and
indeed the role of non-capsulated GBS strains.
Other potential promising vaccine strategies are based on structurally conserved
protein antigens. MinervaX Inc. have developed a protein-only vaccine, based on the
fusion of N-terminal regions of the alpha C and rib proteins, which is in phase I trials.
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MinervaX have completed a phase 1 trial in non-pregnant women, 18-40 years of age
with the use of one fusion proteins (clinical trial reference: NCT02459262), and
another phase trial 1 is ongoing with the inclusion of two fusion proteins
(NCT03807245). Glaxo Smith-Kline have also focused efforts on conserved
sequences encoding pili proteins (Nuccitelli et al., 2011, 2015). Moreover, there are
many GBS surface proteins being investigated at the pre-clinical stage as potential
vaccine candidates (Lin et al., 2018a). Vaccines using serine-repeat rich proteins and
ScpB are also being investigated, as they are conserved among GSB strains and
immunogenic (Santillan et al., 2011; Lin et al., 2018b).

1.8. Antibiotic resistance and Group B Streptococcus
Antibiotics are the underscore of modern medicine and their use has had a significant
impact on human health, aiding in reduced childhood mortality, increasing life
expectancy and providing a vital resource for invasive surgery and treatments of
bacterial infections. However, the incidence of antibiotic resistance continues to rise
and is a significant public health concern (O’ Neill, 2014). The development of
antibiotic resistance has been exacerbated by the over-prescription of antibiotics
(particularly for non-bacterial infections) and the unregulated usage of antibiotics
(Ventola, 2015; Van Boeckel et al., 2014). It is well documented that this increased
use of antibiotics has led to the emergence of isolates where first and second line
treatments are ineffective, and therefore third-line antibiotics are necessary (World
Health Organization, 2014). The increased use of third-line antibiotics is particularly
worrying and has resulted in the emergence of multi-drug resistant bacteria that are
resistant to these last-resort antibiotics, such as vancomycin-resistant Enterococci
(VRE) and carbapenem-resistant Enterobacterales (CRE) (Willems et al., 2005;
Nordmann and Poirel, 2014; Gutiérrez-Gutiérrez et al., 2017). The consequence is that
previously treatable diseases are now serious concerns due to the lack of effective
antibiotics. In 2013, the CDC stated that antibiotic resistance has contributed to at least
2 million illnesses and 23, 000 deaths in the US alone (CDC, 2013). A more recent
study conducted in Europe determined that approximately 33, 000 deaths have
occurred as a result of antimicrobial resistance (Cassini et al., 2019).
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Antibiotic resistance in GBS is of concern owing to the pathogen’s role as a leading
cause of neonatal disease worldwide, as well as an emergent pathogen in non-pregnant
adults (Lamagni et al., 2013). GBS is frequently found in the genito-urinary and
gastrointestinal tracts of healthy pregnant women, with worldwide estimates of 18%
carriage (Russell et al., 2017a). Depending on the established guidelines, mothers are
administered IAP based on risk factors or screening protocols and thus, antibiotic
resistance rates are important to monitor. Penicillin is the first choice of antibiotic for
IAP (Verani et al., 2010; Hughes et al., 2017; ACOG 2019) and in the cases of severe
penicillin allergies, macrolides such as erythromycin, and lincosamides such as
clindamycin were previously considered as second-lines antibiotics. However, the
increase in resistance to both of these antibiotics has limited their use, with the RCOG
now no longer recommending the use of clindamycin as recently as 2017 (Hughes et
al., 2017). Irish studies reporting on the rate of antibiotic resistance in GBS in recent
years have shown that penicillin remains effective for Irish GBS populations (Kiely et
al., 2010; Meehan et al., 2014; Hayes et al., 2017). However, resistance to
erythromycin and clindamycin has remained high, with the most current study
reporting rates of 22.5% for erythromycin and 21.3% for clindamycin (Hayes et al.,
2017). This review aims to summarise the epidemiology and mechanisms of resistance
to antibiotics implicated in GBS infections.
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Figure 1.3: Schematic representation of the antimicrobial resistance mechanisms commonly found in Group B Streptococcus.
Resistance mechanisms to commonly used antibiotics observed in GBS and the genes associated with them.
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Figure 1.4: Antimicrobial resistance mechanisms observed in Group B Streptococcus
strains.
(A) Antibiotic efflux. Macrolides and tetracyclines are exported out of the cell by efflux pumps
encoded by the mefA/E, tetK and tetL genes respectively. (B) Target modification. The
ribosomal target of macrolides is modified through methylation mediated by erm methylases.
(C) Target mutation. Mutations within the gyrA and gyrC and/or parC and parE genes inhibit
fluoroquinolone antibiotics. (D) Drug inactivation. Lincosamides are inactivated by
nucleotidyltransferases encoded by lnu genes. (E) Ribosomal protection proteins. Proteins
encoded by the lsa genes and the tetM and tetO genes encode proteins that cause the
dissociation of lincosamides and tetracyclines from the ribosome, respectively. (F) Drug
modification. Gentamicin resistance in GBS may occur through the production of a
bifunctional enzyme with both acetyltransferase and phosphotransferase abilities. (G)
Mutations of penicillin-binding proteins (PBPs). Mutations within PBPs have been
documented in GBS and the most important of these are mutations within the PBP2x proteins,
V405A and Q557E. (H) Cell wall modifications. Resistance to vancomycin may occur
through modifications in peptidoglycan synthesis, preventing recognition by vancomycin.
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1.8.1. Penicillin
Penicillins are natural or synthetic antibacterial agents derived from fungi (Fleming,
1929; Sheehan and Henery-Logan, 1959). Penicillin was first isolated from
Penicillium in 1928, clinical testing began in the 1940s and it was introduced to the
market in 1946 (Henderson, 1997). All penicillin antibiotics share three structural
elements, a thiazolidine ring attached to a beta-lactam ring and a side chain (Miller,
2002). There are five classes of penicillin antibiotics: natural penicillin (penicillin G
and V), penicillinase-resistant penicillins (methicillin), aminopenicillins (ampicillin),
extended-spectrum penicillins (carbenicillin) and aminopenicillin/beta-lactamase
inhibitor combinations (Amoxicillin/clavulanic acid) (Miller, 2002). Other antibiotics
share the characteristic beta-lactam ring element including cephalosporins,
carbapenems and monobactams and, together with penicillins, are known as betalactam antibiotics. GBS are generally regarded to be susceptible to beta-lactam
antibiotics including penicillin, which remains the first line of treatment for GBS
infections, as well as being used in IAP (Verani et al., 2010; Hughes et al., 2017;
ACOG 2019).
1.8.1.1. Mechanism of action
Beta-lactams are the largest family of antibiotics. They exert their antibacterial effect
by blocking penicillin-binding-proteins (PBPs) and preventing cell wall synthesis.
Penicillin antibiotics inhibit bacterial peptidoglycan synthesis through binding of the
beta-lactam ring to enzymes involved in cell wall synthesis, known as penicillinbinding proteins (PBPs), at the DD-transpeptidase (Gordon et al., 2000). As a result,
peptidoglycan cross-links cannot form, causing an imbalance in cell wall maintenance
and resulting in rapid cell death. Peptidoglycan precursors are still synthesised, and
the resultant build-up of these molecules triggers the activation of hydrolases and
autolysins causing further bacterial cell lysis (Ghuysen, 1991).
1.8.1.2. Mechanism of resistance and reduced penicillin susceptibility
There are three main mechanisms of resistance to beta-lactam antibiotics; reduced
access to PBPs, reduced PBP binding affinity or destruction of the antibiotic through
beta-lactamases (Ambler, 1980). Resistance to beta-lactam antibiotics in Gram
positive organisms is mainly due to target modification, where structural changes
occur in the PBPs (Figure 1.4G) (Fisher and Mobashery, 2016). This mechanism of
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beta-lactam resistance in Gram positive bacteria is owing to the lack of an outer
membrane, making the peptidoglycan cell wall the target for penicillin antibiotics.
Conversely, the production of beta-lactamase enzymes that inactivate beta lactam
antibiotics is more common among Gram negative bacteria (Matthew and Harris,
1976).
Reports of reduced susceptibility to penicillin has been observed in GBS and occurs
through mutations within PBPs, which affect the binding capacity of penicillin
antibiotics (Kimura et al., 2008; Metcalf et al., 2017). These GBS isolates are referred
to as penicillin resistant (PR)-GBS and their emergence is important as PBP mutations
are considered the first step in eventual complete penicillin resistance as was observed
previously in other Streptococci (Jamin et al., 1993; Kimura et al., 2008).
1.8.1.2.1. Mutations of PBPs
PR-GBS acquire mutations within genes encoding penicillin-binding proteins (PBPs),
in particular within PBP2x (Figure 1.3). Several mutations have been identified, but
the most frequently observed resulting amino acid substitutions in GBS are V405A
and/or Q557E (Moroi et al., 2019). In fact, V405A and Q557E mutations are
considered key amino acid substitutions involved in non-susceptibility to penicillin
(Kimura et al., 2015).
A classification system was designed by Kimura et al., (2015) to help distinguish the
different types of PR-GBS strains. They proposed 4 different classes (1-IV) based on
distinct PBPs that harbour different amino acid mutations and the classes are defined
based on ‘critical’ amino acid substitutions. All PBP2x mutations are considered
critical because of their association with being the first step of reduced susceptibility,
and substitutions near the active sites of PB2b, PBP1a and PBP2a are also considered
critical. Class I includes all critical amino acid substitutions within PBP2x, class II
includes critical amino substitutions within PBP2x and PBP1a, class III includes
critical amino acids within PBP2x and PBP2b and class IV includes substitutions
within PBP2x, PBP1a and PBP2a. Furthermore, each group is sub-classified based on
the key amino acid substitutions they harbour: subclass a includes V405A, subclass b
includes Q557E, subclass c includes both V450A and Q557E while subclass z includes
any other mutations (Kimura et al., 2015).
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1.8.1.3. Prevelance of resistance
Table 1.3 highlights the documented cases of PR-GBS reported worldwide. The first
report of characterised reduced penicillin susceptibility in GBS was in 2008 (Kimura
et al., 2008) and since then, it has been documented elsewhere, including the USA,
Canada, Korea and Japan (Dahesh et al., 2008; Gaudreau et al., 2010; Longtin et al.,
2011; Morozumi et al., 2016; Metcalf et al., 2017; Yi et al., 2019). While overall it is
still relatively rare, a recent study highlighted the increased incidence of PR-GBS in
Japan from 2.3% in 2005-2006 to 14.7% in 2012-2013 (Seki et al., 2015). Even more
worrying, 68.9% of these isolates were multi-drug resistant isolates, showing
resistance to macrolides and fluoroquinolones (Seki et al., 2015). The majority of
isolates currently reported as having reduced susceptibility to penicillin have MICs of
0.25 µg/ml; however, two Japanese studies reported strains with MICs as high as 1
µg/ml (Kimura et al., 2008; Seki et al., 2015).
Currently in Europe there has only been one report of reduced susceptibility in Italy
(Matani et al., 2016). Of interest, two separate surveillance studies of GBS disease in
infants carried out in the UK and Ireland as well as the US reported that isolates were
universally susceptible to penicillin (Nanduri et al., 2019; O’Sullivan et al., 2019).
However, vigilance and surveillance are essential as it is clear from other studies that
initial reduced susceptibility to penicillin, associated with mutations in PBPs, can lead
to a rapid spread of penicillin-resistance, as was the case for S. pneumoniae (Jamin et
al., 1993). Importantly, the mosaic nature of mutations associated with penicillin
resistance in S. pneumoniae are different to the point mutations observed in GBS
strains, facilitating easier tracking of resistance in GBS (Metcalf et al., 2017).
1.8.1.4. Multi-drug resistance
Isolates demonstrating reduced susceptibility to penicillin are often found in
conjunction with resistance to other antibiotics and thus represent multidrug resistant
strains. Numerous studies in Japan have reported multi-drug resistance GBS following
the initial report of n = 10 PR-GBS strains that were also resistant to erythromycin,
levofloxacin and tetracycline (Nagano et al., 2012). Subsequent studies in Japan
between 2001-2008 reported high levels of fluoroquinolone (100%) and macrolide
(47.4%) resistance amongst PR-GBS strains (Kimura et al., 2013a). High levels of
PR-GBS (14.7%) were observed in Japan 2012-2013, and high proportions of these
isolates showed resistance to macrolides (71.1%) and/or fluoroquinolones (95.5%)
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indicating multidrug resistance (Seki et al., 2015). Moreover, a more recent Japanese
study reported the high incidence of cefotaxime (28%), ceftriaxone (36%) and
levofloxacin (93%) resistance amongst PR-GBS (Kitamura et al., 2019).

1.8.1.5. Other beta-lactam antibiotic resistance
Strains that are susceptible to penicillin but showing reduced susceptibility to other
beta-lactam antibiotics have also been described. In Japan, reduced susceptibility to
cephalosporins was observed (Nagano et al., 2014). Reduced susceptibility to
ceftibuten was also observed in GBS strains in Japan that had maintained susceptibility
to penicillin (Banno et al., 2018) as well as penicillin-susceptible isolates with reduced
cefotiam susceptibility (Murayama et al., 2009). Penicillin susceptible isolates
showing reduced susceptibility to cephalosporins were also observed in Italy
(Piccinelli et al., 2017). These isolates have been given the umbrella term GBS with
reduced beta-lactam susceptibility (GBS-RBS) (Kimura et al., 2015).
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Table 1.3: Reports of reduced susceptibility to penicillin amongst Group B Streptococcus isolates worldwide.
Country

Sample source

Rates

MIC
(µg/ml)

Africa
1989–2019
Canada 2004
and 2007
Canada 2009

Colonising pregnant
women.
Invasive adult infection.

33.6%

NR

PBP2x
NC

PBP2a
NC

PBP2b
NC

PBP1a
NC

0.25

I377V, G627V, N575D

-

0.5

G371D

T546P

(Longtin et al., 2011)

Hong Kong
2006-2007
Italy 2013

Invasive adult infections.

2 strains.

0.12-0.25

NC

S453N, N682D,
T526A
E636G, S644F,
S676F
NC

V625I, P278L

Invasive adult infections.

Isolated
case.
NR

(Gizachew et al.,
2019a)
(Gaudreau et al., 2010)

NC

NC

(Chu et al., 2007)

Colonising pregnant
women.
Invasive adult infections.

12.07%

NR

NC

NC

NC

NC

(Matani et al., 2016)

14 strains.

0.25-1

Q557E, V405A*

(Kimura et al., 2008)

Invasive infections.

14.7%

0.25-1

V405A, Q557E

(Seki et al., 2015)

Invasive infections.

2.3%

0.25-0.5

S353F, A374V, F395L, V405A, A400V,
R433H, H435Y, A514V, Q557E, G648A

Japan 2007

Invasive adult infections.

NR

0.25

V405A, F395L, R433H, H438Y, G648A

Japan 20102013
Korea
Mozambique
2001-2015
South Africa

Invasive adult infections

2%

0.125-0.5

Invasive adult infections.
Invasive infant infections.

2 strains.
6.3%

0.25-0.5
0.25

K372E, I377V, G398A, V405A, Q412L,
G429D, H438Y, D478A, E513Q, Q557E
G398A, V405A, Q557E
G398A, I377V, G627V

Colonising pregnant
women.
Invasive infections.

4%

NR

NC

NR

0.12

Q557E, T3941, T555S

Invasive infections.

1.38%

0.25

Invasive adult infections.

0.5%

NR

S389Y, I377V, V650I, A579T, V480I,
T394I, V510I, R433C, A400V, A400T,
G406D, G415E, S456P, L534S, Q557E,
N575D, 521-Y-522 insertion.
NC

Japan 19952005
Japan 20122013
Japan 20032004

USA 19992005
USA 2015

USA 20082016

Mutations identified

T175I, L285F,
Y236C

Reference

V80A, Y262N,
G539E, T567I,
G613R
T567I

L45P, N163K, Y470F,
G527V, N723S

(Nagano et al., 2008)

(Nagano et al., 2012)
(Morozumi et al., 2016)
(Yi et al., 2019)
(Sigaúque et al., 2018)

NC

NC

NC
T546N

(Africa and Kaambo,
2018)
(Dahesh et al., 2008)
(Metcalf et al., 2017)

NC

NC

NC

(Francois Watkins et
al., 2019)

Reports of reduced penicillin susceptibility amongst Group B Streptococcus isolates and association mutations. NR indicates where studies did not report the incidence of
reduced-penicillin susceptibility or where MICs were not reported. NC indicates where mutations within the penicillin-binding proteins were not characterised.
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1.8.2. Macrolide and lincosamide antibiotics
Macrolides and lincosamides are chemically distinct antibiotics but share a similar
mode of action and are mostly limited to Gram positive bacteria, particularly
Staphylococci and Streptococci (Leclercq, 2002). Macrolides are composed of 14(e.g. erythromycin), 15- (azithromycin) or 16- (spiramycin) membered lactone rings,
to which several neutral sugars and/or amino sugars have been added (Leclercq, 2002).
Erythromycin was the first macrolide discovered, isolated from Streptomyces
erythreus in 1949 by McGuire and approved for clinical use in 1952 (McGuire et al.,
1952). Other derivatives of macrolides have since been synthesised, such as ketolides,
and all consist of a core lactone ring (Roberts et al., 1999). In contrast, lincosamides
do not have a lactone ring (Leclercq, 2002) and include the naturally-occurring
antibiotic lincomycin and its semi-synthetic derivative obtained by chlorination,
clindamycin (Dhawan and Thadepalli, 1982).
1.8.2.1. Macrolide and lincosamide mechanisms of action
Macrolides exert their antimicrobial action by binding to the 50S subunit of the
bacterial ribosome, thereby preventing protein synthesis (Leclercq, 2002). Binding to
the 50S subunit inhibits protein synthesis by causing the dissociation of peptidyltRNA, thus preventing peptide elongation (Weisblum, 1995a,b;Weisblum, 1998). The
mechanism of action has been further elucidated in recent years owing to the
advancements in genetic, biochemical, X-ray crystallography and ribosome-profiling
techniques (Tu et al., 2005; Dunkle et al., 2010; Kannan et al., 2012, 2014; Gupta et
al., 2016). Specifically, macrolides bind to the bacterial 23S rRNA in the 50S subunit,
adjacent to the peptidyltransferase centre (PTC) within the peptide exit tunnel and
inhibit the extrusion of the nascent peptide, resulting in dissociation of peptidyl tRNA
(Vester and Douthwaite, 2001; Dunkle et al., 2010). When the tunnel is blocked, it
ejects the incomplete peptidyl tRNA-macrolide complex (Dunkle et al., 2010).
Recent studies challenged the conventional view that all macrolide antibiotics inhibit
protein synthesis by causing peptidyl-tRNA drop-off, and that this was the sole
mechanism of action. The mechanism of action of macrolides was demonstrated to be
protein-specific, with the structure of the nascent peptide determining whether protein
synthesis is stopped, stalled or continued (Kannan et al., 2012). For erythromycin,
translation of the polypeptide is aborted due to peptidyl-tRNA dissociation. However,
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certain peptide sequences can bypass the antibiotic-occupied tunnel and allow
synthesis of polypeptides (Kannan et al., 2012). Genome-wide ribosome profiling
techniques were employed to analyse macrolide antibiotic interactions and the general
mode of action was determined to involve selective inhibition of peptide bond
formation (Kannan et al., 2014). This pioneering study demonstrated that the main
mode of action is the protein-specific inhibition of peptide bond formation leading to
impaired translation. Protein synthesis is not only inhibited when the nascent chain
reaches the site of antibiotic-binding in the peptide exit tunnel, but also when the
antibiotic-bound ribosome comes across a codon sequence for specific amino acid
combinations. If the antibiotic-bound ribosome encounters a peptide in the early stages
of translation, the tRNA is still prone to dissociation, resulting in peptidyl-tRNA dropoff, thus; both mechanisms of action may occur (Kannan et al., 2012).
Lincosamide antibiotics are structurally unrelated to macrolides but they share a
similar mode of action. Lincosamide antibiotics bind to 23S rRNA in the bacterial 50S
ribosomal subunit and interfere with protein synthesis (Tenson et al., 2003).
Lincosamide antibiotics also bind to the peptidyltransferase centre (PTC) of the 50S
ribosomal subunit at sites that are overlapping or close to macrolide binding sites (Tu
et al., 2005), which explains the cross-resistance frequently observed for macrolides
and lincosamides (discussed in more detail below). Lincosamides, such as
clindamycin, interfere with the ribosomal A-site for aminoacyl-tRNA binding (Tu et
al., 2005; Dunkle et al., 2010). PTC-targeting antibiotics, such as lincosamides, inhibit
peptide bond formation by preventing the correct positioning of amino-acyl tRNAs in
the PTC (Blair et al., 2015).
1.8.2.2. Resistance mechanisms
Not long after its initial release in 1952, resistance to erythromycin was documented
in Staphylococcus aureus strains and since then, resistance has become widespread
(Weisblum et al., 1995a). Resistance to macrolide and lincosamide antibiotics can
occur through various mechanisms including efflux pumps, ribosomal modification
and drug inactivation and therefore results in a variety of phenotypes of resistance. As
macrolides, lincosamides and streptogramin antibiotics share similar binding sites,
resistance mechanisms for one class often confers cross-resistance to the others
(Leclerq, 2002). Modification of the ribosome confers broad-spectrum resistance to
macrolides and lincosamides, whereas efflux pumps or drug inactivators tend to limit
50

the resistance to only some antibiotics (Leclercq, 2002). Cross-resistance to
macrolides, lincosamides and streptogramin B antibiotics is referred to as the MLSB
phenotype and can be constitutive (c-MLSB) or inducible (i-MLSB). Resistance
confined to 14- and 15-membered macrolides is referred to as the M phenotype, while
isolated resistance to lincosamides is referred to as the L phenotype. Cross resistance
between lincosamides, streptogramin A antibiotics and sometimes pleuromutilins can
also occur and is referred to as LSA/LSAP phenotype.
Each of the resistance mechanisms described are the result of resistance determinants
encoded by genes (Figure 1.3). Alteration of the ribosomal-binding site by methylases
encoded by erm genes confers the MLSB phenotype (Roberts et al., 1999). Efflux
pumps encoded by mef genes confer resistance to macrolides only. The most common
method of lincosamide resistance is through cross-resistance from macrolides via ermmediated methylation of the ribosome. Less frequently, specific lincosamide
resistance is mediated by transferases encoded by lnu genes (Bozdogan et al., 1999).
Moreover, lincosamide resistance may also occur with cross-resistance to
streptogramin A and pleuromutilins antibiotics (LSA/LSAP phenotypes) encoded by
lsa genes (Malbruny et al., 2011; Montilla et al., 2014). Owing to the large number of
antibiotic resistance genes across species and genera, a website has been developed
for the dissemination of information regarding resistance genes conferring resistance
to

macrolide,

lincosamide

and

streptogramin

antibiotics

(http://faculty.washington.edu/marilynr/). However, this review will focus on
resistance mechanisms specific to Group B Streptococcus only.
1.8.2.2.1. Target modification
Ribosomal methylation via methyl-transferases encoded by erm (erythromycin
ribosome methylation) genes is the most widespread mechanism of macrolide
resistance in pathogenic bacteria (Figure 1.3, 1.4B). Erm methylases add one or two
methyl groups to an adenine residue, A2058, in the 23S rRNA of the 50S ribosomal
subunit (Weisblum et al., 1995a; Roberts et al., 1999; Roberts et al., 2008). This
modification of residues crucial to the binding site of the bacterial ribosome generally
confers cross-resistance to macrolides, lincosamides and streptogramin B antibiotics
(Weisblum et al., 1995a), known as the MLSB phenotype, and expression of this
phenotype can be constitutive (c-MLSB) or inducible (i-MLSB). There are over 40
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erm variants, with ermB being the most common in Streptococci (Roberts et al., 1999).
A subset of ermA genes, ermTR, are also found in beta-haemolytic streptococci,
including GBS (Roberts et al., 1999).
Most erm genes are inducible by 14- and 15- membered macrolides, whereby
repression of erm translation due to blocking of its binding site by mRNA is relieved
by the inducer binding to the ribosome (Depardieu et al., 2007). With inducible
resistance, in the absence of an inducer, leader sequences upstream of the translational
start site form structures which sequester the ribosomal start site of the resistance gene
as well as overlapping the ORFs for Erm methylases. Thus, there is no synthesis of
the erm resistance gene (Rosato et al., 1999; Min et al., 2008; Fyfe et al., 2016).
However, when an inducer is present it binds to the ribosome and thus alleviates
repression of translation of the resistance protein. An example of the i-MLSB
phenotype commonly found in GBS is inducible clindamycin resistance, whereby
clindamycin resistance is induced in the presence of erythromycin. This can be clearly
observed using the double disk diffusion test described in the EUCAST guidelines,
whereby a blunting or ‘D’-shaped zone can be seen around clindamycin (EUCAST,
2019) when erythromycin and clindamycin disks are placed 10-12 mm apart.
In constitutive expression, active methylase mRNA is always produced whereas with
inducible expression, bacteria produce an inactive mRNA that is only able to encode
a methylase in the presence of an inducer (Weisblum 1995b; Leclercq, 2002). In
constitutive resistance, mutations in the leader sequence, including deletions of the
attenuator region for ermB in GBS, can destabilize the molecule sequestering the
ribosomal start site or duplicate the initiation sequences leaving one un-sequestered
and available for translation. Clinical GBS strains with variation in the leader sequence
(insertions, deletions and/or duplications) were resistant to both erythromycin and
clindamycin, highlighting that constitutive expression confers a c-MLSB phenotype
(Culebras et al., 2005).
1.8.2.2.2. Target mutation
Mutations in the genes coding for ribosomal proteins may also confer resistance.
Mutations in the domain V of 23S rRNA genes can result in increased resistance to
macrolides, lincosamides, and streptogramin B, with the most common mutations in
domain V at positions A2058 or A2059 (Vester and Douthwaite, 2001). Mutations
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have also been identified in the genes encoding L4 and L22 ribosomal proteins, which
confer macrolide resistance (Tait-Kamradt et al., 2000; Roberts, 2008). Mutations
within these regions have been identified in numerous bacteria including
Streptococcus pneumoniae; however, no such mutations have been identified in GBS
to date.
1.8.2.2.3. Efflux pumps
Efflux pumps do not modify the antibiotic or its target, but instead pump the antibiotic
out of the bacterial cell (Figure 1.4A). Active efflux of antibiotics by bacteria involves
various membrane transporters where efflux is either coupled to an electrochemical
gradient or ATP is used as an energy source. There are two classes of efflux pumps
that can cause macrolide resistance in Gram positive bacteria; the ATP-binding
cassette (ABC) transporter superfamily and the major facilitator superfamily (MFS).
Macrolide efflux (Mef) pumps encoded by the mefA/E gene are commonly detected in
GBS conferring macrolide resistance (Figure 1.3). Mef proteins are members of the
MFS family and do not use ATP as an energy source to pump antibiotics out of the
cell, but instead use secondary active transport (Golkar et al., 2018). Efflux is driven
by the proton motive force and resistance is restricted to 14- and 15-membered
macrolides only, conferring the M phenotype (Sutcliffe et al., 1996; Leclercq, 2002).
1.8.2.2.4. Ribosomal protection ABC-F proteins
The ABC superfamily can be divided into eight different subfamilies (A-H) and most
operate as efflux pumps (described above), forcing antibiotics out of the cell.
However, recent studies provided direct evidence for an alternative mechanism of
resistance through ribosomal protection for one of the sub-families, ABC-F proteins,
which include those encoded by mre and lsa genes (Sharkey et al., 2016). ABC-F
proteins consist of a single polypeptide with 2 ABC domains separated by a linker of
~80 amino acids. Crucially, they are not fused to, or genetically associated with
transmembrane domains (TMDs) required for efflux function (Kerr, 2004; Davidson
et al., 2008; Sharkey et al., 2016). Instead, these proteins exert antibiotic resistance by
binding to the bacterial ribosome to trigger the release of attached antibiotics, thereby
allowing translation to resume (Sharkey and O’Neill, 2018) (Figure 1.4E). More recent
studies suggest ABC-F proteins dislodge antibiotics through nucleoside triphosphate
(NTP)-hydrolysis via direct contact of the linker region to the PTC of the ribosome
(Murina et al., 2018). However, more work is needed to unequivocally confirm the
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role of the linker region in antibiotic displacement, as well as investigate a potential
co-ordinated interaction with a separate efflux pump, as suggested by the authors
(Murina et al., 2018).
ABC-F proteins mediate resistance to the major antibiotic classes that bind to the 50S
ribosomal subunit, including macrolides, lincosamides and streptogramins A and B
(Sharkey et al., 2016). In GBS, this resistance occurs through the expression of lsaC
and lsaE genes (Figure 1.3). Erythromycin-susceptible but clindamycin-resistant GBS
strains were detected in New Zealand, showing cross resistance to streptogramin A
antibiotics and the authors termed this the LSA phenotype (Malbruny et al., 2004).
Later, the authors built on this work to determine the genetic determinant responsible
for this phenotype and identified a gene, lsaC (Malbrunny et al., 2011). Crossresistance to pleuromutilins was also observed, and thus it was renamed the LSAP
phenotype. Since then, there has been relatively few reports of the lsaC gene in GBS,
with the exception of Iceland (Björnsdóttir et al., 2016) the USA (Hawkins et al.,
2017) and Ireland (Hayes et al., 2017). The Active Bacterial Core (ABC) surveillance,
set up by the CDC, retrospectively screened GBS isolates for the presence of such
phenotypes in the USA and found an overall prevalence of 0.31%, with 75% of these
strains harbouring the lsaC gene (Hawkins et al., 2017). In general, the detection of
lsaC in GBS populations is extremely rare, with only 10 strains reported as harbouring
the gene between the initial detection in GBS and the ABC retrospective study
(Hawkins et al., 2017). Interestingly a recent Irish study reported an incidence of
2.77% of GBS strains tested harbouring the lsaC gene and noted that these strains were
obtained in the later part of the study, suggesting a recent emergence (Hayes et al.,
2017).
The lsaE gene had also previously been detected, in GBS isolates (Douarre et al.,
2015) and was found in 18% of strains tested in the ABC study and was always found
in combination with other genes and on plasmids (Hawkins et al., 2017). Thus, while
the reporting of lsa genes in GBS is rare and incidence appears low, it highlights an
area that warrants further investigation.
1.8.2.2.5. Drug inactivation
The enzymatically catalysed modification of antibiotics can also confer resistance to
macrolides and lincosamides where the resultant antibiotics are incapable of binding
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to the 50S subunit of the ribosome (Figure 1.4D). For macrolides, these include
phosphotransferases and esterases. Macrolide phosphotransferases and esterases are
more commonly found in Staphylococci than Streptococci, and extensive reviews are
available for these mechanisms of resistance (Fyfe et al., 2016; Golkar et al., 2018).
This review will focus on the drug inactivation methods observed in GBS, mediated
by nucleotidyltransferases encoded by lnu genes (Figure 1.3).
Seven variations of the lnu genes exist and thus are divided into two groups; these
include lnuA and its two variants, lnuC and lnuD, while the second group consists of
lnuB and lnuF (Petinaki et al., 2008). LnuB was further classified as a member of the
nucleotidyl-transferase (NT) superfamily (Morar et al., 2009). The lnuB gene
(formally linB) was first detected in Enterococcus faecium, conferring resistance to
lincosamides through drug inactivation (Bozdogan et al., 1999) but since then, it has
been detected in GBS strains (de Azavedo et al., 2001). Specifically, this gene encodes
a nucleotidyltransferase that catalyses the adenylation of the hydroxyl group at
position 3 of lincomycin and clindamycin (Bozdogan et al., 1999).
Specific lincosamide resistance (L phenotype) in GBS has been reported in Canada
(de Azavedo et al., 2001), USA (Gygax et al., 2006), Spain (Arana et al., 2014),
Argentina (Faccone et al., 2010), Korea (Seo et al., 2010), South Africa (Bolukaoto et
al., 2015) and the USA (Hawkins et al., 2017) due to the presence of the lnuB gene.
The lnuC gene was also detected in one GBS strain (Achard et al., 2005). More
recently, GBS strains have been observed to harbour lnu genes in combination with
other resistance determinants. Three L phenotype isolates possessing the lnuB gene
were recently characterised as also harbouring the ermB gene, despite being sensitive
to erythromycin. The authors sequenced the ermB genes and found mutations which
may explain the loss of function of the ErmB protein and why the isolates were
susceptible to erythromycin (Moroi et al., 2019). Interestingly, in a recent US study
the lnuB gene was always detected in combination with either the lsaC or lsaE genes,
suggesting they act synergistically to confer the LSAP phenotype (Metcalf et al., 2017;
Hawkins et al., 2017). The lnuB gene was also detected in invasive neonatal samples
in China (Gao et al., 2018).
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1.8.2.3. Prevalence of resistance
Erythromycin and clindamycin worldwide resistance rates for GBS are outlined in
Table 1.4. Resistance to macrolide and lincosamide antibiotics amongst GBS has risen
dramatically in recent years (Lamagni et al., 2013). Resistance varies according to
geographical regions, as well as sample population. Erythromycin resistance is
particularly high in China with rates of 74% reported (Wang et al., 2015; Lu et al.,
2016), while lower rates (4%) were observed in Lithuania (Barcaite et al., 2012).
Clindamycin resistance is also high in China (64-73%), while no resistance to
clindamycin was observed amongst colonising pregnant women in Senegal (Belard et
al., 2015).
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Table 1.4: Resistance to erythromycin, clindamycin and tetracycline in Group B Streptococcus isolates worldwide.
Country

Erythromycin

Algeria 2011-2012
Argentina 2004-2010
Australia 2002-2006

Brazil 2008-2015
Canada 2014
China 2008-2015

45.45%
11.6%
Invasive: 6.4%
Colonising:
6.1%
14%
36%
74.1%

China 2012 –2013
Ethiopia 2016-2017
France 2007-2014

Erythromycin
MIC50, MIC90
(µg/ml)
NR
NR
NR

Clindamycin

Clindamycin
(MIC50)

Tetracycline

Tetracycline
(MIC50)

Sample population

Reference

NR
NR
NR

100%
NR
NR

NR
NR
NR

Maternal colonisation
Maternal colonisation
Colonising and
invasive isolates

(Bergal et al., 2015)
(Oviedo et al., 2013)
(Garland et al., 2011)

NR
0.12, >8
NR

43.18%
1.8%
Invasive: 4.2%
Colonising:
6.7%
2%
33%
64.2%

NR
0.12, >8
NR

86%
89%
68.9%

NR
32, 64
NR

(Botelho et al., 2018)
(Teatero et al., 2017)
(Lu et al., 2016)

85.7%
26.5%
36.2%

16, >256
NR
NR

73.2%
21.4%
26.3%

>256, >256
NR
NR

91%
73.4%
86.5%

NR
NR
NR

France 2006-2013

26.8%

NR

22.11%

NR

84.5%

NR

Germany 2004

11.1%

NR

NR

NR

NR

NR

Ghana 2013
Iceland 1976-2015
Ireland 2010-2016

1%
9%
22.53%

NR
NR
NR

3.1%
NR
21.3%

NR
NR
NR

NR
NR
87.35%

NR
NR
NR

Italy 2013
Italy 2012-2014
Japan 2007-2012
Japan 2007-2008
Korea 2006-2007

43.75%
17%
35%
10.1%
31.9%

NR
NR
NR
NR
NR

32.2%
15.3%
15%
5%
46.5%

NR
NR
NR
NR
NR

NR
NR
NR
NR
NR

NR
NR
NR
NR
NR

Lithuania 2006-2007

4.1%

NR

NR

NR

NR

NR

Malaysia 2010-2011

23.3%

17.5%

NR

71.8%

NR

Maternal colonisation
Maternal colonisation
Colonising and
invasive isolates
Maternal colonisation
Maternal colonisation
Colonising and
invasive isolates
Colonising and
invasive isolates
Maternal and neonatal
colonisation
Maternal colonisation
Invasive adult disease
Colonising and
invasive samples
Maternal colonisation
Invasive infant disease
Invasive infant disease
Maternal colonisation
Colonising and
invasive isolates
Maternal and neonatal
colonisation
Colonising and
invasive isolates

NR
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(Wang et al., 2015)
(Gizachew et al., 2019b)
(Hays et al., 2016)
(Compain et al., 2014)
(Kunze et al., 2011)
(Vinnemeier et al., 2015)
(Björnsdóttir et al., 2016)
(Hayes et al., 2017)
(Matani et al., 2016)
(Creti et al., 2017)
(Chang et al., 2014)
(Kimura et al., 2013b)
(Seo et al., 2010)
(Barcaite et al., 2012)
(Eskandarian et al.,
2015)

Morocco 2013

12%

NR

7%

NR

NR

NR

(Moraleda et al., 2018)

NR

Maternal and neonatal
colonisation
Invasive infant disease
Maternal colonisation
Colonising and
invasive isolates
Invasive adult disease
Maternal colonisation
Maternal colonisation
Maternal colonisation
Colonising and
invasive isolates
Maternal colonisation

Norway 2006-2007
Norway 2009-2011
Poland 1996-2005

18.8%
10.2%
18.4%

NR
NR

19.8%
9.6%
12.3%

NR
NR
NR

NR
76.6%
91.2%

NR
NR
NR

Portugal 2009-2015
Portugal 2005-2012
Romania 2009
Senegal 2008
Serbia 2009-2016

35%
23%
19%
0% - 13%
23.1%

NR
NR
NR
NR
NR

34%
18%
18%
0%
21.3%

NR
NR
NR
NR
NR

86.1%
NR
95%
NR
86%

NR
NR
NR
NR
NR

South Africa 20132014
South Korea 20062008
Spain 2010-2016

17%

NR

6%

NR

NR

25.6%

NR

54%

NR

NR

NR

Maternal colonisation

(Lee et al., 2010)

20.7%

NR

17.6%

NR

NR

NR

(López et al., 2018)

14%

NR

NR

NR

Maternal and neonatal
colonisation
Maternal colonisation

Switzerland 20092010
Taiwan 2006-2015

14.6%

NR

51.1%

NR

47.38%

NR

NR

NR

(Tsai et al., 2019)

68.1%
40%
25%

NR
>256, >256
NR

65.9%
NR
17%

NR
>256, >256
NR

NR
97.3%
94%

NR
NR
NR

Colonising and
invasive isolates
Invasive infant disease
Maternal colonisation
Invasive infant disease

Taiwan 2003-2017
Tunisia 2007-2009
UK and Ireland
2014-2015
USA 2008-2015

54.8%

NR

43.2%

NR

89.9%

NR

Invasive adult disease

44.8%

NR

20.8%

NR

NR

NR

Invasive infant disease

(Francois Watkins et al.,
2019)
(Nanduri et al., 2019)

USA 2006-2015

NR

(Bergseng et al., 2009)
(Brigtsen et al., 2015)
(Sadowy et al., 2010)
(Lopes et al., 2018)
(Florindo et al., 2014)
(Usein et al., 2009)
(Belard et al., 2015)
(Gajic et al., 2019)
(Dangor et al., 2016)

(Fröhlicher et al., 2014)

(Kao et al., 2019)
(Hraoui et al., 2012)
(O’Sullivan et al., 2019)

Incidence of erythromycin, clindamycin and tetracycline resistance amongst Group B Streptococcus worldwide. Studies of maternal colonisation rates are
highlighted in yellow; studies of both maternal and neonatal colonisation are highlighted in blue; studies of invasive GBS strains are highlighted in orange and
studies reporting on both colonising and invasive isolates are highlighted in green. NR indicates studies that did not report the incidence of antibiotic resistance
rates.

58

1.8.3. Tetracycline
Tetracycline antibiotics were first introduced in 1948 and gained popularity due to
their broad spectrum of activity against both Gram positive and Gram-negative
bacteria (Chopra and Roberts, 2001; Connell et al., 2003). Tetracycline was isolated
from Streptomyces aureofaciens and is composed of a linear fused tetracyclic nucleus,
with rings designated A-D, to which functional groups are attached (Chopra and
Roberts, 2001). Tetracycline is a bacteriostatic antibiotic, inhibiting protein synthesis
and thus preventing bacterial growth (Chopra et al., 1992; Roberts, 1996) but also has
additional effects, such as anti-inflammatory and immuno-suppression properties
(Humbert et al., 1991).
1.8.3.1. Mechanism of action
Tetracycline exerts an antibacterial effect by binding to the 30S ribosomal subunit and
inhibiting the elongation phase of protein synthesis (Chopra, 1986). The primary
binding site for tetracycline is in helix 34 of the 16S rRNA of the ribosome,
overlapping with the site where an aminoacyl-tRNA would usually bind, thereby
inhibiting protein synthesis (Chopra et al., 1992; Brodersen et al., 2000; Chopra and
Roberts, 2001; Pioletti et al., 2001).
1.8.3.2. Mechanism of resistance
Tetracycline resistance was first observed in Shigella dysenteriae and was
subsequently rapidly observed in various pathogens including Staphylococcus aureus,
Enterococcus faecalis, Streptococcus pneumoniae and Streptococcus agalactiae
(Akiba et al., 1960; Goldstein et al., 1994). Tetracycline resistance occurs primarily
due to the acquisition of resistance genes and these are often associated with mobile
elements (Levy et al., 1989; Roberts, 1994). As with macrolide resistance, a website
dedicated

to

tetracycline

resistance

determinants

was

established

(http://faculty.washington.edu/marilynr/). Currently there are 71 tetracycline
resistance determinants identified across different genera. Resistance determinants are
grouped as efflux proteins, ribosomal protection proteins, enzymatic inactivators and
one protein of unknown function (Tet U). In Streptococci, efflux proteins Tet K, L, 40
and AB46 have been identified, while ribosomal protection proteins Tet M, O, Q, S,
T, W and 32 have also been detected (Roberts et al., 1996; Chopra and Roberts 2001).
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In GBS, tetracycline resistance is caused by either efflux systems proteins (Tet K and
Tet L), or more commonly by ribosomal protection proteins (TetM and TetO) (Chopra
and Roberts, 2001; Sanchez-Pescador et al., 1988).
1.8.3.2.1 Efflux proteins
Efflux proteins belong to the major facilitator superfamily (MFS) and are among the
best studied of the tetracycline resistance proteins. All tet efflux genes encode
membrane-associated proteins that export tetracycline from the cell, reducing the
intracellular concentration of the antibiotic and protecting the ribosomes within the
cell (Figure 1.4A). Efflux proteins are energy-dependent and exchange a proton for a
tetracycline-cation complex against a concentration gradient (Yamaguchi et al., 1990).
In GBS, efflux proteins are encoded by the tetK and tetL genes (Figure 1.3) and are
generally found on transmissible plasmids capable of becoming integrated into
bacterial chromosomes or larger plasmids (Chopra and Roberts, 2001).
1.8.3.2.2. Ribosomal protection proteins (RPPs)
Ribosomal protection proteins also confer resistance to tetracyclines, with TetM and
TetO being the most commonly found in GBS (Figure 1.3, Figure 1.4E). They share
homology with ribosomal elongation factors EF-Tu and EF-G belonging to the
superfamily of GTPases (Sanchez-Pescador et al., 1988). The tetM gene has the
broadest host range and has been found in over 26 genera including both Gram
negative and positive bacteria (Roberts 1994; Chopra and Roberts, 2001; Roberts,
2002). TetM and TetO can dislodge tetracycline from the ribosome and this activity is
dependent on GTP (Trieber et al., 1998). They confer resistance by catalysing the
release of tetracycline from the ribosome in a GTP-dependent manner, therefore
allowing aminoacyl-tRNA to bind to the ribosomal A-site allowing protein synthesis
to continue (O’ Connell et al., 2003; Trieber et al., 1998). Early studies indicated that
RPPs indirectly cause the release of tetracycline from the ribosome through
conformational changes of the ribosome induced upon binding of the RPP (Trieber et
al., 1998). However, recent studies examining the structure of TetM and TetO bound
to the ribosome in more detail discovered a loop in domain IV of TetM that directly
interacts with the tetracycline binding site, indicating that RPPs use a direct
mechanism of action to dislodge tetracycline from the ribosome (Donhofer et al.,
2012; Li et al., 2013).
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1.8.3.3. Prevalence of resistance
Tetracycline was extensively overused following its discovery and resistance to the
antibiotic is now widely observed in many different bacteria (Jones et al., 2014).
Tetracycline resistance in GBS is ubiquitously high, and multiple resistance
determinants are sometimes found in GBS strains (Hays et al., 2016; Metcalf et al.,
2017). Moreover, tetracycline resistance determinants are frequently detected on
conjugative transposons, facilitating transmission between other bacteria (Da Cunha
et al., 2014). Most GBS strains isolated from humans are resistant to tetracycline, and
the acquisition of resistant elements, tetO and tetM, by a subset of GBS clones led to
their selection and expansion due to the overuse of tetracycline since the 1940s (Da
Cunha et al., 2014). This clone of GBS led to the emergence of strains more adapted
to colonising and infecting humans and in particular led to the dissemination of the
ST-17 clone that is associated with invasive neonatal infections (Da Cunha et al.,
2014).
Rates of tetracycline resistance in GBS populations worldwide are usually >80%
(Lamagni et al., 2013; Hayes et al., 2017) and are summarised in Table 1.4.
1.8.4. Fluoroquinolones
FQ are broad spectrum antibiotics with a core structure related to 4-quinolone and
have a fluorine atom in their chemical structure. Fluoroquinolone (FQ) antibiotics are
commonly used to treat respiratory or urinary tract infections. First generation FQ
antibiotics include norfloxacin and ciprofloxacin which are active against Gram
negative and some Gram positive bacteria. Levofloxacin is a second generation FQ
and is an L-isomer of ofloxacin with improved activity against Gram positive bacteria.
Third generation FQ antibiotics include moxifloxacin and gatifloxacin with improved
antibacterial activity (Scheld, 2003).
1.8.4.1. Mechanism of action
FQ antibiotics prevent bacterial growth by interfering with bacterial DNA replication.
Specifically, FQ antibiotics bind to enzymes involved in DNA replication, namely
type II topoisomerases, DNA gyrase and topoisomerase IV (Hooper, 1999). Binding
to these enzymes by FQ antibiotics inhibits the ligase activity of the enzymes, resulting
in the release of DNA with breaks leading to cell death (Ng et al., 1996). The two
subunits of DNA gyrase, GyrA and GyrB, and their homologous subunits in
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topoisomerase IV, ParC and ParE, are essential for DNA replication and thus are
important targets for FQ antibiotics (Ng et al., 1996; Hooper et al., 1999).
1.8.4.2. Mechanism of resistance
FQ resistance occurs due to either efflux proteins or mutations within genes coding
for type II topoisomerase enzymes, DNA gyrase encoded by gyrA and gyrC or
topoisomerase IV enzymes encoded by parC and parE genes (Figure 1.4C) (Wu et al.,
2008), with these regions referred to as quinolone resistance determining regions
(QRDRs). Mutations within these genes affect the binding of antibiotics and reduce
their effectiveness. FQ resistance in GBS is mainly due to the presence of mutations
within the parC and gyrA genes (Figure 1.3) (Wu et al., 2008; Murayama et al., 2009;
Nagano et al., 2012). Common mutations in the gyrA gene include S81L and E85A/K,
while mutations frequently observed in the parC gene include S79F/A/Y (Kawamura
et al., 2003). While the majority of FQ-resistant GBS strains are associated with the
aforementioned mutations in QRDRs, there has been one report of antibiotic efflux as
a mechanism of FQ resistance in some GBS isolates (Dang et al., 2014). However, it
is important to note that this efflux phenotype only resulted in resistance to norfloxacin
and no mutations within the QRDRs were identified (Dang et al., 2014).
1.8.4.3. Prevalence of resistance
FQ resistance amongst GBS strains is increasing worldwide. The first documented
FQ-resistant GBS strains were in Japan, with three isolates demonstrating elevated
MICs for Levofloxacin, and analysis of these isolates revealed the presence of
mutations within the gyrA (S81L) and parC (S79K) genes with MICs of >32 µg/ml
(Kawamura et al., 2003). Resistance in Japan has since risen, with rates of 43.6%
currently reported and MICs > 8 µg/ml (Nagano et al., 2012). An increased prevalence
of FQ resistance (MIC >32 µg/ml) is also documented in China, with rates of 39.3%
reported and a high level of cross resistance to erythromycin, clindamycin and
tetracycline was observed for these isolates (Wang et al., 2015). FQ resistance in South
Korea has risen from 8.1% (Ki et al., 2012) to 37.2% (Ryu et al., 2014). A North
American study identified a particularly high prevalence (12.4%) among a specific
clone of GBS strains, CC1, with MICs ranging from 8-32 µg/ml (Neemuchwala et al.,
2016), while a more recent US study reported a resistance rate of 2.3% in invasive
GBS disease among non-pregnant adults (Francois Watkins et al., 2019).
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The first documented FQ-resistant GBS isolate in Europe was detected in France in
2008 with a parC mutation confirmed in the strain and an MIC of 4 µg/ml (Maeda et
al., 2008). The reported incidence of FQ-resistant GBS strains from France has since
increased to 1.5% with MICs of >32 µg/ml, with high levels of resistance to macrolide
antibiotics also observed for these isolates (Hays et al., 2016). Similar rates of
resistance have been observed in Spain (1.16%) (Miró et al., 2006) and Italy (2.99%)
where MICs are reported between 4-32 µg/ml (Simoni et al., 2018).

1.8.5. Aminoglycosides and glycopeptides
Aminoglycosides (gentamicin) and glycopeptides (vancomycin) are used to treat GBS
infections in certain conditions. For severe invasive GBS infections such as infective
endocarditis and periprosthetic joint infections, a combination therapy of penicillin
and gentamicin has been suggested (Buu-Hoi et al., 1990); however, more current
studies question the benefit of such combination treatments (Ruppen et al., 2016). This
combination has also been recommended to treat babies suspected of EOD (Hughes et
al., 2017). Vancomycin is used as a last stage antibiotic for treatment of GBS
infections and IAP (Verani et al., 2010; Hughes et al., 2017; ACOG, 2019).
1.8.5.1. Mechanism of action
Gentamicin is bactericidal and binds to the A-site on 16S RNA in the 30S ribosomal
subunit, and inhibits protein synthesis (Kotra et al., 2000). This results in a
conformational change of the A-site leading to errors in protein synthesis causing the
incorrect polypeptide to be released which can cause damage to the bacterial
membrane (Davis et al., 1986). Vancomycin inhibits cell wall synthesis by binding to
the D-Ala-D-Ala termini of peptidoglycan precursors thus inhibiting cross-linking
transpeptidation and transglycosylation (Anderson et al., 1967).
1.8.5.2. Mechanism of resistance
As Gram positive bacteria, GBS have intrinsically low level resistance to gentamicin
as the cell wall is less permeable to the large aminoglycoside molecules. However,
higher levels of resistance have been observed in some GBS isolates, due to the
bifunctional

aminoglycoside-inactivating

enzyme

6’acetyltransferase-2”-

phosphotransferase (AAC(6’)–APH(2”)) encoded by the aacA-aphD gene wherein a
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higher MIC for gentamicin is observed for these isolates (Figure 1.3, 1.4F) (Buu-Hoi
et al., 1990).
Vancomycin resistance occurs through the synthesis of peptidoglycan precursors with
altered residues resulting in low vancomycin affinity. Modifications of the
glycopeptide target site (D-Ala-D-Ala residue) results in resistance and there are
several different phenotypes, referred to as VanA, Van B, Van D and Van G depending
upon which amino acid has been altered (McKessar et al., 2000; Périchon and
Courvalin, 2009). The VanG phenotype is associated with vancomycin resistance
genes, vanG (encoding a D-Ala-D-Ser ligase), vanT (encoding a serine racemase),
vanXY encoding a bifunctional D,D-carboxypeptidase/D,D-peptidase and vanY
encoding a D,D-carboxypeptidase (Depardieu et al., 2004). In GBS, vancomycin
resistance has been associated with the vanG gene which results in the alteration of
the vancomycin target site to D-Ala-D-Ser (Figure 1.3, 1.4H) (Park et al., 2014). Of
note, these vanG genes were insertion elements and represent the first detection of
vanG elements within the Streptococcus genus (Srinivasan et al., 2014).
1.8.5.3. Prevalence
1.8.5.3.1. Gentamicin
The first report of gentamicin resistance in GBS was in France 1987 (Buu-Hoi et al.,
1990), and a more recent French study reported a rate of 8.8% resistance to
aminoglycosides, with 0.3% highly resistant to gentamicin with MICs >128 µg/ml
(Hays et al., 2016). In the UK and Ireland between 2001-2014, 0.2% of strains showed
high-level gentamicin resistance with elevated MICs >1024 µg/ml (Liddy and
Holliman, 2002; Doumith et al., 2017). GBS strains with high MICs for gentamicin
have also been detected in Switzerland (MIC50 24 µg/ml, MIC90 96 µg/ml), although
the genetic basis for this phenotype was not investigated (Ruppen et al., 2017). Two
strains with the aacA-aphD gene were also detected in a multicentre study across 4
different countries, Switzerland, Germany, Portugal and Egypt and MICs ranged from
512 – 1024 µg/ml (Sendi et al., 2016).
1.8.5.3.2. Vancomycin
To date there have only been two incidences of vancomycin resistance in GBS, first
reported by Park and colleagues (2014) and then further characterised by Srinivasan
et al., (2014). The two separate invasive isolates in the US from adult infections
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showed decreased vancomycin susceptibility with MICs of 4 µg/ml and both
harboured the inserted vanG gene (Park et al., 2014; Srinivasan et al., 2014). While
the reports of vancomycin resistance in GBS are still low, this may be a consequence
of a lack of vancomycin-sensitivity testing due to universal susceptibility to penicillin
observed in GBS strains, therefore complacency in monitoring vancomycin resistance
should be avoided.

1.9. Counteracting antimicrobial resistance
There have been significant efforts made to try and combat antibiotic resistance and
antibiotic stewardship has played an important role. Monitoring the incidence of
antibiotic resistance ensures an evolutionary record of resistance rates over time and
surveillance studies are highly valuable in order to detect specific trends or emergence
of new phenotypes. However, more work is needed to improve antimicrobial
stewardship, and newer antibiotics and/or antimicrobials are required in order to
prevent the further spread of antibiotic resistance, both generally and specifically in
GBS disease. Thankfully, penicillin remains effective for GBS strains and our current
Irish study has confirmed this (Hayes et al., 2017). However, while the risk factor
approach to IAP administration is currently adhered to in Ireland, there are arguments
for the use of microbiological screening methods. In this event, antibiotics such as
clindamycin and erythromycin may be re-entered into routine clinical use and thus
monitoring resistance levels within GBS populations is important. Moreover, while
vancomycin resistance in GBS is rare, there is the potential for the spread of further
resistance in the event of an overuse of vancomycin. Proactively looking for
alternative antimicrobials is therefore advantageous as it could help prevent the
development of resistance.
The current antibiotic resistance crisis requires urgent global collaborative action. In
2015 the WHO endorsed a global action plan to combat microbial resistance (WHO,
2015). The current pipeline of drugs in development is insufficient to mitigate the issue
of antimicrobial resistance and more research and investment in drug discovery and
development is required to generate novel and alternative clinically usable
antimicrobial agents. Recent reviews have advocated the development of natural
antimicrobial products as well as combination treatments as a solution for
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antimicrobial resistance (Cheesman et al., 2017; Tyers and Wright, 2019). There are
several naturally occurring antimicrobial agents that are proving beneficial and some
with specific potential for activity against GBS are discussed in detail below.
1.9.1. Bacteriocins
Antimicrobial peptides (AMPs) are secreted by some bacteria as defence mechanisms
and of these, a large subclass called bacteriocins exist. Bacteriocins are small,
ribosomally-synthesised AMPs produced by many Gram positive bacteria (Cotter et
al., 2005). They are classified into two groups as proposed by Cotter et al., (2005).
Class 1 bacteriocins are peptides that undergo extensive post-translational
modifications (lantibiotics, linardins, and thiopeptides) and class II bacteriocins
include peptides that do not undergo modifications. Class II bacteriocins are further
subdivided into 5 groups. IIa; peptides that contain a YGNGV motif, IIb; two peptide
bacteriocins, IIc; circular bacteriocins, IId, non-pediocin single linear peptides and IIe;
microcin E492-like bacteriocins (Cotter et al., 2005).
Bacteriocins are synthesised as an inactive pre-peptide with an N-terminal leader
sequence that is cleaved during export across the cytoplasmic membrane (Chen et al.,
2001). Export is usually carried out by an ABC transporter which contains an Nterminal cysteine protease responsible for cleaving the bacteriocin leader peptide
(Håvarstein et al., 1995). Regulation of bacteriocin production is mediated through
two-component systems (Guder et al., 2002). In addition, bacteria that produce
bacteriocins have an immunity system to prevent a suicide effect. Protection occurs
either through production of an immunity protein and/or specialised ABC transporter
systems which pump the self-produced bacteriocin out of the cell (Guder et al., 2002;
Rincé et al., 1997). Bacteriocins possess many attributes which make them attractive
alternatives to antibiotics, including their antimicrobial activity, potency and low
toxicity, and the fact that they can be easily bioengineered (Cotter et al., 2013).
1.9.1.1. Lantibiotics
Of the bacteriocins identified to date, lantibiotics have received a lot of attention as
potential alternatives to antibiotics. Lantibiotics are expressed as inactive precursor
peptides inside the cell and are post-translationally modified by specific enzymes,
forming a link between cysteine residues and dehydrated amino acids, causing the
formation of (methyl)-lanthionine rings (Buchman et al., 1988; Kaletta and Entian,
66

1989; Dodd et al., 1990; Karakas Sen et al., 1999; Koponen et al., 2002; Chatterjee et
al., 2005). Following this modification, the pre-peptide is secreted into the
extracellular space where it is activated via cleavage of the leader peptide by proteases
(Chatterjee et al., 2005; Lagedroste et al., 2017; Montalbán-López et al., 2018). The
characteristic lanthionine rings are essential for antimicrobial activity and examples of
lantibiotics with antimicrobial activities include nisin, planosporicin, Pep5, epidermin,
gallidermin, mutacin B-Ny266, lacticin 3147 and actagardine (Piper et al., 2009).
1.9.1.1.1. Nisin
Nisin is a bacteriocin produced by Lactococcus lactis and is the most extensively
studied lantibiotic. Structurally, it consists of 34 amino acids arranged in 5 lanthionine
rings (A-E), divided into three main parts (Figure 1.5). The N-terminus contains rings
A-C, responsible for binding to the cell wall precursor lipid II (Hsu et al., 2004)
thereby preventing bacterial cell growth (Wiedemann et al., 2001). Adjacent to this
region is a flexible hinge region of three amino acids, NMK, which facilitates flipping
of the C-terminus (rings D and E) into the cell membrane and its subsequent
perforation (Hester Emilie van Heusden et al., 2002; Hasper et al., 2004; MedeirosSilva et al., 2018). This pore formation in the bacterial cell membrane causes leakage
of vital cell components leading to rapid cell death (Wiedemann et al., 2001; Hsu et
al., 2002, 2004; Hasper et al., 2004; van Hesuden et al., 2004; Medeiros-Silva et al.,
2018).
Nisin is an extremely attractive bacteriocin as it displays high antimicrobial activity
and has low toxicity. Nisin has demonstrated antimicrobial activity against various
clinically relevant bacteria including methicillin-resistant Staphylococcus aureus
(MRSA) with MICs between 0.5-8.4 mg/L (Piper et al., 2009; Okuda et al., 2013),
Clostridioides difficile (Bartoloni 2004), Listeria monocytogenes with MICs between
200-1000 mg/L (Ferreira and Lund, 1996), vancomycin resistant Enterococci with
MICs between 10 and 20 mg/L (VRE) (Severina et al., 1998) and Streptococcus
mutans with MICs ranging from 625-1250 mg/L (Tong et al., 2010). Different MICs
for nisin were determined for each of the pathogens tested and are summarised in
Table 1.5.
Nisin has other biological functions, including immunomodulatory effects. Studies
with nisin have demonstrated an inhibitory effect on the secretion of the inflammatory
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cytokine TNF-alpha in peripheral blood mononuclear cells (PBMCs) stimulated with
lipopolysaccharide (LPS) (Kindrachuk et al., 2013; Mouritzen et al., 2019). In another
investigation, nisin had a time and concentration dependent inhibitory effect on the
interleukin IL-6 production in porcine leucocytes (Małaczewska et al., 2019).
Currently, nisin is not licensed for clinical use. However, it has long been used as a
food preservative in the food industry and has been classified as GRAS status by the
FDA highlighting its safety for use in humans. Furthermore, studies examining the
toxicity of nisin to human cells have shown it is non-toxic and demonstrated safety in
an IV regimen (Goldstein et al., 1998; Gupta et al., 2008; Hagiwara et al., 2010;
Kitigawa et al., 2019). Intramammary infusion of nisin was considered safe and
effective in lactating cows (Guan et al., 2017). Furthermore, the topical use of nisin
was considered safe an effective for use in lactating women (Fernández et al., 2008).
Taken together, this promising studies highlight the strong potential for the clinical
use of nisin, as suggested in a recent review on the biomedical applications of nisin
(Shin et al., 2016).

Figure 1.5: Schematic structure of nisin A.
Schematic of the amino acid structure (1-34) of nisin A. Formation of lanthionine rings are
highlighted and labelled A-E. The flexible hinge region at residues 20-22 is also highlighted.
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Table 1.5: Reported MIC values for nisin against clinically relevant pathogens.
Target bacteria
Clostridium difficile
Enterococcus faecalis
Enterococcus faecalis

Enterococcus faecium
Listeria monocytogenes

MIC (mg/L)
Nisin
Antibiotic
0.032-1
Vancomycin:
0.128-8 mg/L
4.1 – 8.3
NT
1000
Vancomycin:
4-8 mg/L
Penicillin:
2 mg/L
2- 8.3
NT
200-1000
NT

Methicillin-resistant
Staphylococcus aureus
Methicillin-resistant
Staphylococcus aureus

0.5 – 4.1

NT

2-16

Methicillin-resistant
Staphylococcus aureus
Streptococcus mutans
Streptococcus
pneumoniae
Vancomycin-resistant
Enterococcus
NT, not tested.

4.2 – 8.4
625-1250
1

Vancomycin:
0.5-1 mg/L
Ciprofloxacin:
0.5-0.32 mg/L
Vancomycin:
5-10 mg/L
NT
NT

10-20

NT
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Reference
(Bartoloni et al.,
2004)
(Piper et al., 2009)
(Tong et al., 2014)

(Piper et al., 2009)
(Ferreira and Lund,
1996)
(Piper et al., 2009)
(Dosler and
Grecker, 2011)

(Okuda et al.,
2013)
(Tong et al., 2010)
(Severina et al.,
1998)
(Severina et al.,
1998)

1.9.1.1.2. Bioengineering nisin
Several natural variants of nisin exist, including nisin A (Kaletta and Entian, 1989),
nisin Z (Mulders et al., 1991), nisin Q (Zendo et al., 2003), nisin F (de Kwaadsteniet
et al., 2008) all of which have been isolated from Lactococcus lactis. Other variants
including nisin U and nisin U2 have been isolated from Streptococcus uberis
(Wirawan et al., 2006), nisin H was isolated from Streptococcus hyointestinalis and
nisin P isolated from Streptococcus pasteurians (Zhang et al., 2012). The issue with
many of these naturally occurring variants that affects their potential use in a clinical
setting is their low stability at physiological pH and the high cost and extensive labour
associated with production (Field et al., 2015a). However, the identification of these
variants highlighted the robust nature of the nisin peptide and eluded to its potential to
withstand amino acid substitutions through bioengineering. This is an extremely
attractive characteristic of lantibiotics as the encoding genes can be altered to result in
amino acid substitutions that can significantly alter their biological function,
improving their stability, potency and pharmacokinetic properties (Cotter et al., 2013).
The first successful bioengineered derivatives were nisin Z mutants (T2S, M17Q and
G18T) demonstrating increased activity against non-pathogenic bacteria (Kuipers et
al., 1996). This prompted the creation of a large bank of derivatives through
bioengineering strategies and several nisin derivatives with altered amino acids have
subsequently been created through site specific and site maturation mutagenesis
techniques in what is termed ‘The Golden Era’ of lantibiotics (Field et al., 2010). The
first bioengineered derivative of nisin against pathogens included nisin Z mutants
N20K and M21K against Shigella, Pseudomonas and Salmonella (Yuan et al., 2004)
and nisin A mutants K22T, N20P, M21V and K22S (Field et al., 2008), followed by
the identification of variants with enhanced activity against Gram positive and Gram
negative pathogens (Field et al., 2012). In particular, nisin A M21V, now called ‘nisin
V’, displayed enhanced activity against MRSA, VRE, C. difficile and L.
monocytogenes (Field et al., 2008, 2010). Further site-saturation mutagenesis of the
S29 residue revealed mutants, in particular S29A and S29G, with further enhanced
activity against Gram positive pathogens including MRSA, L. monocytogenes,
Streptococcus mitis and Gram negative bacteria Cronobacter sakazakii, E. coli
0157:H7 and Salmonella (Field et al., 2012). Site-saturation mutagenesis of Lysine12
identified the K12A variant as having enhanced activity compared to wild type nisin
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against Streptococcus, Bacillus, Enterococcus and Staphylococcus species (Molloy et
al., 2013).
The hinge region of nisin has been a popular site for mutagenesis studies (Rouse et al.,
2012; Healy et al., 2013) and the length of the hinge region was shown to affect
activity in a strain specific manner (Zhou et al., 2015). Screening of randomly
generated hinge mutants prompted the specific design of two derivatives with triple
mutations and complete replacement of the hinge region residues NMK with AAA
and SAA, and both derivatives showed enhanced activity against S. agalactiae, L.
lactis HP, Mycobacterium smegmatis, S. aureus (Healy et al., 2013).
1.9.1.1.3. Nisin resistance
Overall, resistance to lantibiotics is rare, although there have been some documented
cases. Resistance can be innate or acquired and both mechanisms have been
extensively reviewed (Draper et al., 2015). Moreover, nisin producing strains possess
an immunity system, consisting of a lipoprotein NisI and an ABC transporter system,
NisFEG, with a two component system (TCS) that regulates biosynthesis (Siegers and
Entian, 1995). Furthermore, some pathogenic bacteria produce proteins which confer
resistance to bacteriocins, while others encode ABC transporter systems specific for
bacteriocin removal (Clemens et al., 2017; Khosa et al., 2013). For the purpose of this
review, the mechanisms of nisin resistance specific to GBS will be discussed (Figure
1.6).

71

Figure 1.6: Mechanisms of nisin resistance amongst Group B Streptococcus.
A nisin resistance operon has been detected in GBS, encoding different proteins involved in
nisin resistance. NSR is a protease which cleaves nisin at specific residues therefore reducing
antimicrobial activity. NsrF and NsrP together form an ABC transporter that actively
transports nisin out of the cell. NSR and NsrFP proteins are regulated by the two-component
system (TCS) NsrR/K, where NsrK is a histidine kinase that senses nisin in the environment
and signals the response regulator NsrR which in turn activates expression of NSR and NsrFP.
This induction is conditional to the amount of environmental nisin present. Nisin may also be
repelled by changes in the overall charge of the bacterial cell. The incorporation of D-alanine
into lipoteichoic acid (LTA) increases the positive charge via the dltABCD operon and is
regulated by the TCS DltR/S. This increase in positive charge of the GBS cell wall results in
the repelling of cationic peptides such as nisin.

1.9.1.1.3.1. Nisin resistance operons
A nisin resistance protein (NSR) was identified in a Lactococcus lactis subs. Lactis
biovar diacetylactis DRC3 and the encoding nsr gene was demonstrated to be plasmidborne (Froseth and McKay, 1991). More extensive studies revealed that the NSR
proteolytically cleaves nisin at the C-terminus and this is mediated by a conserved tailspecific protease domain (Chatterjee et al., 2005). Specifically, NSR cleaves nisin at
residues MeLan-28 and Ser-29 generating a truncated nisin (nisin1-28) with reduced
antimicrobial activity (Sun et al., 2009).
72

Recently, a nisin resistance operon (nsr) was identified in GBS that is similar to the
organisation of immunity systems found in nisin producing strains (Khosa et al.,
2013). This conserved operon encodes five proteins including a lipoprotein, nisin
resistance protein (NSR), an ABC transporter designated NsrFP, a histidine kinase
NsrK and a response regulator NsrR (Khosa et al., 2013). The nsr gene encodes a 320
amino acid NSR protein; a C-terminus protease and member of the S41 peptidase
family (Khosa et al., 2013). The expression of NSR in S. agalactiae is thought to be
under tight regulation and conditional to the amount of external nisin (Khosa et al.,
2013). Structural analysis of NSR revealed it consists of three domains; an N-terminal
helix of 65 amino acids (Lys31–Gly96), a protease cap domain and a protease core
domain which contains the conserved TASSAEM domain and catalytically active
Ser236 (Khosa et al., 2016a). Together, they form a hydrophobic tunnel, with Ser236
and His98 forming a catalytic dyad responsible for binding nisin (Khosa et al., 2016a).
The NSR protein of S. agalactiae binds to ring E of nisin which then facilitates the
cleavage of nisin. Removing the last 6-12 amino acids of nisin was shown to result in
a loss of resistance, emphasizing the importance of the C-terminal end of nisin for
recognition by the NSR (Khosa et al., 2016a). The IC50 for strains expressing the NSR
protein from GBS was 69 nM, compared to 3.8 nM for strains lacking the plasmid
(Khosa et al., 2013). However, it is important to note that currently there are no studies
examining the efficacy of nisin against clinical GBS strains and therefore studies
exploring this are highly valuable, particularly if these strains are harbouring NSR
proteins.
The NsrF and NsrP proteins together form an ABC transporter, NsrFP, consisting of
the characteristic transmembrane domain (NsrP) and two hydrophilic domains (NsrF)
(Khosa et al., 2013; Clemens et al., 2017; Reiners et al., 2017). NsrP has a large
extracellular loop thought to be involved in lantibiotic resistance (Khosa et al., 2013).
NsrFP is a member of the BceAB-type transporter family and recognises the Nterminal region of nisin (Reiners et al., 2017). The NSR protein is believed to act as
the first line of resistance, cleaving the nisin peptide, and any remaining nisin is
exported out of the cell by NsrFP (Reiners et al., 2017). NsrR and NsrK are part of a
two component system (TCS) designated NsrR/K, that regulates the expression of
NSR and NsrFP (Khosa et al., 2013); however, this TCS remains poorly understood.
The structure of the NsrR response regulator has been reported (Khosa et al., 2016b),
but biological studies examining the precise function are lacking.
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1.9.1.1.3.2. Other mechanisms of nisin resistance in GBS
The first step for many cationic lantibiotics like nisin is interaction with the bacterial
membrane, which usually has an overall negative charge (Moll et al., 1996; Deegan et
al., 2010). Lipoteichoic acid (LTA) is a surface-anchored component of the Gram
positive cell wall. The dlt operon (dltABCD) is responsible for the D-alanylation of
LTA (Neuhaus and Baddiley, 2003) and is regulated by the dltR/S operon in GBS
(Poyart et al., 2001b). D-alanylation of the cell wall results in the incorporation of
positive charges and therefore cationic peptides are repelled from the bacterial
membrane. LTA alanylation has been shown to affect the susceptibility to nisin in
various bacteria, including S. pneumoniae (Kovács et al., 2006). A study by SaarDover and colleagues demonstrated that the D-alanylation of LTA enhances GBS
resistance to cationic AMPs. They observed a direct correlation between the level of
resistance, the length and density of the peptide and the alteration of the flexibility and
permeability of the bacterial membrane (Saar-Dover et al., 2012).
Other two component systems have been linked to lantibiotic resistance in various
bacteria. Although not extensively studied in GBS, there have been some suggestions
they could play a role in lantibiotic resistance, in particular the LiaR response
regulator, part of the LiaFSR system involved in GBS adaptation to stress. A GBS
mutant with liaR deleted resulted in increased susceptibility to nisin, colistin and
polymyxin B (Klinzing et al., 2013). Moreover, deletion of another response regulator,
bceR, in GBS resulted in increased susceptibility to bacitracin and human cathelicidin
LL-37 (Yang et al., 2019). Although nisin wasn’t specifically examined in this study,
studies investigating the effect of this regulator on nisin susceptibility are warranted.

1.9.1.1.4. Combating nisin resistance
Following the discovery of nisin resistance operons in GBS, a strategic rational was
applied to the bioengineering process to design peptides specifically to counteract
resistance. In particular, this logic was applied to design novel nisin peptides that could
resist proteolytic cleavage by NSRs (Field et al., 2019). The amino acid serine-29 was
altered, alone and in combination with isoleucine-30, to identify amino acid
substitutions that would result in enhanced nisin activity. A serine to proline
substitution (Ser29-Pro) combined with an isoleucine to valine (Ile30-Val)
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substitution resulted in a novel nisin derivative, designated nisin PV, engineered to
prevent cleavage by NSR proteins (Field et al., 2019). The resistance to cleavage was
assessed using peptide release assays whereby both wild type nisin and nisin PV were
incubated with L. lactis DRC3 cells expressing NSR. Following incubation, RP-HLPC
detected a truncated nisin1-28 whereas nisin PV remained intact indicating it had not
been cleaved. Furthermore, simulation studies demonstrated that NSR could still bind
to nisin PV, but it could not cleave the peptide (Field et al., 2019).
Recently, the hinge region of nisin was manipulated to create three mutants,
∆21MK22, 20NIVMK24 and 20NMKIV24 and their ability to resist nisin immunity
and resistance proteins was investigated (Zaschke-Kriesche, Reiners, et al., 2019a).
The authors found that in particular 20NMKIV24, with an extended hinge region, was
not recognised by nisin immunity or nisin resistance proteins NSR and NsrFP,
although it did exert lower antimicrobial activity than wild type nisin. However, this
variant is a promising candidate that can potentially bypass the nisin resistance
mechanisms of GBS. Another nisin variant, nisin C28P, demonstrated a decreased fold
of resistance compared to wild type nisin in L. lactis strains modified to express NSR
from S. agalactiae; however, it is important to note that a higher MIC was obtained
for this variant compared to wild type nisin when tested against S. aureus and E. coli
control strains (Zaschke-Kriesche, Behrmann, et al., 2019b). NSR displayed decreased
cleavage efficiency for the variant compared to wild type nisin. These promising
studies highlight the potential of using bioengineered nisin variants to combat
resistance mechanisms and represent and exciting area of alternative antimicrobial
agents that deserves further investigation.
1.9.1.1.5. Synergistic potential of nisin
Combining nisin with antibiotics or other natural antimicrobials is also a potentially
interesting area of research. To date, there have been several studies that have
examined the synergistic effects of combining nisin with other antimicrobials. Nisin
combined with lactoferrin successfully inhibited E.coli 0157:H7 (Murdock et al.,
2007), while nisin with either polymyxin E or clarithromycin inhibited P. aeruginosa
(Giacometti et al., 2000). Nisin alone or in combination with vancomycin or
ciprofloxacin inhibited MRSA growth (Dosler and Gerceker, 2011), and nisin has
been shown to improve the activity of 18 different antibiotics against E. faecalis strains
(Tong et al., 2014). Nisin combined with p-couramic acid inhibited growth of B.
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cereus and S. typhumurium (Bag and Chattopadhyay, 2017) while nisin and
polymyxins inhibited Acinetobacter baumannii (Thomas et al., 2019).
Bioengineered derivatives have also demonstrated enhanced activity when combined
with natural antimicrobials. Nisin M21A combined with citric acid or cinnamaldehyde
improved activity against L. monocytogenes (Smith et al., 2016), while nisin V plus
thymol or carvacrol also enhanced activity against L. monocytogenes (Field et al.,
2015b). Further studies of nisin derivatives nisin V and S29A with essential oils
demonstrated enhanced activity against C. sakazaki and E. coli. Moreover, when the
derivatives were combined with cinnamaldehyde they reduced E. coli numbers in
apple juice (Campion et al., 2017).
Another useful application of nisin/antibiotic combinations is their ability to inhibit or
reduce biofilm formation. Nisin M21A and citric acid or cinnamaldehyde inhibited
and reduced L. monocytogenes biofilms (Smith et al., 2016), Nisin I4V reduced S.
pseudointermedius biofilms (Field et al., 2015c), nisin A and colistin or polymyxin B
inhibited Pseudomonas biofilms (Field et al., 2016a). Nisin I4V and nisin V combined
with chloramphenicol inhibited S. aureus and S. pseudointermedius biofilms (Field et
al., 2016b).

1.9.2. Natural food products
In the search for alternative antimicrobials, there are a number of food products that
have recognised antimicrobial properties, mainly due to the bioactive compounds
contained within the food matrix. Such foods are attractive antimicrobials as they are
naturally occurring and therefore do not require extensive development strategies.
There has been huge interest in the area of functional foods in recent years, whereby
a food product has potential health benefits beyond nutrition, including antioxidant,
anti-hypertensive, anti-cancer, immunomodulatory and antimicrobial properties
(López-Expósito et al., 2017). Food derived bioactive peptides are of particular
importance and are mostly found in milk, released by proteolysis (Korhonen, 2009).
A potentially interesting approach to limit GBS gastrointestinal colonisation of
through the consumption of food products with natural antimicrobial activities. For
the purpose of this review, food products with strong suggestions of antimicrobial
properties have been examined and reported.
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1.9.2.1. Honey
Honey has a plethora of health benefits, including antimicrobial, anti-inflammatory
and anti-oxidant effects (Carter et al., 2016). Honey has long been used for medicinal
purposes, in particular for wound healing, and in recent years there has been renewed
interest in its antimicrobial properties (Yaghoobi et al., 2013). Currently, some
medical grade honeys are licensed for use and have FDA approval, including
Medihoney wound gel and dressings as well as MANUKA FILL and MANUKA IG
wound dressings (Saikaly and Khachemoune, 2017). Honey has been used in clinical
settings for acute wounds, such as burns and surgical wounds, as well as for more
chronic wounds, like infected surgical wounds or ulcers (Saikaly and Khachemoune,
2017).
The features of honey which contribute to its antimicrobial effect, include the high
sugar content, low pH and ROS peroxidase activity (Yaghoobi et al., 2013; Carter et
al., 2016). In addition, methylglyoxal (MGO) which is found in certain types of
honeys, can interact with DNA, RNA and proteins to exert antimicrobial effects, and
also has anti-biofilm properties (Majtan et al., 2014). Biofilm inhibition by honey has
been documented, with inhibition observed in various bacteria, including
Staphylococcus aureus and Streptococcus agalactiae (Sojka et al., 2016; Grecka et
al., 2018).
Studies have also reported on the immunomodulatory properties of honey, specifically
its ability to stimulate the production of TNF-alpha (Gannabathula et al., 2012).
Furthermore, some authors hypothesise that honey induces the production of
inflammatory cytokines, TNF-alpha and interleukin B, during low inflammation while
supressing them during infection (Majtan et al., 2014).
1.9.2.2. Garlic
Garlic is another food product with many identified health benefits. Chemically, garlic
consists of many different components, including sulphur compounds (alliin, allicin),
enzymes (alliinase), amino acids and glycosides and trace elements such as selenium
and geranium (Rana et al., 2011). Garlic has many different biological effects
including anti-cariogenic, anti-oxidant, anti-lipaemic and antimicrobial effects (Rana
et al., 2011). The compound responsible for antimicrobial activity in garlic, allicin,
was isolated and identified in 1944 (Cavallito and Bailey, 1944). Allicin is produced
when garlic is crushed, causing the release of alliin lyase which converts alliin to
77

allicin (Stoll and Seebeck, 2006). Garlic has displayed antibacterial activity against S.
aureus, E. coli and P. aeruginosa (Cutler and Wilson, 2004; Bachrach et al., 2011;
Fratianni et al., 2016), as well as anti-fungal activity against Pencillium funiculosum
and Candida albicans (Li et al., 2014a; Li et al., 2016). Therefore, the use of garlic to
limit GBS colonisation could prove an interesting approach to preventing GBS
infections. Importantly, a study examining garlic against GBS strains found that a
purified allicin gel exhibited antimicrobial activity against GBS strains (Cutler et al.,
2009), with MICs of 35-95 mg/L. Moreover, bactericidal activity was achieved with
MBCs of 75-315 mg/L and time-kill curves demonstrated a 2-3 log reduction after 3
hours, with complete bactericidal activity achieved after 8 hours, lasting for 24 hours
(Cutler et al., 2009).
1.9.2.3. Fruit phenolic compounds
Phenolic compounds are secondary metabolites of plants found in different sources
such as fruits, vegetables, wine and honey. Phenolic compounds can be characterised
by their structures and include phenolic acids, flavonoids and non-flavonoids (Li et
al., 2014b; Lima et al., 2019). Fruits are the main natural source of phenolic
compounds. Fruit phenolic compounds have broad-spectrum antibacterial properties,
as well as potential roles in modifying resistance to antibiotics by reducing the MIC
of an antibiotic when used in combination. Furthermore, it has been reported that they
can alter the regulation of virulence genes of pathogenic bacteria (Lima et al., 2019).
Several studies have reported the ability of fruit-derived phenolic compounds to
inhibit bacteria. Fruit extracts showing antimicrobial activity include grape pomace
extract inhibiting antibiotic resistant E. coli and S. aureus (Sanhueza et al., 2017),
pomegranate peel extract inhibiting Listeria innocua, Pseudomonas aeruginosa, E.
coli and S. aureus (Gullon et al., 2016) and blueberry pomace and blackberry extract
inhibiting Campylobacter jejuni (Salaheen et al., 2014). Isolated phenolic compounds
or flavonoids have also been tested for their ability to inhibit bacteria, displaying
inhibition of S. aureus, E. coli and L. monocytogenes (Shen et al., 2014; Sanhueza et
al., 2017).
1.9.2.4. Dairy products
Milk is a rich source of bioactive peptides, in particular antimicrobial peptides, and
the release of these peptides through digestion of milk proteins (caseins, βlactoglobulin, α-lactalbumin and lactoferrin) has been extensively studied (Bruni et
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al., 2016). The many health benefits of these bioactive peptides include
antihypertensive, antimicrobial, antiviral, antioxidant and immunomodulatory
activities (Korhonen et al., 2009; Bruni et al., 2016). Goats milk and its products has
gained huge interest in recent years owing to the nutritional benefits associated with
them (Clark and Mora García, 2017; Verruck et al., 2019). More recently, the addition
of functional products such as pre and probiotics to goats milk has gained attention
and this indicates that the consumption of whole goat milk could prove to have health
benefits (Verruck et al., 2019).
While there has been extensive research on the health benefits of milk and its products,
information on the benefits of cheese, particularly antimicrobial benefits, is lacking.
A study by Rizzello et al., (2005) tested nine different Italian cheeses for antimicrobial
activity against Lactobacillus sakei and found five cheeses that exhibited antimicrobial
properties (Rizzello et al., 2005). Water-soluble extracts of Asiago d’ Allevo cheese,
Emmental de Savoie, mozzarella and gouda cheese have demonstrated activity against
L. monocytogenes and L. innocua strains (Lignitto et al., 2012; Nguyen Thi et al.,
2014; Théolier et al., 2014) and Australian cheddar cheese extracts showed inhibitory
activity against Bacillus cereus (Pritchard et al., 2010). Recently six peptides isolated
from Canastra artisanal minas cheese displayed bactericidal activity against E. coli
(Fialho et al., 2018). Bacteriocins may also be responsible for antibacterial activity
observed in cheese extracts, and a study screening goat milk and cheese discovered
bacteria that produced bacteriocins and found the bacteriocins to be inhibitory against
S. aureus, B. cereus, E. coli and L. mono (Hernández-Saldaña et al., 2016).
One of the main milk proteins that has demonstrated antimicrobial properties is
lactoferrin (Yamauchi et al., 1993; Jenssen and Hancock, 2009). This 80kDa
glycoprotein is also found in the excretory systems of many organisms (Sorensen and
Sorensen, 1940). In humans, lactoferrin is highest in colostrum and has displayed
antibacterial activity against different genera including Streptococcus, Salmonella,
Shigella, Staphylococcus and Enterococcus (Arnold et al., 1980). Lactoferrin binds
and sequesters available iron, thereby preventing bacteria from binding to iron and
thus inhibiting their growth (Jenssen and Hancock, 2009). Apo-lactoferrin (non-iron
saturated) demonstrates antimicrobial activity while activity is reduced upon iron
saturation of lactoferrin (halo-lactoferrin) (Arnold et al., 1980). A role in biofilm
prevention has also been established for lactoferrin, with demonstrated inhibition of
biofilms formed by Pseudomonas aeruginosa, Burkholdia cepacia and S. aureus
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(Leitch and Willcox, 1999; Caraher et al., 2007; Singh et al., 2012). Of particular
interest is that lactoferrin can be digested in-vivo to form AMPs. These include Lf(111), lactoferricin (Lfcin) and lactoferrampin (Sinha et al., 2013) and have in certain
cases exhibited greater activity than native lactoferrin. Bovine Lfcin is observed to
have the most potent activity and also has been shown to display synergy with other
antimicrobials (Bruni et al., 2016). Lactoferrin has demonstrated activity against GBS,
where in a mouse model of ascending infection during pregnancy, GBS infection
resulted in the recruitment of neutrophils and the subsequent formation of neutrophil
extracellular trap (NET) covered in lactoferrin. While it has been demonstrated that
apo-lactoferrin inhibits GBS in a dose dependent manner from concentrations between
100 and 1000 µg/ml, (Kothary et al., 2017) additional studies are warranted to further
investigate its inhibitory effects against this pathogen.

1.9.2.5. Human milk oligosaccharides
There is a certain degree of controversy over the role of breast milk in GBS
pathogenesis. Some studies suggest that breast milk is a reservoir for transmission of
GBS and is thus potentially associated with LOD (Brandolini et al., 2014; Filleron et
al., 2014; Le Doare and Kampmann, 2014). However, other studies recognise the
antimicrobial properties of human milk, linked to milk proteins and human milk
oligosaccharides (HMOs). HMOs are complex carbohydrates consisting of only five
monosaccharides, of which there are currently over 200 unique HMOs described to
date (Bode 2012). HMOs in breast milk are not digested by neonates but instead serve
as substrates for beneficial bacteria in the gut as well as acting as receptor decoys to
prevent pathogen attachment (Lin et al., 2017). HMOs have various biological benefits
such as acting as prebiotics, immune modulators and anti-adhesive antimicrobials
(Bode 2012).
Research groups have examined the antimicrobial properties of HMOs and
interestingly they were found to inhibit GBS growth through bacteriostatic activity at
concentrations between 0.25-1 mg/ml. Further characterisation of HMOs by HPLC
analysis identified two oligosaccharides responsible for activity, lacto-N-tetraose
(LNT) and lacto-N-fucopentaose1 (LNFP1) (Lin et al., 2017). Moreover, when
combined with vancomycin, erythromycin and or gentamicin, HMOs significantly
reduced MICs for the antibiotics. Further investigations revealed HMOs potentiate the
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activity of aminoglycosides, lincosamides, macrolides and tetracyclines when used in
combination with an HMO mix against three GBS strains (Craft et al., 2018). HMOs
reduced the MIC of clindamycin and erythromycin 16- and 32-fold, respectively. The
anti-biofilm potential of HMO mixtures has also been investigated and demonstrated
against GBS strains, whereby inhibition of up to 80% and reduction of biofilm
production by 75% was observed (Ackerman et al., 2017).

1.9.3. Antimicrobial combinations
Despite the global increase of antibiotic resistance, there remains a lack of
development of new antibiotics (Roca et al., 2015). Combination therapy is an
attractive response to the current antibiotic crisis. Combination therapy can include
two or more antibiotics with differing modes of action, or the co-administration of an
antibiotic with an adjuvant (Worthington and Melander, 2012; Wright, 2016).
Antibiotics may also act synergistically when two different modes of action are
present. In particular, synergy between drugs and the immune response is an important
avenue of research that has potential, especially for bacterial infections (Anuforom et
al., 2015). Antibiotic adjuvants work by either blocking the mechanism of resistance
to the antibiotic, or by enhancing the activity of the antibiotic.
There are several studies that have reported on the potential of combining
antimicrobial agents against clinically relevant pathogens. Lactoferrin has elicited
synergistic effects when combined with both antibiotics and antimicrobial peptides
against clinically relevant bacteria such as Escherichia coli (Almehdar et al., 2019)
and Staphylococcus aureus (Desbois and Coote, 2011). It has also been shown to act
synergistically with antibiotics against levofloxacin-resistant Helicobacter pylori, as
well as improving therapeutic gain when added to a triple therapy for patients with H.
pylori (Ciccaglione et al., 2019). Combining honey with other antimicrobials has
demonstrated synergy in certain cases. Manuka honey combined with oxacillin
(Jenkins and Cooper, 2012a) as well as tetracycline, imipenem and mupirocin exerted
synergistic effects against MRSA (Jenkins and Cooper, 2012b). Synergy was also
observed for Medihoney and rifampicin combinations against MRSA as well as
exhibiting the capacity to revert rifampicin resistance in S. aureus (Müller et al., 2013).
Phenolic-rich extracts and individual phenolic compounds have been shown to
modulate antibiotic resistance mechanisms, particularly through subverting efflux
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resistance mechanisms and downregulating genes involved with efflux systems. In
some instances, they have restored the effectiveness of antibiotics in previously
resistant bacteria (Lima et al., 2019). Fruit extracts have been recently examined for
their ability to modify antibiotic resistance. The methanol extract of grape pomace
decreased the MIC of specific antibiotics against MRSA (Sanhueza et al., 2017). Subinhibitory amounts of blueberry and blackberry ethanol extracts also restored
methicillin sensitivity in MRSA. Furthermore, genes involved in methicillin resistance
were downregulated, as well as genes involved in efflux activity (Salaheen et al.,
2017). Tannic acid reduced the MIC of norfloxacin for S. aureus and exerted a
synergistic effect (Diniz-Silva et al., 2016). Synergistic effects were observed when
phenolic acids were used in combination with either ciprofloxacin or erythromycin
against C. jejuni strains (Oh et al., 2015). Fruit phenolic compounds are promising
candidates as antibiotic adjuvants, and more investigative studies are required to
explore this potential.

1.10. Conclusion
GBS has remained a significant coloniser during pregnancy and consequently is an
important pathogen in neonatal disease. The introduction of preventative guidelines in
many countries has reduced the incidence of EOD; however, the incidence of LOD in
infants and invasive disease in adults has been unaffected. Currently, penicillin is used
as a first line of treatment and remains effective against GBS. However, reports of
reduced susceptibility to beta-lactam antibiotics, as well as the high rates of resistance
to other commonly used antibiotics among GBS is a warning that alternative treatment
options are needed. Even more worrying is the emergence of resistance elements in
GBS conferring resistance to last resort antibiotics such as vancomycin. A GBS
maternal vaccine would be hugely beneficial in reducing the incidence of GBS disease
and preventing neonatal acquisition of the bacteria. Efforts from pharmaceutical
industries to develop GBS vaccines have been promising; however, the costs and
extensive analysis involved in clinical trials is delaying the introduction of such
vaccines. In the interim, investigating the potential of novel therapeutics as well as
combination therapies would help with to prevent GBS disease.
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2.1. Abstract
Group B Streptococcal isolates (n = 253) from the South of Ireland were characterised
by molecular serotyping, antimicrobial susceptibility and determination of the
phenotypic and genotypic mechanisms of resistance. Both colonising (n = 202) and
invasive isolates (n = 51) were used in the study. Resistance to erythromycin and
clindamycin was observed in 22.5% and 21.3% of the total population respectively.
The c-MLSB resistance phenotype was the most common phenotype detected (61.4%)
and ermB was the predominant genetic determinant, present in 80.7% of resistant
isolates. The rare L resistance phenotype was observed in 2.8% (n = 7) of isolates
(MIC50 = 1 µg/ml, MIC90 = 256 µg/ml), four of which harboured the lsaC gene
responsible for clindamycin resistance. Serotypes Ia, III and II were the most common
amongst the entire study population (28.1%, 26.9% and 13.43% respectively).
Serotype distribution between colonising and invasive isolates differed. Serotypes Ia
(29.7%), III (25.74%) and II (15.35%) were the most common amongst colonising
strains, while serotypes III (31.37%), Ia (21.57%) and Ib (17.65%) predominated
amongst invasive strains. Four of the seven L phenotype isolates were serotype III and
two of these strains were identified as the hypervirulent clone, ST-17, harbouring the
hvgA gene. Continued surveillance for clindamycin resistance, beyond the original
GBS study population, resulted in detection of an additional five L phenotype isolates,
two serotype Ia and three serotype III, with all five isolates harbouring the lsaC gene.
This is the first documented case of the L phenotype in Ireland to date and these
findings emphasise the need for continued monitoring of antibiotic resistance and
serotype distribution in GBS isolates within the Irish population.
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2.2. Introduction
Group B Streptococcus (GBS), or Streptococcus agalactiae, frequently colonize the
genitourinary tract in pregnant women, with the most recent and comprehensive
analysis estimating worldwide rates of 18%, ranging from 11-35% in different
countries (Russell et al., 2017a). GBS is the leading cause of invasive disease in
neonates, with fatality rates as high as 10%; comparably higher in Africa (18.9%) than
in developed countries (Edmond et al., 2012; Madrid et al., 2017). Furthermore, it has
been reported that up to 40% of neonates that survive infection suffer severe
neurological impairment (Libster et al., 2012; Kohli-Lynch et al., 2017). GBS disease
in neonates is classified as either early-onset disease (EOD) or late-onset disease
(LOD). EOD occurs up to 12 hours after birth and manifests itself as pneumonia or
sepsis, while LOD occurs up to 90 days after birth and is predominantly associated
with meningitis (Heath et al., 2004). Case fatalities in EOD are estimated at 10% and
LOD at 7%, again with higher rates observed in Africa (Madrid et al., 2017). The
introduction of intrapartum antibiotic prophylaxis (IAP) has helped decreased the
incidence of EOD, but incidence rates for LOD remain unchanged (Verani et al., 2010;
Schrag and Verani, 2013). In recent years, GBS has also emerged as an important
pathogen in non-pregnant adults, particularly the elderly and those with underlying
diseases such as diabetes (Lamagni et al., 2013).
Ten serotypes of GBS exist but studies have shown that serotypes Ia, Ib, II, III and V
occur most frequently and are largely responsible for invasive disease (Edmond et al.,
2012; Seale et al., 2017). GBS can be further classified by sequence types (ST) based
on multi-locus sequence (MLST) typing. Of these, ST-1, ST-10, ST-17, ST-19 and
ST-23 are more frequently associated with invasive infection (Jones et al., 2003;
Edmond et al., 2012; Meehan et al., 2014). The ‘hypervirulent’ clone, ST-17 is
associated with serotype III and invasive neonatal disease, and predominates among
LOD cases (Tazi et al., 2010). More recently, studies have identified an association
between serotype V, ST-1 strains and invasive disease amongst non-pregnant adults
(Flores et al., 2015).
Current practice in Ireland for prevention and control of neonatal GBS disease
involves a risk-based assessment, as per the Royal College of Obstetricians and
Gynaecologists (RCOG) guidelines, with IAP administered to those considered at a
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significant risk. However, the widespread use of IAP to prevent GBS EOD has raised
concerns regarding the potential development of antibiotic resistance in GBS isolates
(Phares et al., 2008; Schrag and Verani, 2013). Penicillin remains the first line for IAP
and treatment of GBS infections (Verani et al., 2010; Hughes et al., 2017; ACOG,
2019) however, isolates with increased minimum inhibitory concentrations (MIC) to
penicillin and ampicillin have been confirmed in some countries with MICs ranging
from 0.25-1 µg/ml (Dahesh et al., 2008; Kimura et al., 2008; Gaudreau et al., 2010;
Morozumi et al., 2016; Sigaúque et al., 2018). When a patient presents with betalactam allergies alternative treatment options are required, with lincosamides
(clindamycin) and macrolides (erythromycin) considered the next choice of treatment,
but resistance levels to these antibiotics continues to rise (Lamagni et al., 2013).
Indeed according to the RCOG guidelines, clindamycin is no longer offered as
treatment and vancomycin is administered to patients presenting with beta-lactam
allergies (Hughes et al., 2017).
Macrolide antibiotics inhibit bacterial protein synthesis by binding to the 50S
ribosomal subunit (Roberts et al., 1999). Macrolide resistance in bacteria is mediated
by two methods: target site modification by ribosomal methylation and efflux pumps.
Ribosomal modification by methylases, encoded by erm genes, is the most common
mechanism of macrolide resistance. Methylation of an adenine residue in the 23S
rRNA at position 2058 decreases the affinity of the ribosome for macrolide antibiotics
(Leclercq, 2002). In streptococci, ermB and ermTR genes confer resistance to
erythromycin, and promote constitutive or inducible resistance to lincosamide
(clindamycin) and streptogramin A antibiotics (c- or i-MLSB phenotypes,
respectively). Efflux pumps are encoded by mef genes and restrict resistance to 14 and
15 membered-macrolides only (e.g. erythromycin), which is associated with the M
phenotype (Roberts et al., 1999; Leclercq, 2002).
Resistance to clindamycin occurs primarily through erm genes, however, isolates
displaying resistance to clindamycin but susceptibility to erythromycin (L phenotype)
also occur. This rare phenotype of lincosamide-specific resistance occurs by
enzymatic inactivation of the antibiotic by nucleotidyl-transferases and is mediated by
lnu genes (Bozdogan et al., 1999). Furthermore, this type of lincosamide resistance
may occur with cross resistance to streptogramins A and pleuromutilins, designated
LSA and LSAP phenotypes respectively, which are mediated by the ABC-F protein,
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lsaC (Malbruny et al., 2004, 2011). ABC transporters encoded by vga genes are also
associated with LSA phenotypes and confer resistance to streptogramin A (Roberts,
2002). Lincomycin-specific resistance is associated with the lsaE gene (Douarre et al.,
2015). A retrospective study conducted at the CDC in 2016 confirmed that while the
incidence of these rare phenotypes in GBS is low, the rates are increasing (Hawkins
et al., 2017) and thus should be monitored.
With increased movement across borders resulting in more diverse populations, as
well as an expanding ageing population, there is potential to develop more varied GBS
populations in countries, which suggests that continued surveillance is warranted. This
study aimed to provide current epidemiological data relating to GBS serotype
distribution and antibiotic susceptibility rates in the South of Ireland. The genetic basis
for antibiotic resistance amongst GBS was also examined to investigate the emergence
of new phenotypes in the population.

2.3. Materials and methods
2.3.1. Bacterial isolates
A total of 253 GBS isolates collected over a six-year period (2010-2016) were
included in this study. Of the 202 colonising isolates used in the study, 201 were
collected from the Microbiology Department at Cork University Hospital (CUH),
obtained from high vaginal swabs (HVS) of women between the ages of 16 and 45
years. The remaining colonising isolate was provided by the National Maternity
Hospital, Holles Street, Dublin, and recovered from a placental swab. Invasive GBS
isolates (n = 51) were collected from blood culture samples from Cork University
Hospital (n = 34) and University Hospital Limerick (n = 17). All isolates were
cultured on Columbia Blood Agar (Fannin Ltd, Dublin, Ireland) and incubated at 37oC
for 24 h. Isolates were identified as GBS by beta-haemolysis on blood agar, a positive
Gram stain and a negative catalase test and identified to species level by MALDI-TOF
MS (Bruker Daltonics, Leipzig, Germany).
As part of the continued surveillance for rare resistance phenotypes in Ireland (beyond
the original study) an additional five GBS isolates were received from the National
Maternity Hospital, Dublin. These isolates included a HVS sample (n = 1), semen
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sample (n = 1), urine samples (n = 2) and an invasive blood culture sample (n = 1).
These isolates were cultured and identified as previously described.
2.3.2. Antimicrobial susceptibility testing
Antimicrobial susceptibility of the isolates was assessed by a disk diffusion method
according to EUCAST guidelines (EUCAST, 2017a, and subsequently 2019a)
(http://www.eucast.org/ast_of_bacteria/). All isolates were tested for susceptibility to
penicillin, erythromycin, clindamycin, rifampicin and tetracycline. Briefly, fresh
overnight cultures of GBS were used to prepare inoculums in 0.85% saline to a density
of 0.5 McFarland. Sterile cotton swabs were then used to inoculate the cultures onto
Mueller-Hinton +5% Sheep’s Blood (MHB-F) plates (Fannin Ltd, Dublin, Ireland) by
spreading in three directions and ensuring no gaps were present. Antibiotic disks were
applied within 15 minutes of inoculation and incubated at 37oC for 16-20 hours within
15 minutes of application. Following incubation zones of inhibition were measured
using callipers and interpreted according to EUCAST clinical breakpoints (EUCAST,
2017b, and subsequently 2019b) (http://www.eucast.org/clinical_breakpoints/).
Inducible resistance to clindamycin was determined using the double-disk diffusion
method (D test) according to EUCAST guidelines (EUCAST, 2017a). MHB-F plates
were prepared as described previously but erythromycin and clindamycin disks were
placed 12mm apart. A blunting, or ‘D-shaped’ zone around the clindamycin disk was
indicative of inducible resistance. Resistance phenotypes were characterised as
constitutive (cMLSB), inducible (iMLSB), M phenotype (erythromycin resistant,
clindamycin sensitive) or L phenotype (erythromycin sensitive, clindamycin
resistant). Minimum inhibitory concentration (MIC) testing of erythromycin and
clindamycin was performed using MIC Evaluator strips (Oxoid, Basingstoke, UK) and
interpreted according to EUCAST breakpoints (EUCAST, 2017b, 2019b).
2.3.3. DNA extraction from bacterial cultures
DNA was extracted using the PureLink Genomic DNA Kit (Invitrogen, ThermoFisher
Scientific, California, USA) with minor modifications, which included a mechanical
lysis of GBS by bead-beating using the MagNA DNA lyser (Roche, Indiana, USA).
Briefly, an overnight culture of GBS in Brain Heat Infusion broth (BHI, Cruinn
Diagnostics, Dublin, Ireland) was centrifuged at 6,500 rpm for 10 min. The
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supernatant was removed and the cell pellet was re-suspended in 1ml TE buffer. To
the washed cells, 470mg of glass beads (150-212 µm: Sigma-Aldrich, Ireland) were
added and samples were bead-beated at 6,500 rpm for 60 seconds. Samples were then
centrifuged at 13,000 rpm for 10 minutes. From each lysed sample, 240µl of
supernatant was removed and processed using the extraction and purification protocol
described by the manufacturer, beginning with the proteinase K digestion step.
2.3.4. Molecular characterization of antimicrobial resistance genes
A multiplex PCR assay was used to detect the presence of the erythromycin resistance
genes ermB and mefA/E, with inclusion of an S. agalactiae-specific internal control
targeting the cfb gene (Sutcliffe et al., 1996; Ke et al., 2000). Other genes involved in
promoting erythromycin resistance (ermTR and ermT) were detected by PCR as
previously described (De Azavedo et al., 2001; Compain et al., 2014). A multiplex
assay was performed to detect clindamycin resistance genes lsaC and lnuB (Bozdogan
et al., 1999; Malbruny et al., 2011). Additional clindamycin resistance genetic
determinants (lnuA, lsaB, lsaE and vgaC) were investigated by PCR according to
previous studies (Arana et al., 2014; Douarre et al., 2015). All PCR reactions were
performed using RedTaq® ReadyMix™ (Sigma-Aldrich, Ireland). The details of all
primers used and annealing temperatures are outlined in supplementary Table 2.1.
PCR products were analysed by 1% (w/v) agarose gel electrophoresis and visualised
using a geldoc viewing system (DNR Bioimaging systems, Israel). Selected amplicons
were sequenced and used as positive assay controls.
2.3.5. Capsular typing and ST-17 detection
All isolates were assigned serotypes according to the recommended PCR-based
capsular genotype algorithm of Yao et al., (2013). Briefly, isolates were initially
serotyped using two multiplex PCR reactions (Poyart et al., 2007) and any serotype
VII or non-typeable isolates were further identified by a one-step multiplex PCR
(Imperi et al., 2010). For the typing method described by Poyart et al., 2007, two mixes
were used; mix 1 contained primers for serotypes Ia-IV and the second mix contained
primers for V-VIII. For both PCR procedures, primers were used at a final
concentration of 0.4 µM. PCR conditions included an initial denaturation at 95oC for
5 min followed by 35 cycles of 95oC for 1 min, 52oC for 1 min and 72oC for 1 min
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followed by a final extension at 72oC for 10 min. Amplicons were resolved on a 1%
gel and analysed by gel electrophoresis.
For the one-step multiplex PCR described by Imperi et al., 2010, primers were used
at a concentration of 0.25 µM except for primers 1 and 16 which were used at 0.4 µM.
The samples were amplified by initial denaturation for 5 minutes at 95oC, followed by
15 cycles of 95 oC for 60 s, 54oC for 60 s and 72oC for 2 min followed by an additional
25 cycles of 95oC for 60 s, 56oC for 60 s and 72oC for 2 min and a final extension at
72oC for 10 min. PCR products were analysed on a 2% gel.
Detection of the hypervirulent ST-17 clone was performed using a modified version
of a multiplex PCR assay targeting a region of the hvgA gene (Gosiewski et al., 2012).
Primers were used at 0.4 µM and PCR conditions included an initial denaturation at
95oC for 5 min followed by 35 cycles of 95oC for 1 min, 52oC for 1 min and 72oC for
1 min followed by a final extension at 72oC for 10 min.
2.3.6. Statistical analysis
The χ2 test and Fisher’s exact test were used to analyse associations using SPSS v. 25.0
(IBM, UK). A P-value ≤0.05 was considered statistically significant.
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Table 2.1: Primers and PCR conditions used for the detection of antimicrobial resistance determinants in this study.
Targets

Primer sequence 5’-3’

cfb

F: TTTCACCAGCTGTATTAGAAGTA
R: GTTCCCTGAACATTATCTTTGAT
F: GAAAAGTACTCAACCAAATA
R: AGTAACGGTACTTAAATTGTTTA

ermB

Annealing temp. Amplicon size Reference
(oC)
(bp)
55
153
(Ke et al., 2000)
52

639

(Sutcliffe et al., 1996)

ermTR

F: GAAGTTTAGCTTTCCTAA
R: GCTTCAGCACCTGTCTTAATTGAT

57

400

(Desjardins et al., 2004)

ermT

F: AGATTGGTTCAGGGAAAGGTCA
R: AGGCTTGATAAAATTGGTTTTTGGA

62

540

(Compain et al., 2014)

mefA/E

F: AGTATCATTAATCACTAGTGC
R: TTCTTCTGGTACTAAAAGTGG

52

348

(Sutcliffe et al., 1996)

lnuA

F: GGTGGCTGGGGGGTAGATGT ATTAACTGG
R: GCTTCTTTTGAAATACATGGTATTTTTCGATC
F: CCTACCTATTGTTTGTGGAA
R: ATAACGTTACTCTCCTATTC
F: TGCCGAAGCCATGTACCGTCC
R: CGGTTAGACCAACCAGCCGAACG
F: GGCTATGTAAAACCTGTATTTG
R: ACTGACAATTTTTCTTCCGT

57

323

(Lina et al., 1999)

54

944

(Bozdogan et al., 1999)

55

396

(Gómez-Sanz et al., 2010)

55

429

(Malbruny et al., 2011)

F: CCGTATGCCCAGAGTGAGAT
R: TGCTTGGGAACAAGTCCTTC

58

671

(Fessler et al., 2010)

lnuB
lsaB
lsaC
vgaC

* S. agalactiae specific internal control.
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2.4. Results
2.4.1. Antimicrobial susceptibility
All study isolates (n = 253) were susceptible to penicillin and rifampicin. Resistance
to tetracycline, erythromycin and clindamycin (both constitutive and inducible) was
observed in 87.35% (n = 221), 22.53% (n = 57) and 21.3% (n = 54) of isolates
respectively (Figure 2.1). Differences in overall resistance rates were evident between
invasive (n = 51) and colonising (n = 202) isolates, with all but two of the former
group being resistant to tetracycline compared with 85.15% (n = 172) of colonisers.
Erythromycin resistance was significantly higher among invasive isolates (37.25%, n
= 19) than among colonising isolates (18.81%, n = 38; P = 0.008). Similarly,
clindamycin resistance rates were significantly higher among invasive isolates

Percentage resistance (%)

(33.3%, n = 17) than among colonising isolates (18.3%, n = 37; P = 0.034).
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Figure 2.1: Antibiotic resistance (percentage resistance, %) amongst Group B
Streptococcus (GBS) isolates in the total, invasive and colonising populations.
Tetracycline resistance was observed in 87.4%, 96.1% and 85.2% of the total, invasive and
colonising isolates. Erythromycin resistance was observed in 22.5%, 37.3% and 18.8% of the
total, invasive and colonising isolates. Clindamycin resistance was observed in 21.3%, 33.3%
and 18.3% of the total, invasive and colonising populations. Penicillin and rifampicin
resistance was not observed in any of the isolates tested.
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2.4.2. Macrolide resistance phenotypes and genotypes
In total, 57 isolates were resistant to erythromycin (n = 19 invasive; n = 38 colonising)
and of these, 61.4% (n = 35) exhibited the c-MLSB phenotype (n = 13 invasive; n =
22 colonising), while 21.1% (n = 12) were of the i-MLSB phenotype (n = 4 invasive;
n = 8 colonising) and 17.54% (n = 10) the M phenotype (n = 2 invasive, n = 8
colonising) (Table 2.2; Figure 2.2). The ermB gene was the most frequent determinant
detected (80.7%, n = 46) among macrolide resistant isolates, while ermTR and mefA/E
genes were each detected in 24.56% (n = 14) and 19.3% (n = 11) of isolates
respectively. A single isolate harboured the ermT gene but was also positive for the
ermB gene. One isolate harboured a combination of ermB and mefA/E genes, one
isolate was positive for both ermTR and mefA/E, and another isolate harboured ermB,
mefA/E and ermTR genes. The 35 isolates that exhibited the c-MLSB phenotype were
ermB positive and six of these (17.14%) also harboured the ermTR gene. The ermB
gene was detected in 10 of the 12 isolates displaying the i-MLSB phenotype, and five
of these isolates were also positive for the ermTR gene, with another isolate also
harbouring the ermT gene and two isolates harboured solely the ermTR gene. All M
phenotype isolates (n = 10) contained the mefA/E resistance determinant, with one of
these isolate being additionally positive for ermB and another additionally positive for
ermTR (Table 2.2). Figure 2.3 shows representative strains harbouring different
resistant determinants.
2.4.3. Characterizaton of the L phenotype
The rare L phenotype (erythromycin sensitivity, clindamycin resistant) was identified
in 2.77% (n = 7) of GBS isolates tested and confirmed by MIC susceptibility testing
(Table 2.3). MICs ranged from 0.5 – >256 µg/ml (MIC50 = 1 µg/ml, MIC90 = 256
µg/ml). Four of these isolates were positive for the the lsaC gene and the remaining
three isolates were negative for all genetic deteminants investigated. In this study the
L phenotype was detected only among colonising isolates.
Continued surveillance of L phenotype isolates resulted in an additional five isolates
being recovered for testing. Two of these isolates were serotype Ia, while the
remaining three were serotype III, with one being ST-17. Each of these isolates
harboured the lsaC gene and were negative for all other determinants. MICs for
clindamycin for these isolates were low, ranging from 0.5 to 1 µg/ml (Table 2.3).
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Interestingly, these isolates were recovered from various sources, including four
colonising isolates, but also one invasive isolate obtained from a blood culture sample
(Table 2.3).

Figure 2.2: Macrolide and lincosamide resistance phenotypes of Group B Streptococcus
isolates.
Ery, erythromycin; Da, clindamycin. (A) c-MLSB, constitutive resistance to erythromycin and
clindamycin; (B) i-MLSB, erythromycin resistance and inducible clindamycin resistance; (C)
M, erythromycin resistance and clindamycin susceptibility; (D) L, erythromycin susceptibility
and clindamycin resistance.
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Figure 2.3: Gel electrophoresis analysis of antibiotic resistance determinants.
Lane M, 100bp hyperladder (Bioline, Medical Supply Company, Ireland); lane 1, ermB with
cfb internal control; lane 2, mefA/E with cfb internal control; lane 3, erm T; lane 4, lsaC.
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Table 2.2: Genotypic and phenotypic characterisation of erythromycin resistant Group B streptococcal isolates.
Macrolide resistance phenotype
Invasive (n = 19)

Colonising (n = 38)

Phenotype (average zone diameter)

c-MLSB (

i-MLSB

M

c-MLSB

i-MLSB

M

Genotype (average zone diameter)

(n = 13)

(n = 4)

(n =2)

(n = 22)

(n = 8)

(n = 8)

ermB+, mefA/E-, ermTR-, ermT-

9

1

20

3

ermB+, mefA/E-, ermTR+, ermT-

3

1

2

4

ermB+, mefA/E-, ermTR-, ermT+

1

ermB+, mefA/E+, ermTR-, ermTermB+, mefA/E+, ermTR+, ermTermB-, mefA/E-, ermTR+, ermT-

1
1
2

ermB-, mefA/E+, ermTR-, ermT-

2

ermB-, mefA/E+, ermTR+, ermT-

6
1

c-MLSB, constitutive macrolide and lincosamide resistance; i-MLSB, inducible clindamycin resistance in the presence of erythromycin; M, resistance to
erythromycin only.
+ indicates isolate is positive for a genetic determinant; - indicates isolate is negative for a genetic determinant.
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Table 2.3: Characterisation of L phenotype isolates.
Isolate No.

Sample
origin

MIC (µg/ml)
Clindamycin

Erythromycin

Genetic

Serotype

determinant

CIT 278a

HVS

≥256

0.25

-

V

CIT 358 a

HVS

≥256

0.25

-

V

CIT 329 a

HVS

≥256

0.5

-

II

CIT 307 a

HVS

2

0.03

lsaC

III

CIT 405b

BC

2

0.03

lsaC

IIIc

CIT 244 a

HVS

1

0.03

lsaC

IIIc

CIT 340 a

HVS

1

0.03

lsaC

III

CIT 401 a

PS

1

0.03

lsaC

IIIc

CIT 402 b

SS

1

0.03

lsaC

Ia

CIT 404 b

US

1

0.03

lsaC

III

CIT 406 b

US

1

0.03

lsaC

III

CIT 403 b

HVS

0.5

0.03

lsaC

Ia

HVS, high vaginal swab; BC, blood culture; PS, placental swab; SS, semen sample; US, urine
sample. All isolates were screened for the presence of lnuA, lnuB, lsaB, lsaC, lsaE and vgaC
genetic determinants.
a

Part of epidemiological study.

b

Part of surveillance study.

c

Isolates of the ST-17 clone.
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2.4.4. Serotype distribution amongst GBS populations
Ten serotypes were identified among the total study collection, with one isolate nontypeable by both PCR methods. The most common serotypes were Ia (28.1%), III
(26.88%), II (13.44%), V (11.86%) and Ib (11.46%), and serotypes IV, VI, VII, VIII
and IX accounted for 3.95%, 1.19%, 1.58%, 0.79% and 0.4% of isolates, respectively.
Among colonising isolates, the predominant serotypes were serotypes Ia (29.7 %), III
(25.74%), II (115.35%), V (11.39%) and Ib (9.9%). However, the serotype distribution
for invasive isolates differed, with III (31.37%), Ia (21.57%), Ib (17.65%), V (13.73%)
and II (5.88%) being the most prevalent, but the difference between the two isolate
groups did not reach statistical significance (P = 0.198).
The hyper-virulent clone, ST-17, was identified in 15.42% (n = 39) of all isolates,
with rates of 31.37% (n = 16) and 10.89% (n = 22) in invasive and colonising
populations. All but one, of the ST-17 isolates were serotype III, indicating a
statistically significant association between serotype III and the hypervirulent clone
(P < 0.0005). The remaining isolate was confirmed by both PCR methods as serotype
IV.
Table 2.4 summarises the serotype distribution between neonatal and adult invasive
isolates and indicates a significant association between serotype III and neonatal
invasive disease (P < 0.0005). Four invasive adult isolates were serotype III and ST17, and another strain typed as serotype IV/ST-17 was also confirmed from an adult
sample. Of the 52 serotype III colonising isolates, 42.31% (n = 22) were ST-17.
Eleven of the sixteen invasive neonatal strains were serotype III. Conversely, only two
of the twenty-eight invasive adult strains belonged to this phenotype, whereas
serotypes Ia and Ib comprised 50% of this population.
Within the 57 isolates resistant to erythromycin, serotype III predominated (n = 19)
followed by serotype V (n = 12), Ia (n = 11), II (n = 6) and Ib (n = 4). Both serotypes
IV and VII were confirmed for two isolates each and serotype VI was identified in a
single isolate only. Serotypes VIII and IX were not detected within this population.
The majority of the 19 serotype III erythromycin resistant isolates expressed the cMLSB phenotype (89.47%, P = 0.0021) and all harboured the ermB gene. The cMLSB phenotype was also found in 8 of 12 serotype V isolates but these isolates
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harboured varied erythromycin resistance determinants (Table 2.5). Significant
associations were found between serotype Ia and the M phenotype (P = 0.0005) and
serotype Ia and the mefA/E gene (P = 0.00084). Serotype III predominated among the
erythromycin resistant invasive and colonising isolates (36.84% and 31.58%
respectively) and there was no significant difference in serotype distribution within
these two populations (P = 0.582). Seven of the 19 erythromycin resistant invasive
isolates were ST-17 and were also resistant to clindamycin; correspondingly, three
colonising isolates of the same resistance phenotype were members of the same ST17 clone.
In the study population four of the seven isolates exhibiting the L phenotype were
serotype III, two were serotype V and one was serotype II (Table 2.3). All four of the
serotype III L phenotype isolates harboured the lsaC gene and two were ST-17
positive. Of the L phenotype isolates identified as part of the prospective surveillance
study, two isolates were serotype Ia and three belonged to serotype III, with one of
these being ST-17 positive (Table 2.3). All five of these isolates harboured the lsaC
gene.
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Table 2.4: Correlation of sample origin and serotype distribution amongst invasive
and colonising isolates of Group B Streptococci.
Invasive
(n = 51)

Colonising
(n = 202)

Total
(n = 253)

Serotype

Neonatal
(n = 16)

Adult
(n = 28)

Unknowna
(n = 7)

HVSb
(n = 201)

Ia

2

7

2

60

71

7

2

20

29

31

34

Ib
II

1

2

III

11f100

4f100

1f100

2f50

IV
V

1

VI

1

5

1

VII
VIII
IX

1

51f41.2

b

High vaginal swab; c placental swab.

f

Percentage of ST-17 isolates within group.

68f55.9
10f10

23

30

2

3

4

4

1

2
1

NT
Lack of clinical information.

1f100

8

1

a

PSc
(n = 1)

1

100

1

Table 2.5: Correlation between serotype, phenotype and genotype of Group B
Streptococcus isolates.
Serotype

Phenotype

Genotype

c-MLSB (3)

erm B (2), ermB+ermTR (1)

i-MLSB (2)

ermTR (2)

M (6)

mefA/E (5), ermB+mefA/E (1)

c-MLSB (2)

ermB (2)

i-MLSB (2)

ermB (1), ermB + ermTR (1)

c-MLSB (3)

ermB (3)

i-MLSB (3)

ermB + ermTR (2), ermB + ermT (1)

(No. of
isolates)
Ia (11)

Ib (4)

II (7)

L (1)
III (23)

IV (2)

V (14)

c-MLSB (17)

ermB (14), ermB + ermTR (2), ermB + ermTR + mefA/E (1)

i-MLSB (2)

ermB (2)

L (4)

lsaC (4)

c-MLSB (1)

ermB + ermTR (1)

i-MLSB (1)

ermB (1)

c-MLSB (8)

ermB (7), ermB + ermTR (1)

i-MLSB (2)

ermB + ermTR (2)

M (2)

mefA/E (2)

L (2)
VI (1)

c-MLSB (1)

ermB (1)

VII (2)

M (2)

mefA/E (1), mefA/E + ermTR (1)
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2.5. Discussion
Despite recent reports of reduced beta-lactam susceptibility among GBS isolates
(Kimura et al., 2008; Morozumi et al., 2016; Gizachew et al., 2019a), data from this
epidemiological study, conducted from 2010-2016, indicate that susceptibility to
penicillin is universal amongst GBS populations in Ireland. This reaffirms the
appropriateness of penicillin as the antibiotic of choice for first line IAP and for the
treatment of GBS infections in Ireland. The incidence of erythromycin resistance
found (22.53%) is similar to previous studies conducted in Ireland (18.6%), Poland
(18.4%), Spain (20.7%), Serbia (23.1%) and Malaysia (23.3%) (Sadowy et al., 2010;
Meehan et al., 2014; Eskandarian et al., 2015; López et al., 2018; Gajic et al., 2019).
Higher rates have been reported in France (34.7%), Italy (43.75%), China (74.1%) and
Taiwan (46%) (Hsueh et al., 2001; Bergal et al., 2015; Lu et al., 2016; Matani et al.,
2016). Interestingly the rate of clindamycin resistance in the current study indicates
that resistance has increased in the Irish population from 15.25% (Meehan et al., 2014)
to 21.3 %. While our reported rate is similar to some countries, including France
(22.1%) and Spain (17.6%) (Compain et al., 2014; López et al., 2018), worryingly, it
is higher than reports from other countries, including Brazil (2%), Morocco (7%),
Poland and Africa (0%) (Sadowy et al., 2010; Belard et al., 2015; Botelho et al., 2018;
Moraleda et al., 2018). As with other countries, a high rate of tetracycline resistance
(87.35%) was evident for the isolates reported here (Sadowy et al., 2010; Bergal et al.,
2015; Botelho et al., 2018).
Colonising GBS isolates can be reservoirs of virulence and antibiotic resistance
markers, and vaginal colonisation is a major risk factor for subsequent invasive disease
in neonates. In this study erythromycin and clindamycin resistance are statistically
significantly higher among invasive isolates compared to colonising isolates (P =
0.008 and P = 0.034 for erythromycin and clindamycin respectively). This has been
observed in other studies, namely in Spain and the USA (Borchardt et al., 2006; López
et al., 2018)
Regarding antibiotic resistance mechanisms, the c-MLSB phenotype predominated
overall (61.4%) and was more frequent among invasive isolates (68.4%) than
colonising isolates (57.9%). The ermB gene was the most common resistance
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determinant identified (80.7%) which is in agreement with another recent Irish study
(Meehan et al., 2014). Interestingly, in 2010, Kiely et al reported that ermTR was the
most common resistance determinant amongst GBS isolates (Kiely et al., 2010). In
the current study the presence of the ermT gene, although only in a single isolate, is
notable as it was associated with the i-MLSB phenotype. This detection of this
determinant may be important as it is plasmid-borne and has been shown to be readily
transferable between GBS and Enterococcus faecalis, which could promote its wider
dissemination (Compain et al., 2014). It is interesting to note the co-occurrence of
ermB and ermTR genes in eight isolates and mefA/E and ermTR genes in another
isolate. Co-occurrence of resistant determinants has also been noted in other studies,
although in a lower number of isolates (Sadowy et al., 2010; Seo et al., 2010; Metcalf
et al., 2017). Currently, studies do not report any associations between resistance
phenotype and MIC levels; however, going forward this data would be useful for
clinical practise.
The L phenotype was first documented in E. faecium in 1999 (Bozdogan et al., 1999)
and was followed shortly after by the first report in a GBS strain in Canada in 2001
(De Azavedo et al., 2001). Since then there have been reports of the L phenotype in
Spain (Arana et al., 2014), Korea (Seo et al., 2010), the US (Gygax et al., 2006),
Argentina (Faccone et al., 2010), China (Lu et al., 2016) and South Africa (Bolukaoto
et al., 2015) with incidence rates varying from 0.26% in Italy (Rojo-Bezares et al.,
2016) to 15.9% in Korea (Seo et al., 2010). Recent studies in China have also reported
isolates resistant to clindamycin but susceptible to erythromycin. In their study Wu et
al., (2019) reported that the lnuB gene was present in 22.22 % of strains, collected
over the period 2008-2015, and the determinant was detected in neonatal invasive,
neonatal colonising and maternal colonising isolates. In another Chinese study three
L phenotype isolates harbouring the lnuB gene were reported, and interestingly, the
determinant was located within a multi-drug resistance cluster flanked by a mobile
element in two of these isolates, suggesting the potential for dissemination of multidrug resistance among GBS strains (Zhou et al., 2019). A Korean study also recently
characterised three clindamycin resistant GBS isolates harbouring the lnuB gene, but
also possessing the ermB gene, despite being erythromycin sensitive. Further analysis
revealed amino acid substitutions suggesting loss of function of the methylase (Moroi
et al., 2019). The L phenotype in GBS strains has not been previously reported in
103

Ireland but was found in this study to represent 2.77% of isolates which, interestingly,
were collected in the latter part of the study period (2015-2016). A further five isolates
exhibiting this phenotype were identified during the period of 2016-2018 as part of a
prospective screening.
Overall, nine of the twelve L phenotype isolates harboured the lsaC gene, seven of
which were serotype III and two were serotype Ia. This observation concurs with
reports from previous studies where serotype III was the most common serotype
among L phenotype isolates (Malbruny et al., 2011; Arana et al., 2014; Björnsdóttir
et al., 2016; Hawkins et al., 2017). Moreover, the three remaining isolates of this
phenotype, with an MIC for clindamycin >256 g/ml, were negative for all
determinants tested including the lnu A, lsaB, lsaC, lsaE and vgaC genes. Two of these
isolates were confirmed as serotype V and the other was serotype II. Interestingly, a
US study also identified isolates with extremely high MICs for clindamycin (>256
g/ml) for which no genetic determinants could be detected through whole genome
sequencing and resistance databases. This suggests a potentially new mechanism of
resistance may be occurring for which no known determinant exits. Future studies to
elucidate this unusual mechanism of resistance is being carried out by Metcalf and
colleagues. To the best of our knowledge, this is the first documented report of GBS
isolates in Ireland with the L phenotype and characterised as containing the lsaC gene.
Although the L phenotype was predominantly identified in colonising isolates in this
study (11 out of the 12 isolates), it has been found in patients with invasive GBS
disease (Malbruny et al., 2011; Björnsdóttir et al., 2016). Also of interest, three of the
twelve isolates were confirmed as belonging to the hypervirulent ST-17 clone. The
emergence of this rare phenotype in Irish GBS strains corroborates the need for
continued surveillance of emerging antibiotic resistance, as recently reported by
Hawkins et al., (2017). This USA study also revealed the presence of L phenotypes
with cross-resistance to streptogramin A and pleuromutilins, the LSA/LSAP
phenotypes, which have also been reported elsewhere (Malbruny et al., 2011;
Björnsdóttir et al., 2016). Another recent study using whole genome sequencing to
identify resistance mechanisms in GBS, identified the LSA/LSAP phenotypes and
highlighted the co-occurrence of certain genes, particularly lsaC and ermB, amongst
isolates displaying this phenotype (Metcalf et al., 2017). While we did not specifically
investigate the LSA/LSAP phenotypes in the current study, they may be clinically
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significant going forward and thus warrant further study and surveillance.
Furthermore, the RCOG updated their guidelines, as of September 2017, to no longer
recommend the use of clindamycin in therapy due to the high levels of resistance being
detected (Hughes et al., 2017) therefore strengthening the need for continued
surveillance of resistance rates.
Here, nine serotypes were confirmed among the study collection and only one isolate
proved non-typeable by both PCR methods used. Overall, serotype Ia predominated
(28.1%), followed by types III, II and V. This distribution is comparable with a
previous Irish study (Meehan et al., 2014) and indicates a level of stability within the
Irish GBS population. Serotype IV was present in 3.95% of isolates, which is lower
than previously reported for Ireland (Kiely et al., 2011). Serotype IV has been
recognised as a cause of invasive GBS disease (Teatero et al., 2015) and is now also
commonly found amongst colonizing isolates (Teatero et al., 2017). In contrast to the
study reported by Meehan et al., (2014) serotype IV was found in both invasive and
colonizing isolates in the current study. This suggests that serotype IV would be an
important serotype to include in potential future vaccine development. Serotype III
was also predominant among erythromycin-resistant isolates in contrast to a previous
study in the South of Ireland where serotype V was more frequently associated with
erythromycin-resistant strains (Kiely et al., 2010). Serotype III was the most common
among invasive neonatal strains, which corresponds to worldwide frequencies
(Russell et al., 2017). For invasive adult infections, serotype Ia and Ib together
comprised 50% of the serotypes detected which is similar to recent studies (Seale et
al., 2017). This difference between serotype distribution among neonatal and adult
infections has been reported in the literature and is likely due to different sources of
infection between the two populations.
The ST-17 lineage accounted for 15.42% of all isolates studied with rates of 33.33%
and 10.68% in the invasive and colonising populations respectively. The high
prevalence of this clone in the latter group is of particular concern because of its
potential to progress to invasive disease, thus highlighting the importance of
monitoring reservoirs of colonising GBS strains. Eleven of the ST-17 invasive isolates
were of neonatal origin and serotype III, and five were from invasive adult infections,
but of different serotypes (III and IV) which may suggest the occurrence of capsular
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antigen switching as reported in other studies (Bellais et al., 2012; Meehan et al.,
2014). Capsular switching among GBS strains has been associated with a switch from
serotype IV to III via entire replacement of the cps operon (Bellais et al., 2012). The
detection of strains capable of replacing their capsule even before the introduction of
a vaccine highlights the strong potential for GBS to undergo capsule switching or
replacement post-vaccine implementation. Together, these findings serve to
emphasise the need for continuous surveillance of serotypes, which is highly relevant
to the development of future vaccines (Dzanibe and Madhi, 2018).
In conclusion, the increase in resistance to erythromycin and clindamycin in GBS
strains is of significance, particularly for individuals with penicillin allergies. While
current guidelines adhered to in Ireland no longer recommend the use of clindamycin,
future implementation of screening policies may see it’s reintroduction and therefore
monitoring and exploring resistance in GBS populations is important. Furthermore,
combination therapies as a strategy to combat antibiotic resistance as focussed on the
use of erythromycin and clindamycin therefore resistance among GBS strains is
significant. The emergence of the L phenotype in the Irish GBS population is a concern
and warrants continued surveillance of resistance rates and further elucidation of the
underlying genetic mechanisms.
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2.7. Supplementary information

Figure S2.1: Molecular serotyping of Group B Streptococcus isolates.
(A) Molecular detection of GBS capsular serotypes Ia-VIII according to Poyart et al., 2007.
M1, 1 kb hyperladder (Bioline, Medical Supply Company, Ireland); M2, 100bp hyperladder
(Bioline, Medical Supply Company, Ireland); N, negative control. (B) Molecular detection of
GBS serotypes Ia-IX according to Imperi et al., 2010. M, 100bp hyperladder (Bioline, Medical
Supply Company, Ireland); N, negative control.
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Chapter III

Investigation of nisin and bioengineered nisin
derivatives for use against clinical GBS strains.
___________________________________________________

Published in the Journal of Global Antimicrobial Resistance.
Hayes K, Field D, Hill C, O’Halloran F and Cotter L (2019) A novel bioengineered
derivative of nisin displays enhanced antimicrobial activity against clinical
Streptococcus agalactiae isolates. Journal of Global Antimicrobial Resistance 19, 14–
21.
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3.1. Abstract
Group B Streptococcus (GBS) is the leading cause of neonatal disease worldwide and
infections caused by this opportunistic pathogen are becoming increasingly more
prevalent in adults. With the global incidence of antibiotic resistance continuing to
rise, there is a recognised need for new therapeutic agents. Nisin is a potent
antimicrobial peptide that has demonstrated broad spectrum activity against a range of
clinically significant pathogens. This study aimed to examine the efficacy of nisin and
26 bioengineered derivatives against a clinical population of GBS strains. A deferred
antagonism assay was initially used to assess the bioactivity of wild type nisin and the
derivatives against n = 17 GBS strains. MICs were then evaluated to determine the
specific activity of wild type nisin and two of the derivatives that displayed enhanced
activity against the strains, designated nisin PV and nisin PGA. Subsequently, the
activities of nisin and nisin PV were screened against a larger bank of clinical GBS
strains (n = 122). The genetic basis of nisin resistance among the collection of strains
was investigated by PCR detection of the nsr and nsrFP genes. In total 91% of the
collection showed some level of susceptibility to nisin (displaying zones of inhibition)
while 9% displayed complete resistance (no zones of inhibition). Interestingly, nisin
PV exhibited enhanced antimicrobial activity for 64.8% of isolates according to the
deferred antagonism assay. An MIC50 of 20.1 µg/ml and 6.3 µg/ml was established for
nisin A and nisin PV respectively. The frequency of the nsr gene, which confers nisin
resistance, was also investigated and the gene was detected in 98.4% of isolates
suggesting that resistance may be linked to levels of expression of the protein or other
regulatory elements. This study indicates that there is potential for use of nisin and its
derivatives as therapeutic agents against GBS infections.
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3.2. Introduction
Group B Streptococcus is a frequent coloniser of the gastrointestinal and genitourinary
tracts of healthy adults. It remains a leading cause of neonatal disease and invasive
disease amongst adults is becoming more prevalent (Lamagni et al., 2013). Penicillin
is an effective antimicrobial agent for treating GBS infections, however, there have
been reports of reduced susceptibility to this antibiotic (Chu et al., 2007; Dahesh et
al., 2008; Kimura et al., 2008). In addition, resistance to previously used second line
antibiotics, used in cases of penicillin-allergies, continues to rise (Lamagni et al.,
2013). Current guidelines adopted by Irish hospitals advise the use of vancomycin in
the case of penicillin allergy, and there have been two reported cases on vancomycin
resistant GBS strains in the US (Srinivasan et al., 2014). Indeed, as the burden of
antibiotic resistance increases globally, there is a need for alternatives to
conventionally used antibiotics, for use as novel therapeutics within a clinical setting.
Bacteriocins are small, ribosomally synthesised antimicrobial peptides produced by
many Gram-positive bacteria (Cotter et al., 2005). Within the bacteriocin family, a
large subgroup called lantibiotics (class I bacteriocins) have been identified, which
undergo extensive post-translational modifications (Bierbaum et al., 1996; Breukink
and de Kruijff, 1999; Chatterjee et al., 2005). Lantibiotics contain unusual amino
acids, dehydro-alanine and dehydro-butyrine, formed by the dehydration of serine and
threonine residues which then link covalently to cysteine thiols to form (methyl)lanthionine rings (Chatterjee et al., 2005). Lantibiotics are characterised by the
formation of these lanthionine rings which stabilize the peptide, protect it from
proteolytic activity and importantly, ensure high antimicrobial activity.
Nisin, produced by Lactococcus lactis, is the most extensively characterised lantibiotic
(Rogers and Whittier, 1928; Mattick et al., 1947) and has demonstrated antimicrobial
activity against a wide variety of bacteria, including methicillin-resistant
Staphylococcus aureus (MRSA) (Okuda et al., 2013), Clostridium difficile (Bartoloni
et al., 2004) and Listeria monocytogenes (Ferreira and Lund, 1996), with MIC ranging
from 4.2-8.4 mg/L, 0.032-1 mg/L and 200-1000 mg/L for each of the bacteria,
respectively. Nisin is a 34-amino acid peptide with five structural rings, including one
lanthionine and four methyl-lanthionine rings (Chatterjee et al., 2005). The first three
rings (A-C) are located at the N-terminus and are separated from the last two rings (D
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and E) by a hinge region (Figure 3.1) (Lian et al., 1992; Wiedemann et al., 2001).
Active nisin exerts its antimicrobial dual-action by the initial binding of the A-C rings
to lipid II, a bacterial peptidoglycan and an important precursor in cell wall synthesis.
Nisin uses lipid II as a docking molecule and then employs its hinge region to flip into
the membrane bilayers, where rings D and E perforate the bacterial cell membrane
(Breukink and de Kruijff, 1999; Wiedemann et al., 2001; van Heusden et al., 2002;
Hsu et al., 2002, 2004; Hasper et al., 2004). While nisin is not currently licensed for
use in a clinical setting, it has proven to be a viable option in many studies. Specific
to GBS, the administration of nisin through an IV regimen for IAP could be
considered. Nisin has demonstrated bactericidal activity against various pathogens and
therefore would lend itself useful for rapid killing of GBS required during IAP
administration. Furthermore, nisin has been proven to be non-toxic against various
human cell lines at various concentrations and proven safe for use in an iv regimen at
20 mg/kg (Goldstein et al., 1998; Aranha et al., 2008; Shin et al., 2015; Dreyer et al.,
2019; Mouritzen et al., 2019).
Resistance to nisin is infrequently reported, however some clinically relevant bacteria
exhibit innate resistance, through cell wall modifications and biofilm formation
(Draper et al., 2015). Resistance can also occur through the presence of two
component systems (TCS) linked to ABC transporters and through the presence of
nisin resistance proteins (NSRs) (Draper et al., 2015). Froseth and McKay (1991)
identified a nisin resistance protein in the Lactococcus lactis subsp. lactis biovar
diacetylactis DRC3 strain and confirmed that the encoding nsr gene was contained on
a plasmid (Froseth and McKay, 1991). Further studies revealed that the mode of action
of the NSR protein involves proteolytic cleavage of nisin at the C-terminus, mediated
by a conserved tail-specific protease domain (Chatterjee et al., 2005; O’Driscoll et al.,
2006). NSR cleaves nisin at residues MeLan-28 and Ser-29 generating a truncated
nisin (nisin1-28) with reduced affinity for the cell membrane and subsequently reduced
antimicrobial activity (Sun et al., 2009).
Recently, a gene encoding a nisin resistance protein (nsr) was discovered in the S.
agalactiae reference strain ATCC 13813 and was shown to confer resistance to nisin
when expressed in L. lactis (Khosa et al., 2013). The nsr gene in GBS was found to
be part of a conserved operon that encodes six proteins which include a lipoprotein,
an NSR protein, an ABC transporter designated NsrFP, a response regulator denoted
112

NsrR and a histidine kinase NsrK. The histidine kinase and response regulator are part
of a TCS that regulates the expression of both the NSR and the ABC transporter, which
cleave nisin and export nisin out of the cell respectively (Khosa et al., 2013; Reiners
et al., 2017). The expression of NSR in GBS is thought to be under tight regulation by
a TCS and is conditional upon the amount of external nisin (Khosa et al., 2013).
Several natural variants of the originally described nisin A exist, including nisin F (de
Kwaadsteniet et al., 2008), nisin H (O’Connor et al., 2015), nisin P (Zhang et al.,
2012), nisin U and U2 (Wirawan et al., 2006) and nisin Z (Mulders et al., 1991). These
variants highlight the ability of the peptides to withstand amino acid and domain
changes. As therapeutic agents, this is an attractive attribute of lantibiotics as their
proteinaceous structure is easily modified and changing a single residue can
significantly alter their biological function by increasing their potency and stability as
well as potentially improving their pharmacokinetic properties (Cotter et al., 2013).
Successful bioengineering of nisin was first observed with nisin Z mutants (T2S,
M17Q and G18T) exerting activity against non-pathogenic bacteria (Kuipers et al.,
1996). This prompted the creation of a large bank of derivatives through
bioengineering strategies and several nisin derivatives with altered amino acids have
subsequently been created through site specific and site saturation mutagenesis
techniques (Table 3.1) (Field et al., 2008; Healy et al., 2013; Field et al., 2015a).
Importantly, many of these bioengineered derivatives of nisin have been shown to
display enhanced antimicrobial activity against a variety of Gram positive and Gramnegative pathogens (Field et al., 2008, 2010, 2012; Healy et al., 2013).
The first bioengineered variants of nisin demonstrated to display activity against
pathogenic bacteria were nisin Z mutants N20K and M21K which exhibited activity
against Shigella, Pseudomonas and Salmonella with MICs ranging from 9 -13 µg/ml
(Yuan et al., 2004). Bioengineered nisin A variants were later determined to exert
activity against Gram positive pathogens (Field et al., 2008, 2010), with one variant
in particular, nisin V, displaying enhanced activity against clinically relevant bacteria
including methicillin-resistant Staphylococcus aureus (MRSA) (MIC 0.26 µg/ml) ,
vancomycin-resistant Enterococci (VRE) (MIC 1 µg/ml), Clostridioides difficile (MIC
4.19 µg/ml )and Listeria monocytogenes (MIC 6.28 µg/ml) (Field et al., 2008, 2010).
Subsequently, nisin A variants were identified with enhanced activity against Gram
positive and negative pathogens (Field et al., 2012). Site-saturation mutagenesis of the
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S29 residue revealed mutants, in particular S29A and S29G, with enhanced activity
against Gram positive pathogens including MRSA, L. monocytogenes, Streptococcus
mitis and Gram negative bacteria Cronobacter sakazakii, E. coli 0157:H7 and
Salmonella with MICs ranging from 0.26 – 6.28 µg/ml (Field et al., 2012). Mutations
at other residues have also resulted in improved antimicrobial activity and sitesaturation mutagenesis of Lysine12 identified the K12A variant as having enhanced
activity compared to wild type nisin against Streptococcus, Bacillus, Enterococcus
and Staphylococcus species (Molloy et al., 2013). The hinge region of nisin has been
extensively studied as a ‘hot-spot’ for mutagenesis (Rouse et al., 2012; Healy et al.,
2013) and the length of the hinge region was determined to have an effect on activity
in a strain specific manner (Zhou et al., 2015). Randomly created hinge mutants were
screened to identify variants with superior antimicrobial activity compared to wild
type nisin. This prompted the specific design of triple mutations and complete
replacement of the hinge region, resulting in variants designated AAA and SAA which
showed enhanced activity against S. agalactiae, L. lactis HP, Mycobacterium
smegmatis, S. aureus (Healy et al., 2013). Another nisin derivative with mutations of
the hinge region is nisin PGA, whereby the natural hinge region of residues asparagine,
methionine and lysine are altered to proline, glycine and alanine (Table 3.1; Figure
3.1). This particular variant has not previously been examined for enhanced
antimicrobial activity compared to wild type nisin.
The success of nisin bioengineering stimulated the design of nisin derivatives with
specific functions. This strategy was applied to identify derivatives of nisin that could
resist proteolytic cleavage by NSRs and design a novel nisin peptide that could combat
nisin resistance (Field et al., 2019). It is known that the NSR cleaves nisin at the
specific residues MeLan-28 and Ser-29 (Figure 3.1), thus these specific residues were
altered in an attempt to prevent cleavage. The amino acid serine-29 was altered alone
and in combination with isoleucine-30 to identify amino acid substitutions that would
result in enhanced activity. A serine to proline substitution (Ser-29→Pro) combined
with an isoleucine to valine (Ile-30→Val) substitution resulted in a novel nisin
derivative, designated nisin PV, that was engineered to prevent cleavage by NSR
proteins (Figure 3.1) (Field et al., 2019). The resistance to cleavage was assessed using
peptide release assays whereby both wild type nisin and nisin PV were incubated with
L. lactis DRC3 cells expressing NSR. Following incubation, RP-HLPC detected a
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truncated nisin1-28 whereas nisin PV remained intact indicating it had not been cleaved.
Furthermore, simulation studies demonstrated that NSR can still bind to nisin PV, but
cannot cleave it (Field et al., 2019).
This study aimed to investigate the level of susceptibility to nisin amongst a clinical
collection of GBS strains. Additionally, we sought to identify bioengineered nisin
derivatives with enhanced antimicrobial activity against the isolates. The specific
activity of one such derivative, nisin PV, was further investigated to determine if it
could combat potential nisin resistance conferred by the NSR protein.
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Figure 3.1: Schematic of the amino acid structures of peptides used in this study.
(A) Nisin A showing where cleavage by the NSR protein occurs; (B) Nisin PGA showing
amino acid substitutions in the hinge region; (C) Nisin PV showing substitutions at the site of
cleavage by NSR
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Table 3.1: Bioengineered nisin derivatives and their associated amino acid substitutions.
Nisin variant
Wild type
(Nisin A)
PV
K12S
M17Q
S29G
PAQ
M21L
PIT
K12T
G18T
H31K
S29R
K12A
I4V
AAA-S29A
K22M
T2L
S29D
K22T
M21V
S29A
SVA
HTK
N20P
AAA
PGA
M21A

Nisin A amino acid sequence and highlighted amino acid substitution in nisin variant
1 2 3 4 5 6 7
8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 3031 32 33 34
I Dhb Ala I Dha L Ala Abu P G Ala K Abu G A L M G Ala N M K Abu A Abu Ala H Ala S I H V Dha K
PV
S
Q
Q
P A Q
L
P I T
T
T
K
R
A
V
A A A
A
M
L
D
T
V
A
S V A
H T K
P
A A A
P G A
A
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3.3. Materials and methods
3.3.1. Bacterial strains and growth conditions
GBS strains (n = 122) were collected over a 6-year period (2010-2016) from Cork
University Hospital and University Hospital Limerick. Invasive isolates (n = 47) were
obtained from blood culture samples while colonising isolates (n = 75) were obtained
from high vaginal swab samples. GBS strains were grown in brain heart infusion broth
(BHI, Cruinn, Ireland) or Todd-Hewitt broth (THB, Sigma-Aldrich, Ireland) and
incubated aerobically at 370C. Lactococcus lactis (L. lactis) strains were cultured in
M17 broth (Sigma-Aldrich, Ireland) supplemented with 0.5% glucose (GM17) or on
GM17 agar plates and incubated at 300C. The nisin A and derivative-producing L.
lactis strains (Table 3.2) were grown in either GM17 broth or on GM17 agar plates
containing 10 g/ml chloramphenicol and incubated at 300C.

Table 3.2: Bacterial strains used in this study.
Strain
L. lactis NZ9700

Relevant characteristics
Wild type nisin producer
(nisin A)

Reference
(Kuipers et al.,
1993)

L. lactis
NZ9800pCI-S29PV

Nisin derivative producer (nisin PV)

(Field et al.,
2019)

L. lactis
NZ9800pCI-PGA

Nisin derivative producer (nisin PGA)

Unpublished
data

L. lactis subsp.
diacetylactis DRC3

Carries nsr gene on plasmid pNP40

(Froseth and
McKay 1991)

L. lactis
MG1614pNP40

Carries nsr gene on plasmid pNP40

(O’ Driscoll et
al., 2006)

S. agalactiae
ATCC13813

Reference strain, carries nsr gene

(Khosa et al.,
2013)

GBS
(n = 47)

Invasive isolates from blood culture
samples

(Hayes et al.,
2017)

GBS
(n = 75)

Colonising isolates from high vaginal
swabs

(Hayes et al.,
2017)

118

3.3.2. Deferred antagonism assay
The antimicrobial activity of wild type nisin and the nisin derivatives (n = 26) was
initially investigated against n = 17 clinical GBS strains chosen at random and the
reference S. agalactiae ATCC 13813 strain using a deferred antagonism assay
described by Field et al., (2010). Fresh overnight cultures of each L. lactis bacteriocinproducing strain were spotted onto large GM17 agar plates using a 48 pin replicator
and incubated overnight at 30oC before being exposed to UV radiation for 45 minutes.
The plates were then overlayed with 0.75% BHI agar (0.75% w/v) seeded with 0.2%
GBS and incubated overnight at 37oC. Any resulting zones of inhibition were
measured the following day.
Based on data from preliminary screening assays, nisin PV was selected for further
analysis. The deferred antagonism assay was then performed using wild type nisin and
nisin PV for a larger bank of n = 122 GBS strains. These GBS strains were chosen to
reflect the different serotypes and antibiotic resistance profiles identified in a previous
epidemiological study (Hayes et al., 2017). L. lactis subsp. diacetylactis DRC3 and L.
lactis pNP40 were used as control strains for enhanced activity of nisin PV. The assay
was performed as described above, however, only fresh overnight cultures of L. lactis
strains producing nisin A and nisin PV were spotted (5 l) onto GM17 agar plates and
incubated overnight at 30 0C, and UV exposure was carried out for 30 minutes. The
plates were then overlayed with 0.75% w/v agar (GM17 for L. lactis and BHI for GBS)
that were seeded with the indicator strains at 0.2%. Plates were incubated overnight at
appropriate conditions, 30oC for L. lactis and 37oC for GBS strains. The resulting
zones of inhibition were measured to identify how sensitive the isolates were to both
compounds. As there are no standardized cut-off points for lantibiotic resistance, we
evaluated this collection as having enhanced, equal or decreased susceptibility to nisin
PV when compared to the nisin A. Zones of inhibition were measured and an increase
in zone size was considered as enhanced susceptibility, as observed in other studies
(Field et al., 2010, 2012). When there was no zone of inhibition, isolates were
identified as resistant to the peptides.
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3.3.3. Nisin purification
The wild type peptide nisin A was purified according to published methods (Field et
al., 2010). Briefly, two litres of modified Tryptic Yeast (TY) broth (Oxoid) were
inoculated with 1% fresh culture of L. lactis NZ9700 (producing nisin A) and then
incubated at 300C overnight. The following day the culture was centrifuged at 7000
rpm for 15 minutes and the supernatant was passed through a 60g column of preequilibrated Amberlite XAD16 beads (Sigma-Aldrich, Ireland) to collect the peptide.
The beads were then washed in 30% ethanol and the peptide was eluted with 70%
isopropyl alcohol (IPA) containing 0.1% triflouroacetic acid (TFA). The original cell
pellet was resuspended in 300 ml of 70% IPA:0.1% TFA solution and stirred at room
temperature for 3 hours, before centrifuging at 7000 rpm for 15 minutes. This
supernatant was combined with the eluted supernatant and IPA was evaporated using
a rotary evaporator (Buchi, Switzerland). The sample was then adjusted to pH 4 and
applied to a 60 ml Varian C-18 Bond Elut Column (Varian, Harbor City, CA) that had
been pre-equilibrated with methanol and water. Following this, 120 ml of 30% ethanol
was used to wash the column and the peptide was eluted in 60 ml of 70% IPA:0.1%
TFA. Ten millilitre aliquots were concentrated to volumes of 2 ml by rotary
evaporation and purified by HPLC using a Phenomenex C12 reverse-phase HPLC
column (Jupiter 4u proteo 90 A, 250 X 10.0mm, 4 µM). The column was developed
in a gradient of 30-50% acetonitrile:0.1% TFA. The relevant fractions were pooled
and acetonitrile was removed using rotary evaporation before the sample was freezedried (LABCONCO).
The nisin derivatives, nisin PGA and nisin PV were purified by the same protocol but
using the L. lactis NZ9800N20PGA (nisin PGA producer) and L. lactis
NZ9800S29PV (nisin PV producer) strains.

3.3.4. Minimum Inhibitory Concentration Assays
Minimum inhibitory concentrations (MIC) of nisin A, nisin PV and nisin PGA were
determined as described by Field et al., (2010). Initially, 96 well microtitre plates
(Sarstedt) were pre-treated with 200 l of phosphate buffered saline (PBS; SigmaAldrich, Ireland) containing 1% (w/v) BSA and incubated at 370C for 30 minutes,
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before washing with 200 l PBS. When dry, 100 l of fresh THB was added to each
test well. Purified nisin A, nisin PGA or nisin PV was added to the first well (100 l)
and 2-fold serial dilutions of each peptide were made, resulting in 12 dilutions, ranging
from 7.5 M to 0.0036 M. Overnight cultures of test GBS strains were sub-cultured
into fresh THB (10 ml) and grown to an OD600 of 0.5, before adjusting to a
concentration of 106 cfu/ml. From each test culture 100 l was then transferred into
each test well, resulting in a final concentration of 5 X 105 cfu/ml. Plates were
incubated at 370C for 16 hours. The MIC was defined as the lowest peptide
concentration causing visible inhibition of growth. Experiments were performed in
triplicate.
3.3.5. Growth Curves
GBS strains were grown overnight in THB at 37C and diluted to an OD600 of 0.05 in
fresh THB broth supplemented with nisin A or nisin PV, using equimolar
concentrations of peptides at approximately one-third the MIC of nisin A (Field et al.,
2010). Following this, 200 l of each culture was added to a 96 well plate and cell
growth

was

monitored

spectrophotometrically

at

600nm

(SpectraMax

spectrophotometer) over a 24-hour period at 370C. The assay was performed in
triplicate for all test isolates.
3.3.6. PCR investigation of nisin resistance genes, nsr and nsrFP
The presence of the nisin resistance (nsr) gene was investigated in each GBS study
isolate using a novel PCR assay with the following primer pair: nsrFor 5’and

CTGGCGGCAATATGATCCCT-3’

nsrRev

5’-

AGCACCGTCGTAAAGCATGA-3’. Briefly, primers were designed using the NCBI
Blastn software (https://blast.ncbi.nlm.nih.gov/Blast.cgi) with the S. agalactiae ATCC
13813 nsr gene as the query sequence to retrieve homologous sequences from other
GBS genomes. All homologous sequences were aligned using MUSCLE software
(https://www.ebi.ac.uk/Tools/msa/muscle) and a consensus sequence was generated.
Primers were designed from this sequence using Primer3 software using default
parameters. Bacterial DNA was extracted from all GBS strains used in this study as
previously described (Hayes et al., 2017). PCR amplification was carried out in a final
volume of 25 l, using 12.5 l REDTaq® ReadyMix™ (Sigma-Aldrich, Ireland), with
0.4 M of each primer and 100 ng template DNA. The thermocycler conditions were
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as follows: initial denaturation at 95 C for 3 min, 35 cycles of 95 C for 1 min, 50 C
for 1 min and 72 C for 1 min, with a final extension at 72 C for 10 min. The 317 bp
PCR products were analysed by electrophoresis using a 1% (w/v) agarose gel and
visualised using a geldoc viewing system (DNR Bioimaging systems, Israel). Selected
PCR products were confirmed as the nsr gene by sequencing and were included a
positive assay control for screening of isolates.
The NsrFP ABC transporter was detected by PCR using primers targeting a 2, 781 bp
product described by (Reiners et al., 2017). The reaction was carried out in a final
volume of 50 µl, using a final concentration of 2.5 U of FastStart™ High Fidelity Taq
polymerase (Roche Applied Science, Germany), 2 mM MgCl2, 0.2 µM dNTP, 0.25µM
primers, 6% DMSO and 100ng of template DNA. The conditions were as follows:
initial denaturation at 95oC for 3 minutes followed by 35 cycles of denaturation at
95oC for 1 minute, annealing at 50oC for 1 minute, extension at 72oC for 3 minutes
with a final extension at 72oC for 10 minutes. PCR products were resolved using 0.5%
(w/v) agarose gel electrophoresis and visualised as above.
3.3.7. Sequencing of the nsr gene
Primers were designed to detect the entire nsr gene with SnapGene software (GSL
Biotech) using the S. agalactiae COH1 reference genome as a template sequence. The
primers were identified as: WGNsr-For 5’–GTTATAGTAAACCATTTTGCCA–3’
and WGNsr-Rev 5’–GAGCCCTTGTGTCTTCTTTT–3’. PCR reactions were carried
out in a final volume of 50 µl using 25 µl RedTaq ReadyMix with 0.4 µM of each
primer and 100ng template DNA. Thermocycler conditions were as follows: initial
denaturation at 95 oC for 3 minutes followed by 35 cycles of denaturation at 95 oC for
1 minute, annealing at 50 oC for 1 minute and extension at 72 oC for 1 minute with a
final extension at 72oC for 10 minutes. The resulting 1114bp PCR products were
analysed using a 1% (w/v) agarose gel and visualised as before.
PCR products were purified using the High Pure PCR product purification kit (Roche
Applied Science, Germany) according to the manufacturer’s instructions. Samples
were then mixed with primers (5 µl of 20-100 ng/µl purified template and 5µl of 5 µM
primer) and sequences were determined by Sanger sequencing at GATC Biotech
(GATC Biotech, AG, Cologne, Germany). The resulting nucleotide sequences were
assembled and consensus sequences obtained, which were then aligned with reference
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gene sequences using MEGA software version 7 to identify any nucleotide and
subsequent amino acid differences.
3.3.8. Statistical analysis
A related samples t-test was used to analyse differences between groups using SPSS
v. 25.0 (IBM, UK). A P-value of ≤ 0.05 was considered statistically significant.

3.4.

Results

3.4.1. Deferred antagonism screen of nisin and the bioengineered derivatives
The preliminary screening of the activity of nisin and its derivatives against the GBS
strains (n = 17) established that there was some level of susceptibility detected for
each strain, and zones of inhibition ranged from 1-19mm (Table 3.3; Figure 3.2). Wild
type nisin resulted in zones of inhibition ranging from 2.5-13mm for GBS strains. The
largest level of zone of inhibition (19mm) was observed for nisin S29G, although this
was only observed for one isolate, CIT 245. Of the twenty-six bioengineered
derivatives tested, n = 17 displayed enhanced antimicrobial activity compared to nisin
A against over half of the tested strains (Table 3.4). Variants with noted enhanced
activity compared to nisin A included K12A, 14V, AAA-S29A and K22T and each of
these variants displayed improved activity against >50% of strains tested, with zones
of inhibition up to 16mm. Two variants, G18T and S29R, exerted improved activity
against only two GBS isolates and zones of inhibition were low (Table 3.3). Nisin PV
displayed enhanced activity against 50% of isolates, with zones of up to 10mm
observed, while nisin PGA displayed improved activity against 83.3% of isolates and
zones of up to 16mm.
Of the nisin derivatives exerting improved activity against ≥50% of isolates tested,
only T2l, HTK, and PGA have not been extensively studied to date. Nisin PGA exerted
the greatest antimicrobial activity and thus was selected for further analysis. As nisin
PV was designed specifically to prevent cleavage by the NSR protein observed in
GBS, this variant was also selected for further analysis with MIC evaluation and also
investigation of the genetic basis of nisin resistance.
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Figure 3.2: Deferred antagonism assay of wild type nisin (nisin A) and bioengineered
nisin derivatives.
Image shows the results of a deferred antagonism assay with a representative GBS isolate,
CIT 239. Zones of inhibition are highlighted for wild type nisin, nisin PGA and nisin PV.
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Table 3.3: Overlay assay screen of wild type nisin and 26 nisin derivatives for bioactivity against Group B Streptococcus strains.
GBS isolate

Zone of inhibition (mm)

(CIT- isolate no.)

239

101

273

245

76

364

274

289

85

358

278

110

106

112

114

116

103

ATCC Average
-13813 zone size

Nisin derivative
WT
PV
K12S
M17Q
S29G
PAQ
M21L
PIT
KI2T
G18T
H31K
S29R
K12A
I4V
AAA-S29A
K22M
T2L
S29D
K22T
M21V
S29A
SVA
HTK
N20P
AAA
PGA
M21A

3.5
4.5
3.5
4.5
5
4
4.5
3
3.5
2
3.5
3
4.5
2
4.5
5
4
4.5
3
4
6
4. 5
3
4.5
6
7.5
6

2.5
2
5
4
2.8
3.1
3.2
1
4.8
2
1
1
4
5.5
2.5
2
3
2.5
3
3
4
5
4
3.5
5
6
3

4
4
2
3
3.5
4
5.5
2
3
1.5
3.5
3
5
4
3.2
2.5
5
2
5
3
3.5
2.5
5
4.5
2.5
5.5
6

9.5
NA
NA
NA
19
NA
13
13
NA
5
6
5.5
NA
NA
NA
NA
10
9.5
NA
NA
NA
NA
NA
NA
NA
NA
NA

5.5
5
3.1
4.1
4.5
5.9
4
2
5.5
1
4
3
6
6
5
3.5
5.5
3
4.5
8
5.5
8
6.8
5.4
5.5
6.1
6

13
NA
11
14
12
10
NA
NA
NA
6
9
NA
NA
14.5
14
NA
11
15
14
NA
NA
NA
NA
12
15
NA
NA

11
10
10
11
12
12.5
9.5
7
12.5
5
9
6.5
13.5
16
11.5
7
11.5
13
14.5
16
14
15.5
14
9.5
11
14.5
13

3.5
5.5
4
3.5
2.5
2
3
4
5
1.5
2.5
2.5
4.5
4
5
4
3
3.5
5
5
4
5
6
5.5
3.5
5.5
5

5
4
5
5.5
3
5.5
6
4
6
2
4
4
7
6.5
4
6
4
4
6
6.5
4.5
6.5
6
4
3.5
7
5

3
4
3
3
2
2.5
3
2.5
3
3
4
3
2.5
2
2.5
3.5
4
4.5
2.5
3
3
5
4
2
2
4.5
3

3
3
3
4
3
2
5
3
4
3
3.5
3
4
3.5
4.5
5
5
4
5
3
4
6
4
3
3.5
4
4

5
6
5
6
4
5
6
3.5
6
2.5
4
5
7
14.5
7
5
4
6
7
7.5
6
9
5
5.5
7
6
8

4.5
5.3
6.3
5.6
5.6
5.3
6.3
4.8
6.7
5.1
5.6
5.2
5.9
6.3
7
5.9
5.9
5.3
7.1
7.5
6.3
8.3
5.6
6.1
5.8
5.1
5.9

5
5.3
4.5
4.5
5.1
5.8
5.8
4.5
4.4
4.3
4.3
4.9
6.5
5
4.7
4.4
4.6
4.5
5.3
5.4
4.9
6.1
4.4
6
4.5
5.8
4.8

6.6
7
5.2
5.9
5.4
5.8
6.2
5.4
5.7
4.2
5.3
4
5.5
6.5
8.2
4.7
6.1
7.1
6.1
6.7
5.4
8.1
5.4
6.9
6.5
8.1
6.8

5.5
5.6
4.4
5.7
4.5
6
6.3
NA
5.3
4.7
4.7
6.3
5.1
5.4
5.1
5.7
6.6
6.5
6.1
4.9
5.7
7.3
5.3
5.6
5.3
7.0
6.2

7
8
9.5
7.5
NA
NA
7.5
8
11
10.5
12
7
13
8
13.5
5.5
8
12
8
12
8
NA
9
10
NA
NA
NA

11.5
10
11.5
13
9
10
9
3
14
3
8.5
6.5
13.5
13
13.5
10.5
10
10
12.5
12
13
13.5
11
5
14
16
14

6
5.6
5.6
6.2
6.1
5.6
6.1
4.4
6.3
3.7
5.2
4.3
6.7
7.2
6.8
5
6.2
6.5
6.7
6.7
6.1
7.6
6.2
5.8
6.3
7.2
6.4

WT, wild type nisin. Derivative names are indicative of amino acid changes from sequence of wild type nisin. Values represent the zone of inhibition produced
by the corresponding bacteriocin-producing L. lactis strain. Shaded values indicate those where the bioengineered derivative exhibited enhanced antimicrobial
activity compared to wild type nisin. NA indicates isolates for which a zone of inhibition could not be measured.
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Table 3.4: Bioengineered nisin derivatives displaying enhanced antimicrobial
activity compared to nisin A.
Nisin variant

Percentage of strains
displaying enhanced
susceptibility to nisin
variant

Percentage of strains
displaying decreased
susceptibility to nisin
variant

PV

50%

27.8%

Percentage of
strains displaying
equal susceptibility
to nisin A and
variants
11.1%

K12S

22.2%

38.9%

33.3%

M17Q

55.6%

22.2%

22.2%

S29G

27.8%

55.6%

11.1%

PAQ

44.4%

33.3%

11.1%

M21L

61.1%

27.8%

5.6%

PIT

22.2%

66.7%

0%

K12T

50%

22.2%

16.7%

G18T

5.6%

77.8%

11.1%

H31K

16.7%

72.2%

5.6%

S29R

11.1%

55.6%

27.8%

K12A

72.2%

16.7%

0%

14V

61.1%

11.1%

22.2%

AAA-S29A

55.6%

33.3%

5.6%

K22M

38.9%

44.4%

5.6%

T2L

55.6%

38.9%

5.6%

S29D

55.6%

27.8%

16.7%

K22T

66.7%

22.2%

0%

M21V

66.7%

11.1%

11.1%

S29A

50%

16.7%

16.7%

SVA

77.8%

5.6%

0%

HTK

55.6%

22.2%

11.1%

N20P

44.4%

27.8%

16.7%

AAA

38.9%

22.2%

27.8%

PGA

83.3%

0%

0%

M21A

66.7%

5.6%

11.1%

Variant code indicates the amino acid substitution. Percentage of strains refers to n = 17
clinical GBS strains and S. agalactiae ATCC 13813 that demonstrated enhanced susceptibility
to the nisin derivatives based on the overlay assay (total strains n = 18).
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3.4.2. Purification of nisin derivatives, nisin PGA and nisin PV
Following production of nisin PGA and nisin PV by their respective producing L.
lactis strains, both peptides were purified by reverse-phase high performance liquid
chromatography (RP-HPLC). Analysis of the chromatogram for nisin PGA
purification (Figure 3.3A) established that this peptide had a retention time of 23
minutes. Analysis of the chromatogram for nisin PV established that this peptide had
a retention time of 29 minutes (Figure 3.3B). Peaks observed at these retention times
are representative of nisin PGA and nisin PV, respectively. Samples eluted at these
times were collected and pooled and lyophilised for use in MIC assays.

Figure 3.3: Reverse Phase-HPLC chromatogram for purified nisin PGA and nisin PV.
RP-HPLC profile of (A) nisin PGA and (B) nisin PV. Both peptides were developed in a
gradient of 30% acetonitrile + 0.1% TFA to 60% acetonitrile + 0.1% TFA from 10 to 40
minutes at a flow rate of 2.2 ml/min. The retention time (min) and the response of the detector
(mV) are represented by the X and Y axes, respectively.
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3.4.3. MIC-based investigations of nisin A and nisin PGA
The specific activities of both purified nisin A and nisin PGA were investigated using
broth-based microdilution MIC assays for three isolates, displaying varied levels of
susceptibility to both peptides (Table 3.5). All three isolates displayed an increased
MIC for nisin PGA, demonstrating a reduction in specific activity for this peptide
compared to the wild type. This was in contrast to the overlay assay for which an
increased level of susceptibility to nisin PGA was observed for the three isolates. An
MIC for nisin A of 12.6 µg/ml and an MIC for nisin PGA of >25.2 µg/ml were
established for both CIT 85 and 358, indicating a 2-fold increase in MIC for nisin PGA
compared to nisin A. Similarly, a 4-fold increase in MIC was observed for nisin PGA
(12.6 µg/ml) compared to nisin A (3.1 µg/ml) for CIT 273.

Table 3.5: MIC evaluation of wild type nisin and nisin PGA against three Group B
Streptococcus isolates.
Isolate

Zone of inhibition (mm)a

MIC (µg/ml)b

Nisin A

Nisin PGA

Nisin A

Nisin PGA

CIT 85

5

7

12.6

25.2

CIT 273

11

14.5

3.1

12.6

CIT 358

3

4

12.6

25.2

a

Deferred antagonism agar diffusion-based assessment of the bioactivity of the nisin A and
nisin PGA producers against GBS strains.
b

Broth-based MIC assays of nisin A and nisin PGA for selected GBS strains.
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3.4.4. Phenotypic assessment of the bioactivity of nisin A and nisin PV
Deferred antagonism assays were employed using the producer strains L. lactis
NZ9700 and L. lactis NZ9800S29PV, to screen specifically for the bioactivity of nisin
A and nisin PV against a larger bank of 122 clinical GBS isolates and the reference
strain S. agalactiae ATCC 13813. Results indicated that 91% (n = 111) of the clinical
population displayed some level of susceptibility to nisin A, with 9% of isolates
identified as resistant to nisin A. Interestingly, 64.8% (n = 79) of isolates displayed
enhanced susceptibility to nisin PV compared to nisin A (Table 3.6), with a statistically
significant increase in zone size (P < 0.0005). Of these strains, 41.8% (n = 33) were
isolated from blood culture samples while 58.2% (n = 46) were HVS isolates. Equal
levels of susceptibility to both peptides were detected in 23.8% (n = 29) of isolates
with 34.5% of these strains (n = 10) being invasive isolates and 65.5% (n = 19) being
colonising isolates. Only 9% (n = 11) of this clinical collection of strains displayed
complete resistance (no zone of inhibition) to both peptides with two of these strains
isolated from blood culture samples and nine isolates from HVS samples. Three
isolates (n = 2.5%) showed decreased susceptibility to nisin PV when compared to
nisin A (Table 3.6). Two of these isolates were isolated from blood culture samples
and one from a HVS sample.
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Table 3.6: Characterisation of Group B Streptococcus strains by deferred
antagonism overlay assay.

Susceptibility characteristics

Representative overlay assay result

(no. of isolates)

Enhanced susceptibility to nisin
PV compared with nisin A
(n = 79, 64.8%)

Equal susceptibility to nisin A
and nisin PV
(n = 29, 23.8%)

Complete resistance to nisin A
and nisin PV
(n = 11, 9%)

Decreased

susceptibility

to

nisin PV
(n = 3, 2.5%)
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3.4.5. Further MIC-based investigations of nisin A and nisin PV activity
The specific activities of both nisin A and nisin PV were investigated using MIC
assays on 10% of the total population tested, and reflecting the different phenotypes
observed by the deferred antagonism assay (Table 3.7). Of the fourteen isolates
selected, 64.3% (n = 9) had lower MICs for nisin PV, thereby demonstrating an overall
increase in specific activity for this derivative of nisin. Isolates exhibiting enhanced
susceptibility to nisin PV by deferred antagonism assays had MIC values ranging from
3.1-8.4 µg/ml, while the MICs for nisin A ranged from 0.1-25.2 µg/ml (Table 3.7).
Interestingly, nisin PV demonstrated an 8-fold increase in specific activity for one
isolate, CIT 67. Another isolate, CIT 263, exhibited enhanced susceptibility to nisin
PV using the overlay assay, but appeared to be more susceptible to nisin A when
evaluated by the MIC method. However, the MIC values for both peptides established
for this isolate were much lower than other isolates within this group. Overall, the MIC
values established for nisin PV were significantly lower (P < 0.0005) compared to
nisin A for isolates with this phenotype. MICs were established for three isolates
which had equal susceptibility to both peptides by the overlay assay (CIT 276, 106
and 274) and results indicated a lower MIC for the nisin A peptide for all three strains
(Table 3.7), although this was not statistically significant (P = 0.189). Two isolates
(CIT 221 and CIT 395) displaying complete resistance to both peptides by the overlay
assay had lower MICs with nisin PV (Table 3.7). For comparative purposes, data
regarding the MIC of penicillin amongst GBS strains were obtained from a previous
study and ranged from <0.06-0.25 µg/ml (Teatero et al., 2017).
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Table 3.7: Susceptibility testing with nisin A and nisin PV and PCR screening of
representative Group B Streptococcus strains.
Isolate

Zone size (mm)a

Nisin A

Nisin PV

MIC (µg/ml)b

Nisin A

nsr

nsrFP

genec

gened

Nisin PV

Isolates with enhanced susceptibility to nisin PV
CIT 10

0

12.33

21

6.3

+

+

CIT 239

0

15.33

25.2

6.3

+

+

CIT 351

0

11.33

6.3

4.7

-

+

CIT 223

7.33

15.67

25.2

6.3

+

+

CIT 67

10.33

15.33

25.2

3.1

+

+

CIT 113

10.67

12.67

25.2

6.3

+

+

CIT 114

15.33

18.33

16.8

8.4

+

+

CIT 263

22.33

24.33

0.01

0.5

-

+

Isolates with equal susceptibility to both peptides
CIT 106

15.33

15.33

4.2

6.3

+

+

CIT 276

16

16

1.8

6.3

+

+

CIT 274

23

23

0.2

0.8

+

+

Isolates with complete resistance to both peptides
CIT 221

0

0

21

5.2

+

+

CIT 395

0

0

>25.2

12.6

+

+

+

+

Isolates with decreased susceptibility to nisin PV
CIT 211

12.33

8.33

6.3

12.6

a

Deferred antagonism agar diffusion-based assessment of the bioactivity of the nisin A and
nisin PV producers against GBS strains. Values represent the zone of inhibition and are the
mean of triplicate assays.
b

Broth-based MIC assays of nisin A and nisin PV for selected GBS strains. Values are the
mean of triplicate assays.
c

PCR screening assay for detection of the nsr gene and d nsrFP gene.
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3.4.6. Growth curve analysis of GBS in the presence of nisin A and nisin PV
Growth curves provide a more detailed assessment of the bactericidal impact of
purified peptides. Representative strains were chosen for growth curve analysis to
reflect the differences observed by DAA assay. Two isolates with enhanced
susceptibility to nisin PV, one isolate with equal susceptibility to nisin A and PV and
one isolate with resistance to both peptides were selected for analysis. Strains were
cultured in the presence of equimolar concentrations of the peptides and growth was
monitored over a 24-hour period (Figure 3.4). In the presence of nisin A (8.4 µg/ml),
an extended lag phase of 3 hours was observed for isolate CIT 67 and CIT 239, when
compared to the untreated control. The enhanced potency of nisin PV against these
strains was evident, with complete inhibition of the strain at the concentration tested
(8.4 µg/ml) (Figure 3.4A, B). For isolate CIT 395, an extended lag phase of 9 hours
and a short log phase was observed in the presence of nisin PV (8.4 µg/ml) compared
to nisin A and the untreated control (Figure 3.4C). Growth analysis of CIT 106 in
equal concentrations of both peptides (1.3 µg/ml) resulted in similar growth rates when
compared to the untreated control (Figure 3.4D). For the two isolates with enhanced
susceptibility to nisin PV, a complete bactericidal activity was achieved lasting across
24 hours, inferring that a bactericidal effect would also be achieved for other isolates
within this DAA group.
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Figure 3.4: Growth curve analysis of Group B Streptococcus isolates in the presence of
nisin A and nisin PV.
Comparison of the effect of equimolar concentrations (established from MIC data) of nisin A
and nisin PV on the growth of representative GBS strains. Images A, B and C show isolates
CIT 67, 239 and 395 respectively in the presence of 8.4 µg/ml nisin A and nisin PV. Image D
shows CIT 106 in the presence of 1.3 µg/ml nisin A and nisin PV. Data represent the average
of triplicate experimental results from three independent experiments.

3.4.7. Detection of the nisin resistance genes, nsr and nsrFP
All isolates in the study (n = 122) were screened for the presence of the nsr gene using
a novel PCR assay. Specificity testing was initially carried out using reference strains
S. agalactiae ATCC 13813 and S. agalactiae COH1 harbouring the nsr gene as well
as two L. lactis strains harbouring the nsr gene. No amplification of the nsr gene in
the L. lactis strains was observed, ensuring specificity of the primers to nsr in GBS
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strains (Figure 3.5A). The collection of GBS strains were then screened for the
presence of nsr and Figure 3.5B shows 15 representative samples. In this clinical GBS
collection 98.4% of isolates (n = 120) were positive for the nsr gene, with only two
isolates testing negative for the gene. Interestingly, for one of these isolates, CIT 263,
nisin PV displayed a decrease in specific activity, while for the other isolate, CIT 351,
nisin PV displayed an increase in specific activity (Table 3.7). The nsrFP gene was
also detected amongst the population, although at a slightly lower rate of 84.4% (n =
103). Figure 3.5C shows a PCR screen of 20 representative GBS isolates. Of the
nineteen isolates lacking the nsrFP gene, ten were invasive isolates while nine
belonged to the colonising population.
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Figure 3.5: Representative gels of the PCR screen for the nsr and nsrFP genes.
(A) Specificity testing of the nsr primers. Lanes M, 100bp hyperladder; lanes 1 and 2, nsr
detection in S. agalactiae ATCC 13813 and S. agalactiae COH1; lane 3, L. lactis DRC3
harbouring the nsr gene; lane 4, L. lactis pnp40 harbouring the nsr gene; lane 5, negative
control. (B) Detection of a 317bp fragment of the nsr gene in Group B Streptococcus strains.
Lanes M, 100bp hyperladder (Bioline, MSC, Ireland); lanes 1-15 positive detection of the nsr
gene; lane 16, negative PCR control. (C) Detection of the nsrFP gene. Lanes M2, 1kb
Hyperladder (Bioline, MSC, Ireland); lanes 1, 2, 4, 5, 7, 9-15 and 17-20, detection of the 2,
781 bp product corresponding to the nsrFP gene; lanes 3, 6, 8 and 16, isolates which did not
harbour the gene; lane 21; negative control.
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3.4.8. Sequence analysis of representative nsr genes and comparison to reference
GBS nsr gene sequence
Five isolates representative of each of the defined susceptibility groups (enhanced,
equal or decreased susceptibility to nisin PV or complete resistance to both nisin A
and nisin PV) were selected for sequencing analysis of the entire nsr gene. Initially,
the entire nsr gene was amplified by PCR (Figure 3.6). Nucleotide sequence analysis
and comparison to a reference GBS nsr gene sequence revealed putative amino acid
changes, outlined in Table 3.8. Two isolates, CIT 67 and CIT 211, did not contain any
amino acid differences compared to the reference gene. CIT 106 displayed a
substitution of phenylalanine for leucine at position 9 while both CIT 239 and 395
both displayed a substitution of valine for leucine at position 180. Importantly, no
differences were observed at the catalytically active residues, His-98 and Ser-236
(Figure 3.7).

Figure 3.6: PCR amplification of the entire nsr gene for sequence analysis.
Lanes M, 1kb Hyperladder (Bioline, MSC, Ireland); lane 1, positive control S. agalactiae
ATCC 13813; lane 2, isolate CIT 263 lacking the nsr gene; lanes 3-6, detection of the 1, 114
bp nsr product; lane 7, negative control.
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Figure 3.7: Amino acid sequence alignment of the NSR protein derived from nsr
nucleotide sequences.
All images show sequence alignments for five representative GBS isolates with the reference
strain, GBS COH1. Alignments were performed on MEGA software, version 7, using
MUSCLE analysis. (A) Alignments showing amino acid substitution of phenylalanine for
leucine at position 9 in CIT 106; (B) Alignments showing amino acid substitutions of leucine
for valine at position 180 in CIT 239 and 395. (C) Alignments highlighting the catalytically
active His 98 residue, with no observed differences. (D) Alignments highlighting the
TASSAEM region with the catalytically active Ser 236 residue, with no observed differences.
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Table 3.8: Predicated amino acid substitutions in NSR based on nucleotide mutations within the nsr gene of selected Group B Streptococcus
isolates compared to reference GBS COH1 strain.
Isolate

Overlay assay profile

CIT 67

Enhanced susceptibility Increased specific activity Complete inhibition by nisin PV.
to PV.
of nisin PV.

CIT 106

CIT 211

CIT 239

CIT 395

MIC result

Growth curve

nsr
gene
+

Predicted
substitution
None detected.

Equal susceptibility to Slight increase in specific No difference compared to control.
nisin PV.
activity of nisin A.

+

Phenylalanine
→
leucine at position 9.

Decreased
susceptibility to nisin
PV.
Enhanced susceptibility
to nisin PV.

Increase
in
specific Not tested.
activity for nisin A.

+

None detected.

Increase
in
specific Complete inhibition by nisin PV.
activity for nisin PV.

+

Valine → leucine at
position 180.

Complete resistance to Increase
in
specific Extended lag phase by 9 hours +
both nisin A and nisin activity for nisin PV.
observed with nisin PV.
PV.

Valine → leucine at
position 180.

Potential substitutions are as established from sequence alignment on MEGA 7 software using MUSCLE analysis compared to the reference GBS COH1 strain.
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3.5.

Discussion

Group B Streptococcus remains the leading cause of invasive neonatal disease
worldwide (Madrid et al., 2017) and has become increasingly more prevalent amongst
non-pregnant adults (Lamagni et al., 2013). Resistance to second line antibiotics
continues to rise (Lamagni et al., 2013) and a recent study we conducted highlighted
the emergence of new antibiotic resistance patterns among Irish GBS strains (Hayes
et al., 2017). Thus, there is a continuing need to monitor resistance and identify
alternative and novel treatment options for this opportunistic pathogen. In this study,
we examined the susceptibility of our clinical GBS isolates to nisin A and we explored
if bioengineered derivatives of nisin demonstrated enhanced activity compared to the
wild type nisin. As some GBS strains were recently determined to possess nisin
resistance operons, the genetic basis for nisin resistance was examined among the GBS
collection, namely through detection of the nsr and nsrFP genes. As nisin PV was
designed specifically to resist proteolytic cleavage by NSRs, we sought to determine
if this derivative could combat nisin resistance and infer enhanced antimicrobial
activity against GBS strains.
The potential for nisin to be used as an alternative antimicrobial agent has been
explored; however, it is yet to be implemented for use in a clinical setting (Cavera et
al., 2015; Cotter et al., 2013). Nisin is FDA approved for use in cheese production and
has long been used as a preservative in the food industry (de Arauz et al., 2009). The
use of nisin as an antibiotic has also been investigated and it has been shown to exert
antimicrobial activity against a variety of clinically relevant pathogens such as MRSA
(Piper et al., 2009; Okuda et al., 2013) and vancomycin-resistant enterococci (VRE)
(Severina et al., 1998). In vitro studies have also demonstrated the anti-biofilm
properties of nisin (Okuda et al., 2013; Ahire and Dicks, 2015; Field et al., 2015c) as
well as its ability to work synergistically with other antibiotics to improve therapy
(Dosler and Gerceker, 2011; Field et al., 2016a). However, to the best of our
knowledge the efficacy of nisin has never been examined with respect to a clinical
collection of GBS strains.
We screened a bank of nisin derivatives for activity against GBS strains and identified
variants that had enhanced antimicrobial activity compared to wild type nisin. Nisin
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PGA demonstrated improved activity against 83.3% of strains. Nisin PGA is a
derivative of nisin harbouring mutations of the hinge region. Other variants with hinge
region substitutions have previously demonstrated enhanced antimicrobial activity
against bacteria such as S. aureus and even S. agalactiae (Healy et al., 2013).
However, MIC results observed for three strains in this study indicated a decrease in
specific activity of nisin PGA. The discrepancy between the DAA and MIC results
may be explained by the validity of the DAA assay and the low threshold of activity
used to define enhanced activity. Had a more stringent classification of zone sizes been
applied, perhaps more agreement would have been observed between the two assays.
More recently; however, the hinge region of nisin was manipulated to create three
mutants, ∆21MK22, 20NIVMK24 and 20NMKIV24, and while they were able to
evade nisin resistance proteins, they did exert lower antimicrobial activity than wild
type nisin (Zaschke-Kriesche et al., 2019a).
Another derivative, nisin PV, demonstrated superior antimicrobial activity against
50% of GBS isolates examined in our initial screen. Furthermore, this particular nisin
derivative was specifically bioengineered to evade proteolytic cleavage by the NSR
protein found in GBS strains. Consequently, we investigated the rates of susceptibility
to nisin amongst a larger clinical population of GBS strains and additionally assessed
if this novel derivative, nisin PV, was a more potent peptide. In this collection the nisin
PV derivative was determined to be significantly more effective than nisin A (P <
0.0005). Furthermore, MICs were significantly lower for nisin PV compared to nisin
A (P < 0.0005). The MIC results corresponded with the overlay assay results for
isolates with enhanced susceptibility to nisin PV (n = 8), with the exception of two
strains, CIT 263 and 351. Interestingly, these were the only isolates to test negative
for the nsr gene within the entire collection and this could explain the lack of
concordance between the assay results. A number of factors can influence the zone of
inhibition produced by a peptide in the deferred antagonism assay including solubility,
ability to diffuse through the agar, as well as the mechanisms of resistance to nisin that
GBS strains possess. These factors may explain the discrepancies observed between
the two assays.
Despite the considerable potential of nisin to be used in a clinical setting, there have
been reports of resistance amongst certain bacteria through production of nisin
resistance proteins (NSR), including GBS strains (Froseth and McKay, 1991; Khosa
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et al., 2013). The nsr gene was detected in a significant proportion of GBS isolates
within this study (98.4%) and even more worrying is the fact that nsr genes are
frequently located on naturally transmissible elements (Froseth and McKay, 1991; Liu
et al., 1997). Bioengineered derivatives of nisin are an attractive counteract to
resistance as nisin is easily manipulated and mutant derivatives have been shown to
be more stable and more effective against bacteria (Field et al., 2008, 2016a,b; Healy
et al., 2013), including S. agalactiae ATCC 13813 (Rouse et al., 2012). Nisin PV was
designed specifically to resist proteolytic cleavage by the NSR protein due to specific
amino acid substitutions at the C-terminal cleavage site. We therefore postulated that
strains producing an NSR would be potentially more susceptible to nisin PV.
However, in the study some strains (26.3%) showed equal or reduced susceptibility to
nisin PV when compared with nisin A, despite harbouring the nsr gene. This is
possibly due to strains harbouring the nsr gene but not expressing it, and therefore the
strains remain susceptible to proteolytic cleavage by nisin. Alternatively, other
mechanisms of nisin resistance, including expression of the ABC transporter (NsrFP)
(Reiners et al., 2017), regulatory systems (NsrR and NsrK) (Khosa et al., 2013) and
cell wall modifications such as the D-alanylation of bacterial membranes (Draper et
al., 2015) may also explain the varied responses to nisin and nisin PV observed in this
study. NsrFP is an efflux pump that exports nisin out of the bacterial cell (Reiners et
al., 2017) and we detected the nsrFP gene in 84.4% of isolates, suggesting this
mechanism of resistance may also be in effect. NsrFP acts on the N-terminus of nisin,
whereas the NSR cleaves nisin at its C-terminus. Therefore, despite the fact that nisin
PV prevents nisin cleavage by NSR, strains may retain nisin resistance through NsrFP.
It would be interesting to further modulate nisin PV with additional amino acid
changes at the N-terminus to see if this would confer increased susceptibility to nisin
in GBS strains. Another possibility is that Nisin PV may not be recognised by the
regulatory two component system and therefore its presence does not induce
production of NSR proteins. As little is known about the two component system
(NsrR/K) of the GBS nsr operon, further analysis of the operon is required to confirm
this hypothesis.
Recently the hinge region of nisin was manipulated to create three mutants, ∆21MK22,
20NIVMK24 and 20NMKIV24, and the authors found that in particular, 20NMKIV24
was not recognised by NSR and NsrFP proteins found in GBS (Zaschke-Kriesche et
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al., 2019a). Another nisin variant, nisin C28P, demonstrated improved antimicrobial
activity compared to wild type nisin in L. lactis strains expressing NSR from S.
agalactiae; however, it is important to note that a higher MIC was obtained for this
variant compared to wild type nisin when tested against S. aureus and E. coli control
strains (Zaschke-Kriesche et al., 2019b). The specific design of these peptides with
the objective of circumventing the activity of nisin resistance proteins represents an
exciting area of research; however more extensive studies examining their activity
against clinical GBS strains such as the present study is required.
The NSR protein belongs to a family of S41 peptidases and analysis of the 3D crystal
structure revealed that it contains a conserved TASSAEM region (Khosa et al., 2016a).
This sequence motif contains the catalytically active serine at position 236, which
forms a dyad with the conserved Histidine at position 98 and is crucial for the
proteolytic activity of NSR (Khosa et al., 2013, 2016a). Therefore, we sought to
determine if any amino acid changes occurred within the nsr gene sequence of selected
isolates when compared to the reference S. agalactiae COH1 sequence. We detected
potential single amino acid substitutions within three of the strains tested. CIT 106
possessed a substitution at Phe→Leu9 while both CIT 239 and 395 harboured a
Val→Leu180 substitution, however, these alternations were not considered significant
as the amino acids were of the same non-polar, hydrophobic group. Importantly, these
substitutions did not occur at the His98 or Ser236 positions. It is interesting to note
that CIT 211 did not harbour any mutations despite showing decreased susceptibility
to nisin PV by both deferred antagonism assay and MIC methods.
The global threat of antibiotic resistance remains a significant issue for the treatment
of infections, particularly those caused by multi-drug resistant pathogens (Hawken and
Snitkin, 2019). The rate of antibiotic resistance has surpassed the rate of discovery and
development of new and effective antibiotics, resulting in a public health emergency
(Jackson et al., 2018). More than ever there is a need for alternatives to antibiotics, or
indeed novel derivatives of existing antibiotics. The data here demonstrates the
enhanced bioactivity of nisin derivatives, as has been observed in other studies (Field
et al., 2010, 2012; Healy et al., 2013), which strengthens the argument for their
potential use in clinical therapies. Interestingly, the MIC range for both nisin A (0.2> 25.2 µg/ml) and nisin PV (0.5-12.6 µg/ml) were considerabley higher than observed
for penicillin in previous study (<0.06 – 0.25 µg/ml) (Teatero et al., 2017). However,
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it is important to note that the MIC ranges for both nisin A and nisin PV observed here
are lower than concentrations observed as non-toxic to cell lines in other studies.
Concentrations of nisin at 100.6-1623 µg/ml, 200 µg/ml and 83.9-168 µg/ml were
non-toxic to vaginal cell lines, dental cell lines, keratinocytes, red blood cells and
gastrointestinal cell lines, respectively (Aranha et al., 2008; Shin et al., 2015; Dreyer
et al., 2019. The MICs observed in this study are therefore encouraging to facilitate
the use of nisin and nisin PV in clinical use. However, the future of such antimicrobials
necessitates continued studies to investigate the bioavailability of nisin and its
derivatives in-vivo (Gough et al., 2018).
To the best of our knowledge, this is the first investigation demonstrating nisin
susceptibility within a clinical population of GBS strains. Furthermore, the study
reports a derivative of nisin (nisin PV) that exhibited enhanced activity against GBS
isolates. Resistance to certain antibiotics for the treatment of GBS infections continues
to rise, and published guidelines no longer recommend the use of clindamycin due to
high levels of resistance, indicating that there is a need for alternative therapies. Nisin
and its derivatives could prove a viable option in these cases.
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3.7. Supplementary information

Table S3.1: Primers used for the detection of nisin resistance genes in Group B Streptococcus strains
Target

Sequence 5’ – 3’

nsr

For: CTGGCGGCAATATGATCCCT
Rev: AGCACCGTCGTAAAGCATGA

nsrFP

For: GGGTATAATAAATAAAGGAGAATTATATG
Rev: CGGTTTCTATTAATGCAAAAGG

nsr
entire For: GTTATAGTAAACCATTTTGCCA
gene
Rev: GAGCCCTTGTCTCTTCTTTT
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Annealing temp.
(o C)
50

Product size (bp)

Reference

317

This study

50

2, 781

(Reiners
2017)

50

1, 114

This study
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Figure S3.1: Nucleotide sequences of representative nsr genes.
Nucleotide sequences of nsr genes from representative GBS isolates. Alignment of sequences was performed using Mega software, v. 7 with MUSCLE analysis.
Differences in nucleotide sequences are highlighted in red.
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Figure S3.2: Amino acid sequence alignments translated from the nsr gene from two reference GBS strains and five representative GBS strains from
this study.
Alignments showing substitution of phenylalanine for leucine at position 9 in CIT 106 and substitutions of leucine for valine at position 180 in CIT 239 and
395. All alignments were performed on MEGA software, version 7, using MUSCLE analysis.
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Figure S3.3: Optimisation of the PCR for the detection of nsrFP by magnesium chloride
titration.
The PCR detection of nsrFP required optimisation of MgCl2 concentrations. Lane M, 1kb
Hyperladder (Bioline, MSC, Ireland); lane 1, S. agalactiae ATCC 13813 with 1.5 mM MgCl2;
lane 2, S. agalactiae COH1 with 1.5 mM MgCl2; lane 3, negative control; lane 4, 0.5 mM
MgCl2; lane 5, 1 mM MgCl2; lane 6, 1.5 mM MgCl2; lane 7, 2 mM MgCl2; lane 8, 2.5 mM
MgCl2; lane 9, 3 mM MgCl2; lane 10, 3.5 mM MgCl2; lane 10, negative control.
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4.1. Abstract
Group B Streptococcus (GBS) is the leading cause of invasive neonatal disease
worldwide and is becoming increasingly more prevalent in invasive adult disease.
Resistance to some conventional antibiotics, such as erythromycin and clindamycin,
continues to rise amongst GBS, indicating a need for alternative treatment options.
The focus of this study was to examine the combined effects of conventional
antibiotics

(erythromycin,

clindamycin

and

tetracycline),

with

alternative

antimicrobials (nisin, nisin PV and lactoferrin) for improved activity against clinical
GBS isolates. The combination of erythromycin and nisin was examined for
synergistic activity using checkerboard and time-kill assays against invasive and
colonising GBS strains. Additionally, the immunological effect of the antimicrobial
combination was investigated in-vitro using human U937 cells and ELISA analysis.
Growth curve analysis identified erythromycin and nisin as having enhanced
antimicrobial activity when combined, through either complete inhibition of growth
or extended lag phases of up to 15 hours. Checkerboard assays confirmed an additive
effect when these antimicrobials were combined with FICI values of 0.56 – 1, while
time-kill assays demonstrated a synergistic effect for the antimicrobial combination
against invasive GBS isolates (>2log CFU/ml reduction after 24 hours). Furthermore,
a significantly lower TNF-alpha response (P < 0.05) was observed in U937 cells
challenged with GBS when erythromycin and nisin were used in combination. The
results suggest that erythromycin and nisin can act synergistically to inhibit the growth
of GBS. This study demonstrates the potential of combination therapies for treatment
of GBS infections and encourages further investigation of this treatment option.
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4.2. Introduction
The rate of discovery and development of new and effective antibiotics has slowed
considerably (Jackson et al., 2018) despite the fact that the global threat of antibiotic
resistance remains a significant problem, particularly for treatment of infections
caused by multi-drug resistant pathogens (Hawken and Snitkin, 2019). Thus, there is
an urgent need for alternatives to antibiotics or changes to existing treatment regimes
in order to prevent further development of antimicrobial resistance and/or improve the
mode of action of current antibiotics. Indeed, in 2015, the World Health Organisation
(WHO) established a Global Action Plan for antimicrobial resistance outlining the
necessary social, scientific and economic measures to be taken to help combat
antimicrobial resistance. The development of new compounds and the implementation
of alternative therapies are at the helm of this plan (World Health Organization, 2016).
Combination antimicrobial therapy is an attractive option and has many advantages,
including the potential for synergism, whereby the combination of antimicrobials
improves the effect of either antimicrobial alone (Brooks and Brooks, 2014).
Combining antibiotics can also potentially reduce the concentrations needed to treat
bacterial infections, thereby limiting future antimicrobial resistance (Brooks and
Brooks, 2014). In addition, with combination therapy bacteria are less likely to
develop resistance due to the usually different modes of action of each antimicrobial
(Tong et al., 2014).
GBS remains the leading cause of invasive neonatal disease worldwide, causing
pneumonia, sepsis and meningitis (Edmond et al., 2012). Maternal colonisation with
GBS is a major risk factor for neonatal infection and is estimated at 18%, with rates
of up to 35% in some countries (Russell et al., 2017a). An extensive analysis in 2015
revealed that up to 3.5 million preterm births, 57, 000 stillbirths and up to 90, 000
infant deaths per year were associated with GBS infections worldwide (Seale et al.,
2017). Furthermore, 32% of patients that survive GBS-mediated meningitis present
with neurodevelopmental impairment (Kohli-Lynch et al., 2017). Invasive GBS
infections amongst non-pregnant adults continues to rise and now pose a serious
threat, in particular to immunocompromised patients, with fatality rates of up to 24%
(Lamagni et al., 2013). Infection with GBS can cause many adverse pregnancy
outcomes, including premature rupturing of membranes, preterm labour, stillbirth and
early onset disease (EOD) (Seale et al., 2017). Some of these adverse effects are driven
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by the host inflammatory immune response to infection, which can be further
exacerbated by the antibiotics used in treatment (Sutton et al., 2019). In some cases,
even after treatment with antibiotics, components released from bacterial cells can
trigger an uncontrolled inflammatory response in the host that can be fatal to neonates
and immunocompromised adults (Upadhyay et al., 2017a). A good candidate for
treatment of bacterial infections should eradicate the bacteria and produce a limited
but effective inflammatory response (Upadhyay et al., 2017b).
Our recent Irish study confirmed that penicillin remains an effective treatment option
for most GBS infections, where 100% (n = 253) of GBS isolates were susceptible to
penicillin (Hayes et al., 2017). However, there have been reports of reduced
susceptibility to penicillin in some countries (Chu et al., 2007; Dahesh et al., 2008;
Kimura et al., 2008). In the event of penicillin allergies second line antibiotics are
given and as per the RCOG guidelines used in Ireland, vancomycin is offered (Hughes
et al., 2017). However, in other countries such as America second line antibiotics
including erythromycin and clindamycin are used, but resistance to these antibiotics
continues to rise (Lamagni et al., 2013; Hayes et al., 2017). Indeed, in 2017, the Royal
College of Obstetricians and Gynaecologists (RCOG) amended their prophylaxis
guidelines for treating GBS infections, indicating that clindamycin was no longer
recommended for use due to the high resistance rates being reported (Hughes et al.,
2017). CDC guidelines however, have not been amended and clindamycin is still
recommended for use in the case of penicillin allergies, provided that susceptibility
testing is performed (ACOG 2019). Of interest, our group recently reported the
emergence of isolated clindamycin resistant GBS phenotypes, and an overall increase
in clindamycin resistance amongst GBS isolates in the Irish population (Hayes et al.,
2017). Erythromycin resistance rates amongst GBS in Ireland have remained high in
recent years (22.1%) (Hayes et al., 2017) and resistance in other countries has
increased, with high rates reported in France (34.7%) (Bergal et al., 2015) and China
(74.1%) (Lu et al., 2016). Tetracycline resistance is ubiquitously high in GBS
populations, and our recent study confirmed this within the Irish population (87.5%)
(Hayes et al., 2017). It has been hypothesised that the extensive use of tetracycline
antibiotics, since their discovery, may be responsible for the selection of a niche GBS
population adapted for human infection (Da Cunha et al., 2014).
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Antimicrobial peptides (AMPs) are naturally occurring peptides produced by the host
to self-protect from invading pathogens (Izadpanah and Gallo, 2005). They are
cationic, hydrophobic peptides, which allows them to interact with negatively charged
bacterial membranes (Hancock, 1998, 2000). AMPs elicit fast, broad-spectrum killing
of bacteria and can also play a role in immunomodulation (Mansour et al., 2014). A
recent review highlighted the potential to use AMPs as therapeutic agents (Kang et al.,
2017), and studies have demonstrated their anti-bacterial and anti-inflammatory
effects, both in-vitro and in-vivo (Capparelli et al., 2012; Pfalzgraff et al., 2018).
Bacteriocins are a family of AMPs produced by certain bacteria and of these a subclass
exits called lantibiotics, characterised by extensive post-translational modifications
(Chatterjee et al., 2005). The most extensively characterised lantibiotic is nisin,
produced by some Lactococcus lactis strains, with an array of applications. A recent
review on the biomedical applications of nisin supported the use of nisin in clinical
therapy, including treatment of bacterial infections, oral health and cancer therapy
(Shin et al., 2016). In particular, nisin is a potent antimicrobial and exhibits high
efficacy against several clinically relevant pathogens, with MICs ranging from 1
mg/ml for S. pneumoniae to between 4 and 16 mg/ml for MRSA (Severina et al., 1998;
Dosler and Gerceker, 2011; Okuda et al., 2013). Studies investigating the
antimicrobial potential of nisin against GBS are lacking; however, our previous study
characterised the susceptibility of clinical GBS strains to nisin and we detected some
level of activity in 91% of isolates tested (n = 111). Moreover, a bioengineered
derivative of nisin was demonstrated to perform better for 64.8% of isolates (Hayes et
al., 2019). Interestingly, studies have demonstrated synergistic activity when nisin was
used in combination with antibiotics, including ciprofloxacin to treat S. aureus
infections where a >3 log reduction in CFU/ml was observed after 24 hours (Dosler
and Gerceker, 2011) and combined with polymyxin to reduce biofilm formation in
Pseudomonas (Field et al., 2016a). Murdock et al., (2007) reported synergistic effects
between nisin and lactoferrin that inhibited the growth of Listeria monocytogenes and
E. coli 0157:H7 with an FICI of 0.35 achieved for the combination against both
pathogens (Murdock et al., 2007). In addition, nisin improved the activity of 18
different antibiotics used to treat Enterococcus faecalis infections whereby the
addition of 200 U/ml nisin reduced the MICs of antibiotics by up to 16-fold (Tong et
al., 2014). These results are encouraging and suggest that nisin has potential for use
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in combination with conventional antibiotics to treat infections and/or help prevent
further development of antibiotic resistance.
Lactoferrin is a glycoprotein found in the exocrine secretions of many mammals and
was first isolated from bovine milk (Sorensen and Sorensesn, 1940). Lactoferrin has
demonstrated antimicrobial activity, whereby its main mode of action is via the
binding and sequestering of available iron, preventing bacteria from acquiring iron
and thus inhibiting their growth (Arnold et al., 1980; Jenssen and Hancock, 2009).
Lactoferrin has exerted activity against a variety of bacteria including Streptococcus
mutans, Staphylococcus epidermidis and Campylobacter jejuni, with MICs ranging
from 1.6-6.5 mg/L (Arnold et al., 1980; Yamauchi et al., 1993; Jenssen and Hancock,
2009; Jahani et al., 2015). Synergistic effects have been reported when lactoferrin was
combined with other antimicrobial agents against clinically relevant bacteria such as
Escherichia coli with an FICI of 0.35 (Almehdar et al., 2019), Helicobacter pylori
with an MIC50 of 10 mg/ml that resulted in a 16-fold reduction in the MIC of
levofloxacin (Ciccaglione et al., 2019) and Staphylococcus aureus whereby a 3 log
reduction in CFU/ml was observed using lactoferrin and lysostaphin (Desbois and
Coote, 2011). Of interest, lactoferrin was shown to inhibit GBS growth by 46 – 94%
in a dose-dependent manner at concentrations of 100 – 1000 mg/L, but only when
lactoferrin was in an iron-free state (Kothary et al., 2017).
As resistance to both erythromycin and clindamycin continues to rise in GBS, and
tetracycline resistance remains high, this study aimed to investigate if antibiotic
resistance could be counteracted by combining these conventional antibiotics with
nisin and lactoferrin. Combining antimicrobial agents with differing modes of action
can encourage synergistic effects against bacteria (Worthington and Melander, 201;
Wright, 2016; Tyers and Wright, 2019) and while erythromycin and clindamycin have
similar modes of action to one another, they have distinct modes of action to
tetracycline, nisin, and lactoferrin, making them potentially suitable candidates for
combination therapy. Erythromycin and clindamycin exert a bacteriostatic effect by
binding to the 50S subunit of the bacterial ribosome and inhibiting protein synthesis
(Mazzei et al., 1993). Tetracycline also has a bacteriostatic effect and binds to the 30S
ribosomal subunit, as well as preventing the association of amino-acyl tRNA with the
bacterial ribosome (Chopra and Roberts, 2001). Lactoferrin primarily exerts its
bacteriostatic effects through iron sequestering, preventing bacteria from binding to
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iron, but it has also been shown to destabilize bacterial membranes, resulting in
bactericidal effects (Ellison et al., 1988; Samaniego-Barrón et al., 2016). Nisin has a
dual mode of action and uses lipid II as a docking molecule, thereby inhibiting
bacterial cell wall synthesis while also forming pores in bacterial membranes
(Breukink and de Kruijff, 1999; Wiedemann et al., 2001; van Heusden et al., 2002;
Hsu et al., 2002, 2004; Hasper et al., 2004).
There is currently a lack of novel antibiotics being developed which has prompted
renewed interest in the potential of naturally occurring antimicrobial agents.
Combining antibiotics with natural antimicrobials could prove an effective treatment
strategy against clinically relevant bacteria. Nisin and lactoferrin have been used in
combination with antibiotics and the combinations have proven effective against
various bacteria, including Staphylococcus spp., Enterococcus faecalis and
Pseudomonas (Desbois and Coote, 2011; Dosler and Gerceker, 2011; Tong et al.,
2014; Field et al., 2016b). One study reported the inhibition of GBS growth by
lactoferrin alone; however, investigations examining the effect of lactoferrin
combined with conventional antibiotics has not been carried out for GBS isolates to
date. We have previously characterised the susceptibility of a clinical collection of
GBS strains to purified nisin; however, to the best of our knowledge, the potential to
use bacteriocin-antibiotic combination therapy to treat GBS infections has not been
extensively studied to date. Moreover, bacteriocins such as nisin can be easily
bioengineered to produce modified derivatives with enhanced antimicrobial activities
(Field et al., 2008). We previously identified a nisin derivative, nisin PV, with
improved activity against clinical GBS isolates (Hayes et al., 2019); however, for this
previous study we did not investigate the synergistic potential of this derivative in
combination with other antimicrobials.
In this study a variety of antimicrobial combinations, that included erythromycin,
clindamycin, tetracycline, lactoferrin, nisin or nisin PV, were screened to identify
combinations that displayed improved activity against selected GBS strains. The
combination of erythromycin and nisin was selected for further analysis to evaluate
potential synergistic effects against GBS and assess the effect of the combination on
the host immune response.
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4.3. Materials and methods
4.3.1. Bacterial strains and antimicrobials
The bacterial strains (n = 6) used in this study were clinical samples of various origins.
The relevant characteristics of selected strains are summarised in Table 4.1. Each
isolates was previously determined to be resistant to erythromycin and harboured
either the ermB or mefA/E gene for macrolide resistance (Hayes et al., 2017).
Furthermore, the isolates had been examined for their susceptibility to nisin and
displayed varying degrees of susceptibility, with all strains harbouring the nsr gene
associated with nisin resistance (Hayes et al., 2019).
GBS strains were cultured in cation-adjusted Mueller-Hinton broth (Fannin, Ireland)
supplemented with 5% defibrinated horse blood (MHB-F) and incubated at 37oC
overnight. Erythromycin, clindamycin, tetracycline, nisin and lactoferrin powders
were purchased from Sigma-Aldrich, Ireland. Nisin A and its derivative nisin PV were
purified as previously described (Hayes et al., 2019).
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Table 4.1: Bacterial isolates with relevant clinical and molecular characteristics.
GBS isolates Sample
origin

Clinical
information

Erythromycin
resistance
genes
ermB +

Nisin
resistance
Gene
nsr +

CIT-66

BC

Invasive,
neonatal

CIT-67

BC

Invasive, adult

mefA/E +

nsr +

CIT-85

BC

Invasive, adult

ermB +

nsr +

CIT-223

HVS

Colonising, adult

ermB +

nsr +

CIT-239

HVS

Colonising, adult

ermB +

nsr +

CIT-395

HVS

Colonising, adult

ermB +

nsr +

BC, blood culture sample; HVS, high-vaginal swab.
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4.3.2. Minimum inhibitory concentration (MIC) and minimum bactericidal
concentration (MBC) determinations
The MICs and MBCs of each antimicrobial were determined by the broth
microdilution method, according to published guidelines (CLSI, 2012). Briefly, 100
μl of antimicrobial suspensions were added to the first well in each column of a 96
well plate and two-fold serial dilutions were carried out, resulting in a total of 12
dilutions. For erythromycin, clindamycin and tetracycline, concentrations ranged from
256 – 0.125 μg/ml as specified by the CLSI guidelines, and for lactoferrin,
concentrations ranged from 500 - 0.5 μg/ml. Purified nisin A and nisin PV preparations
ranged from 25.2 – 0.013 μg/ml. Concentrations of commercial nisin A ranged from
640 – 0.3125 μg/ml, as the commercial powder was of lower purity. Fresh overnight
GBS cultures were adjusted to a density of 0.5 McFarland in 0.85% saline before being
diluted to a final concentration of 5 x 105 CFU/ml and 100 μl was added to each test
well. Wells with media and GBS without antibiotics served as positive controls and
wells with only media served as negative controls. Plates were incubated for 16-20
hours at 37oC and examined the following day. The MIC was defined as the lowest
concentration of antimicrobial substance that completely inhibited growth as seen by
the unaided eye. Experiments were performed in triplicate.
For MBC determination, 100 µl was taken from the MIC, 2X MIC and 4XMIC well
for each antimicrobial. Serial dilutions and viable plate counts were carried out to
determine the bacterial count at each concentration tested. The MBC was defined as
the lowest concentration at which killed 99.9% of the cells compared to the initial
inoculum (CLSI, 2012).
4.3.3. Growth curve analysis
Growth curves were used as initial screens to assess the combined activity of the
antimicrobials. Combinations were assessed using ½ MIC of each antimicrobial (Field
et al., 2016b). Overnight cultures of GBS were diluted to a density of approximately
5 x 105 CFU/ml in Todd Hewitt Broth (THB) with the appropriate antimicrobials,
alone or in combination. Following this, 200 μl of each culture/antimicrobial mixture
was added to a 96 well plate and growth was monitored spectrophotometrically at 600
nm (SpectraMax) for 24 hours at 370C. THB with GBS but without antibiotics was
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used as a positive growth control and THB alone was used as a negative growth
control.
For interpretation of combined antimicrobial activity, the combination was defined as
having no effect (no difference in growth compared to the control), an extended lag
phase (delayed lag phase by ≥3 hours compared to the control), reduced growth (lower
OD600nm values after 24 hours growth compared to the control), increased growth
(higher OD600nm values after 24 hours growth compared to the control) or complete
inhibition (no growth observed over 24 hours).
4.3.4. Checkerboard assay
Combined effects of erythromycin and nisin were investigated by the checkerboard
assay as described previously (Kitazaki et al., 2017). Briefly, nisin and erythromycin
were serially diluted two-fold along the X and Y axes of a 96 well plate, respectively.
The concentrations ranged from 4 X to 1/64 X MIC for nisin and from 4 X to 1/16 X
MIC for erythromycin. Overnight GBS cultures were standardised to a density of 0.5
McFarland and plates were then inoculated with GBS cultures at a concentration of 5
X 105 CFU/ml and incubated overnight at 37oC. Bacterial growth was assessed
visually and the fractional inhibitory concentration (FIC) index for each combination
was calculated as follows: FIC index = FIC of erythromycin + FIC nisin. FIC antibiotic
= MIC combination/MIC alone. The FIC index values were interpreted as: ≤ 0.5,
synergistic; > 0.5 - 1.0, additive; > 1.0 - 2.0, indifferent; > 2.0, antagonistic (Kitazaki
et al., 2017). Experiments were performed in triplicate.
4.3.5. Time-kill assay
A time-kill assay was also used to assess the interaction between erythromycin and
nisin (Kitazaki et al., 2017). Briefly, 5 ml of MHB-F, containing ½ X, 1 X or 2 X MIC
of the antimicrobial, either alone or in combination, were inoculated with GBS to a
final concentration of 5 x 105 CFU/ml. Five ml of MHB-F with bacteria, but without
antibiotics, served as the positive control for growth, and 5 ml of MHB-F alone served
as the negative control. During incubation, 100 μl aliquots of each sample were taken
at 0, 3, 6, 9 and 24 hours of incubation at 370C. Each aliquot was serially diluted
tenfold and 100 μl was inoculated onto BHI agar from at least two dilutions per time
point, incubated overnight at 37oC and colony counts were then determined.
Synergism was defined as ≥ 2 log10 CFU/ml growth reduction with the combination
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of antibiotics relative to either antimicrobial alone after 24 hours. A reduction of 1 - <
2 log10 reduction in CFU/ml was defined as an additive effect, while an increase or
decrease of < 1 log10 was defined as an indifferent effect. An antagonistic effect was
defined as a > 2 log10 increase in CFU/ml after 24 hours (Kitazaki et al., 2017).
4.3.6. Cell line and MTT cytotoxicity assay
The human macrophage U937 cell line was purchased from ECACC (ECACC #
85011440). Cells were cultured in RPMI 1640 media (Sigma-Aldrich, Ireland)
supplemented with 10% heat-inactivated foetal bovine serum (FBS) (GIBCO,
ThermoFisher) and 1% penicillin-streptomycin (Sigma Aldrich, Ireland). Cells were
maintained at 37oC + 5% CO2 and cell viability was assessed using trypan blue
exclusion staining and haemocytometer counts. The 3-(4, 5-Dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT) assay was used to assess the viability of U937
cells in the presence of erythromycin and nisin (Riss et al., 2004). For this, cells were
seeded at a density of 1 x 106 cells/ml in antibiotic-free RPMI media supplemented
with 2.5% FBS in a 96 well plate and incubated for 24 hours at 37 oC + 5% CO2. Cells
were then exposed to either erythromycin or nisin at concentrations of ¼, ½ 1 and 5 X
MIC and incubated for 24 hours. The total volume in each well was 100 µl. A positive
control (100% viability) consisted of U937 cells and media, while a negative control
contained only media. Following incubation, 10 µl of MTT reagent was added to each
well and incubated for a further 4 hours, after which 100 µl solubilisation solution
(1.2% acetic acid, 40% DMF and 0.16 g/ml SDS) was added. The wells were
thoroughly mixed to ensure that any crystals formed by MTT reduction of
metabolically active cells were fully dissolved and plates were then incubated for 24
hours at 37 0C. The optical density of samples was determined at OD 540 and OD 630
nm. The background absorbance at 630 nm was subtracted from absorbance at 540 nm
to yield the corrected OD for samples. The % viability of cells was calculated as
follows and a viability of >80% was considered non-toxic:
%𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =

(𝑂𝐷 𝑠𝑎𝑚𝑝𝑙𝑒 − 𝑂𝐷 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
X 100
(𝑂𝐷 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝑂𝐷 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
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4.3.7. Cell differentiation and infection assay
Differentiation of U937 monocytes into macrophages was achieved by treatment with
phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich, Ireland). Cells were seeded at
1 x 106 cells/ml in a 24 well plate in serum-free RPMI 1640 culture media containing
50 ng/ml PMA. Following PMA treatment for 24 hours, cells were examined
microscopically to confirm differentiation into macrophages and subsequently left to
recover for 48 hours in fresh media without PMA (Rosas et al., 2016). The medium
was then removed, and the cells were challenged with antibiotics and infected with
GBS according to a method previously described (Upadhyay et al., 2017a). Briefly,
erythromycin and nisin were added to wells at a final concentration of 1 X MIC (0.5
μg/ml erythromycin and 160 μg/ml nisin, respectively). Immediately after, GBS prewashed with PBS were added to each relevant well at a final concentration of 106
CFU/ml. Plates were centrifuged at 700 rpm for 3 minutes before incubation at 37oC
+ 5% CO2 for 18 hours. Samples were then centrifuged at 13, 000 rpm for ten minutes
and cell free-supernatants were collected and stored at -20oC until further analysed.
Positive controls included GBS without antibiotics, heat-inactivated GBS without
antibiotics and lipopolysaccharide (LPS) without antibiotics. Negative controls
included non-differentiated U937 cells, cells treated with antibiotics but without GBS
and differentiated cells without bacteria or antibiotics. All experiments included
duplicate samples and were performed in triplicate.
4.3.8. Cytokine measurement
The concentration of TNF-alpha in the cell free supernatants was determined using the
human TNF-alpha ELISA kit (R&D systems) according to the manufacturer’s
instructions. The level of cytokine expression in the samples was calculated using a
standard curve of recombinant TNF-alpha ranging from 0 - 1000 pg/ml. Samples were
tested in duplicate and the average of three experimental repeats was used.
4.3.9. Statistical analysis
A one-way ANOVA was used to analyse statistical differences using SPSS v. 25.0
(IBM, UK) with Dunnett’s post-hoc tests to evaluate the differences in TNF-alpha
production. A P-value of ≤ 0.05 was considered significant.
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4.4. Results
4.4.1. MIC data and initial screen of combined antimicrobial activity
The MICs of erythromycin, clindamycin, tetracycline, lactoferrin, commercial nisin
and purified nisin A and nisin PV were determined for the six GBS isolates (Table
4.2). MICs for erythromycin ranged from 0.5 to >256 g/ml, clindamycin MICs
ranged from 0.0625 - >256 g/ml and tetracycline MICs ranged from 16-32 g/ml.
The MIC of lactoferrin was >500 g/ml for all six isolates. MICs of both purified
Nisin A and Nisin PV ranged from 3.14 – 25.16 g/ml and MICs of commercial nisin
ranged from 40 - >640 g/ml.
A preliminary screen of antimicrobial combinations using ½ X MIC of each
antimicrobial agent was assessed against six GBS isolates by growth curve analysis.
Figures 4.1-4.10 show the results of the growth curve analysis and Table 4.3
summarises the outcomes. We initially screened the antibiotics erythromycin,
clindamycin and tetracycline for potentially improved activity when combined at ½ X
MIC. Erythromycin combined with tetracycline resulted in complete inhibition of
growth or an extended lag phase (Figure 4.1). The combination of erythromycin and
clindamycin inhibited the growth of two isolates (CIT 67 and CIT 85), both of which
were susceptible to clindamycin. The remaining four isolates did not display greater
sensitivity to the antibiotic combination (Figure 4.2). Tetracycline combined with
clindamycin exerted either complete inhibition or an extended lag phase for the
isolates tested (Figure 4.3). Erythromycin combined with purified nisin A caused a
delay of growth for five isolates and complete inhibition of growth for one isolate, CIT
67 (Figure 4.4), while the combination of clindamycin and purified nisin A resulted in
the complete inhibition of growth for four isolates, reduced growth for one isolate
(CIT 239) and had no effect on the growth of isolate CIT 66 (Figure 4.5). Tetracycline
and purified nisin A combined caused a delay in growth for CIT 66, and resulted in
complete inhibition for the remaining isolates (Figure 4.6). Nisin PV combined with
erythromycin caused complete inhibition or delayed growth of four isolates, however,
the combination appeared to promote the growth of CIT 85 and CIT 395 (Figure 4.4).
A varied response to the combination of nisin PV and clindamycin was observed, with
no effect observed for three isolates (CIT 66, 67 and239), and conversely, complete
inhibition was observed for one isolate, CIT 85, reduced growth for CIT 395 and an
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extended lag phase for CIT 223 (Figure 4.5). Nisin PV and tetracycline also exerted a
varied effect, with complete inhibition of CIT 66 and 67, reduced growth for CIT 85
but no effect observed for CIT 223, 239 and 395 (Figure 4.6). Lactoferrin and purified
nisin A resulted in complete inhibition of two isolates (CIT 67 and 85), and an
extended lag phase for three isolates (CIT 66, 223 and 239), but increased growth was
observed for one isolate, CIT 395 (Figure 4.7). When used in combination with nisin
PV, lactoferrin elicited a varied response with reduced, delayed or complete inhibition
of growth for four isolates (CIT 67, 85, 223 and 239), increased growth for one isolate
(CIT 66) and no effect on CIT 395 (Figure 4.7). Lactoferrin in combination with
erythromycin did not exert an improved effect for four isolates but did reduce growth
for two isolates (Figure 4.8). Similarly, combinations of clindamycin and lactoferrin
had no effect for four isolates, reduced growth for one isolate and complete inhibition
of another isolate (Figure 4.9). When used in combination with tetracycline, lactoferrin
delayed or reduced growth for three isolates, increased growth for two isolates and
had no effect on one isolate (Figure 4.10).
In summary, combinations of erythromycin and tetracycline, tetracycline and
clindamycin, erythromycin and nisin, tetracycline and nisin and erythromycin and
nisin PV resulted in improved antimicrobial activity by growth curve analysis for all
six isolates (Figures 4.1-4.4, 4.6; Table 4.3).
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Table 4.2: Minimum inhibitory concentrations (MIC) of each antimicrobial tested
against six Group B Streptococcus isolates.

MIC (µg/ml)
Antimicrobial
substance

CIT 66

CIT 67

CIT 85

CIT 223 CIT 239 CIT 395

Erythromycin

0.5

1

>256

>256

>256

>256

Clindamycin

2

0.0625

>256

32

0.5

128

Tetracycline

32

16

32

16

16

32

Nisin A

12.6

25.16

3.14

25.16

25.16

25.16

Nisin PV

12.6

3.14

25.2

6.3

6.3

12.6

Lactoferrin

>500

>500

>500

>500

>500

>500

Commercial

160

160

40

>320

>320

>640

nisin
MIC values as determined by the broth microdilution method. Data represent the mean of
triplicate experiments.
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Figure 4.1: Growth of Group B Streptococcus isolates in the presence of erythromycin
and tetracycline.
Growth curve analysis of Group B Streptococcus isolates in the presence of sub-lethal
concentrations of erythromycin and tetracycline, alone and in combination. Images A-F show
isolates CIT 66, 67, 85, 223, 239 and 395, respectively.
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Figure 4.2: Growth of Group B Streptococcus isolates in the presence of erythromycin
and clindamycin.
Growth curve analysis of Group B Streptococcus isolates in the presence of sub-lethal
concentrations of erythromycin and clindamycin, alone and in combination. Images A-F show
isolates CIT 66, 67, 85, 223, 239 and 395, respectively.
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Figure 4.3: Growth of Group B Streptococcus isolates in the presence of tetracycline and
clindamycin.
Growth curve analysis of Group B Streptococcus isolates in the presence of sub-lethal
concentrations of tetracycline and clindamycin, alone and in combination. Images A-F show
isolates CIT 66, 67, 85, 223, 239 and 395, respectively.
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Figure 4.4: Growth of Group B Streptococcus isolates in the presence of erythromycin,
purified nisin A and nisin PV.
Growth curve analysis of Group B Streptococcus isolates in the presence of sub-lethal
concentrations of erythromycin and purified nisin A and nisin PV, alone and in combination.
Images A-F show isolates CIT 66, 67, 85, 223, 239 and 395, respectively.
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Figure 4.5: Growth of Group B Streptococcus isolates in the presence of clindamycin,
purified nisin A and nisin PV.
Growth curve analysis of Group B Streptococcus isolates in the presence of sub-lethal
concentrations of clindamycin and purified nisin A and nisin PV, alone and in combination.
Images A-F show isolates CIT 66, 67, 85, 223, 239 and 395, respectively.
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Figure 4.6: Growth of Group B Streptococcus isolates in the presence of tetracycline,
purified nisin A and nisin PV.
Growth curve analysis of Group B Streptococcus isolates in the presence of sub-lethal
concentrations of tetracycline and purified nisin A and nisin PV, alone and in combination.
Images A-F show isolates CIT 66, 67, 85, 223, 239 and 395, respectively.
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Figure 4.7: Growth of Group B Streptococcus isolates in the presence of lactoferrin,
purified nisin A and nisin PV.
Growth curve analysis of Group B Streptococcus isolates in the presence of sub-lethal
concentrations of lactoferrin and purified nisin A and nisin PV, alone and in combination.
Images A-F show isolates CIT 66, 67, 85, 223, 239 and 395, respectively.
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Figure 4.8: Growth of Group B Streptococcus isolates in the presence of erythromycin
and lactoferrin.
Growth curve analysis of Group B Streptococcus isolates in the presence of sub-lethal
concentrations of erythromycin and lactoferrin, alone and in combination. Images A-F show
isolates CIT 66, 67, 85, 223, 239 and 395, respectively.
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Figure 4.9: Growth of Group B Streptococcus isolates in the presence of clindamycin
and lactoferrin.
Growth curve analysis of Group B Streptococcus isolates in the presence of sub-lethal
concentrations of clindamycin and lactoferrin, alone and in combination. Images A-F show
isolates CIT 66, 67, 85, 223, 239 and 395, respectively.
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Figure 4.10: Growth of Group B Streptococcus isolates in the presence of tetracycline
and lactoferrin.
Growth curve analysis of Group B Streptococcus isolates in the presence of sub-lethal
concentrations of tetracycline and lactoferrin, alone and in combination. Images A-F show
isolates CIT 66, 67, 85, 223, 239 and 395, respectively.
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Table 4.3: Summary of combined antimicrobial activities of antibiotics, nisin, nisin
PV and lactoferrin against six Group B Streptococcus strains by growth curve
analysis.
Effect of antimicrobial combination on GBS growth
(No. of isolates)
Antimicrobial
combination at ½ X MIC
of each compound
Antibiotic combinations

Complete
inhibition

Extended
lag phase

Reduced
growth

Increased
growth

Erythromycin +
clindamycin
Erythromycin +
tetracycline
Tetracycline +
clindamycin
Nisin and antibiotic
combinations
Nisin + erythromycin

2

Nisin + clindamycin

4

Nisin + tetracycline

5

1

Nisin + lactoferrin

2

3

1

Nisin PV and antibiotic
combinations
Nisin PV + erythromycin

1

4

1

Nisin PV + clindamycin

1

1

Nisin PV + tetracycline

2

Nisin PV + lactoferrin

1

Lactoferrin and antibiotic
combinations
Lactoferrin +
erythromycin
Lactoferrin + clindamycin

No
effect

4

3

3

5

1

1

5
1

1

1

0

1
1

2

1

1

1

Lactoferrin + tetracycline

2

0

3
3

1

1

4

1

0

4

1

2

1

The effects of antimicrobial combinations at ½ X MIC on the growth of Group B Streptococcus isolates.
Reduced growth was defined as an overall reduction in growth when antimicrobials were combined,
compared to either antimicrobial alone. Increased growth was defined as instances where bacterial
growth improved in the presence of the combination compared to either antimicrobial alone. No effect
indicates that growth in the presence of the combination was comparable to the individual antimicrobial
agents or where the combination was comparable to the individual antimicrobial agents or where the
combination decreased growth compared to one agent only.
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4.4.2. Investigations of erythromycin and nisin combinations using the checkerboard
assay
The combination of erythromycin and nisin A was selected as the most promising due
to the fact that it resulted in either complete inhibition or a reduced lag phase for all
isolates. Furthermore, erythromycin is sometimes used for GBS prophylaxis regimens
in the cases of penicillin allergies. As resistance to erythromycin has remained high in
recent years, we sought to investigate if resistance could be overcome when used in
combination with nisin. However, due to the labour-intensive nature and cost
associated with the purification of nisin, commercially available nisin A was used for
further analyses. While commercial nisin did not have the same bactericidal activity
as the purified peptide, this was expected given the commercial preparation has a
purity of 2.5% and is reflected in the MIC values obtained for both preparations. The
MIC of this nisin preparation was determined for all six isolates and ranged from 40 –
640 g/ml (Table 4.4) and improved activity when combined with erythromycin was
confirmed by growth curve analysis (Figure 4.11). For all six isolates, an increased lag
time or delayed growth by 6-12 hours was observed when erythromycin and nisin A
were used in combination (Figure 4.11). Thus, further investigation was conducted to
evaluate the interaction between erythromycin and commercial nisin A, herein
referred to as nisin unless otherwise stated.
Checkerboard assays were used to establish MICs for erythromycin and nisin when
used alone and in combination. These MIC values were used to calculate the fractional
inhibitory concentration (FIC) for the antimicrobial combination (Table 4.4). The
fractional inhibitory concentration index (FICI) was then determined to assess
synergy. The FICI for the six isolates ranged from 0.57 – 1.44, with an additive effect
identified for five isolates (CIT 66, 67, 85, 223 and 239) and an indifferent effect
identified for one isolate (CIT 395). According to the checkerboard assay, there were
no synergistic or antagonistic interactions observed for this antimicrobial combination.
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Figure 4.11: Growth of Group B Streptococcus isolates in the presence of erythromycin
and commercial nisin, alone and in combination.
Growth curve analysis of Group B Streptococcus isolates in the presence of sub-lethal
concentrations of erythromycin (Ery) and nisin, alone and in combination. Concentrations
used were established from MIC evaluation and represent ½ X MIC of each antimicrobial.
Images A-F represents CIT 66, 67, 85, 223, 239 and 395 respectively and are representative
of the mean ± standard deviation of triplicate experiments.
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Table 4.4: Summary of antimicrobial activity and checkerboard assay investigations for erythromycin (Ery) and nisin against Group B
Streptococcus isolates.
Isolate

MIC

MBC

MIC

MBC

MIC

MIC

FIC

FIC

FIC

Ery

Ery

Nisin

Nisin

Ery-

Nisin-

Ery

Nisin

Index

(µg/ml)

(µg/ml)

(µg/ml)

(µg/ml)

combination

combination

(µg/ml)

(µg/ml)

Interpretation

CIT 66

0.5

1

160

640

0.14

46.7

0.28

0.29

0.57

Additive

CIT 67

1

2

160

640

0.5

30

0.5

0.19

0.69

Additive

CIT 85

>256

1024

40

160

15

20

0.06

0.5

0.56

Additive

CIT 223

>256

1024

>320

1280

256

6.7

1.00

0.02

1.02

Additive

CIT 239

>256

1024

>320

1280

141

33.33

0.55

0.1

0.65

Additive

CIT 395

>256

1024

>640

2560

155

533.3

0.61

0.83

1.44

Indifferent

Table shows the MIC and MBC (µg/ml) determined for each antibiotic. The FIC for ery or nisin is the ratio of the MIC of antibiotics in combination and the
MIC of antibiotics alone (FIC=MICcombo/MICalone). The FIC Index is defined as FIC ery + FIC nisin. The FIC index values were interpreted as: ≤ 0.5, synergistic;
> 0.5 - 1.0, additive; > 1.0 - 2.0, indifferent; > 2.0, antagonistic (Kitazaki et al., 2017).
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4.4.3. Time-kill assay
For all the GBS isolates tested, incubation with a combination of erythromycin and
nisin at ½ X MIC resulted in an indifferent response (Table 4.5; Figure 4.12).
Combinations of the antimicrobials at 1 X MIC exerted an additive effect for five
isolates, CIT 66, 85, 223, 239 395, and a synergistic effect for CIT 67 (Table 4.5,
Figure 4.13).
When used at 2 X MIC, erythromycin or nisin alone did not result in bactericidal
activity for isolates CIT 66, 67 and 85, however, combining the two antimicrobials at
these concentrations resulted in complete bactericidal activity (Figure 4.14 A-C). A
decreased bacterial count of over 4 log10 CFU/ml was observed when these isolates
were grown in the presence of erythromycin and nisin combined compared to either
antimicrobial alone, which indicates a synergistic effect. Similarly, erythromycin or
nisin used alone at 2 X MIC did not exert bactericidal activity for isolates CIT 223,
239 and 395. The combination of both antimicrobials did reduce bacterial growth over
9 hours for these isolates, however, a subsequent re-growth of viable bacteria was
observed (Figure 4.14 D-F) and the growth reduction after 24 hours was < 2
log10CFU/ml, indicating an additive effect.
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Table 4.5: Log reduction of the colony forming unit (CFU/ml) of Group B Streptococcus isolates using the time-kill curve assay after 24 hours
incubation with erythromycin and nisin, alone and in combination.
∆log10 CFU/ml after
24 hours:
erythromycin

∆log10 CFU/ml after
24 hours: nisin

CIT 66
CIT 67
CIT 85
CIT 223
CIT 239
CIT 395

1.83
2.26
1.94
2.15
1.92
2.14

2
2.68
2.38
1.94
2.41
2.48

CIT 66
CIT 67
CIT 85
CIT 223
CIT 239
CIT 395

1.99
2.14
1.98
1.57
2.14
2.15

2.85
2.99
1.54
1.65
2.17
3.13

CIT 66
CIT 67
CIT 85
CIT 223
CIT 239
CIT 395

2.02
-2.75
1.88
2.13
1.99
1.96

2.6
2.88
-1.81
1.49
2.42
2.1

Isolate

∆log10 CFU/ml after
24 hours:
combination
½ X MIC
1.8
2.73
1.4
2.27
2.14
2.38
1 X MIC
1.63
-5.1
0.22
1.31
2.1
2.14
2 X MIC
-4.82
-4.76
-4.2
0.26
0.91
0.56

∆log10 CFU/ml
erythromycin alone
– ∆log10 CFU/ml
combination

∆log10 CFU/ml nisin
alone – ∆log10
CFU/ml
combination

Outcome

0.03
-0.047
0.74
-0.12
-0.22
-0.24

0.2
-0.05
0.98
-0.33
0.27
0.1

Indifferent
Indifferent
Indifferent
Indifferent
Indifferent
Indifferent

0.36
7.24
1.76
0.26
0.04
0.01

1.22
8.09
1.32
0.34
0.07
0.99

Additive
Synergistic
Additive
Indifferent
Indifferent
Indifferent

6.84
2.01
6.08
1.87
1.08
1.4

7.42
7.64
2.39
1.23
1.51
1.54

Synergistic
Synergistic
Synergistic
Additive
Additive
Additive

Group B Streptococcus isolates were grown in presence of different concentrations of erythromycin and nisin combinations (½ MIC, 1 MIC and 2 X MIC).
Synergy was defined as a >2log10 CFU/ml reduction after 24 hours when antimicrobials were combined compared to each individual antimicrobial. Additive
effect was defined as a 1-2 log10 CFU/ml reduction after 24 hours and Indifferent effect was defined as <1 log10 CFU/ml reduction or increase after 24 hours.
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Figure 4.12: Time-kill curve analysis of Group B Streptococcus isolates in the presence
of erythromycin, nisin and a combination of both erythromycin and nisin at ½ X MIC.
Images A and C show the additive effect of erythromycin and nisin at ½ X MIC for isolates
CIT 66 and 85, respectively. Image B shows the synergistic effect of the combination on
isolate CIT 67. Images D, E and F show the indifferent effect of erythromycin and nisin on
isolates CIT 223, 239 and 395 respectively.
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Figure 4.13: Time-kill curve analysis of Group B Streptococcus strains in the presence
of erythromycin, nisin and a combination of both erythromycin and nisin at 1 X MIC.
Images A-C show the synergistic effect of erythromycin and nisin at 1 X MIC of each
antimicrobial for isolates CIT 66, 67 and 85 respectively. Images D-F show the additive effect
of both antimicrobials combined for isolates CIT 223, 239 and 395.
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Figure 4.14: Time-kill curve analysis of Group B Streptococcus strains in the presence
of combinations of erythromycin, nisin and a combination of both erythromycin and
nisin at 2 X MIC.
Images A-C show the synergistic effect of erythromycin and nisin at 2 X MIC of each
antimicrobial for isolates CIT 66, 67 and 85 respectively. Images D-F show the additive effect
of both antimicrobials combined for isolates CIT 223, 239 and 395.
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4.4.4. Immunomodulatory effects of erythromycin, nisin and their combination
Erythromycin did not, at any concentration tested, affect cell viability (Table 4.6).
Nisin used at ¼, ½ and 1 X MIC was non-toxic to the cells, however when used at 5
X MIC, nisin exerted a cytotoxic effect on the cell line. Therefore, concentrations of
1 X MIC of each antimicrobial were selected for use in the immunomodulatory assay
with U937 cells.
Optimisation of U937 differentiation was initially carried out using concentrations of
10, 20, 50 and 100 ng/ml PMA (Figure 4.15). Successful differentiation was
determined by assessment of cell morphology and confirmed by aggregation and
adherence of the cells in the wells after washing (Schwende et al., 1996; Ragg et al.,
1998). Based on this criterion, 50 ng/ml PMA was selected as the optimal
concentration due to the highest degree of aggregation and adherence observed (Figure
4.15D). Differentiated U937 cells were then challenged with GBS in the presence and
absence of erythromycin, nisin and the antimicrobial combination (Figure 4.16) and
TNF-alpha secretion was measured. Differences in U937 cell morphology (Figure
4.16A) can be observed when cells were challenged with GBS (Figure 4.16C), GBS
and erythromycin (Figure 4.16D), GBS and nisin (Figure 4.16E) and GBS,
erythromycin and nisin (Figure 4.16F).
Cells infected with GBS but without antibiotics produced 876 pg/ml of TNF-alpha
after 18 hours of stimulation. The addition of erythromycin increased TNF-alpha
secretion, with levels reaching 1083 pg/ml. Nisin induced a low level of TNF-alpha
secretion (193 pg/ml). When erythromycin and nisin were used in combination,
significantly less TNF-alpha levels (56 pg/ml) was expressed compared to the
untreated control group (P < 0.05; Figure 4.17).
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Table 4.6: Cell viability study investigating the effect of erythromycin and nisin concentrations on U937 viability (% viability).

5 X MIC

1 X MIC

½ X MIC

¼ X MIC

[Antimicrobial]

Ery

Nisin

Ery

Nisin

Ery

Nisin

Ery

Nisin

µg/ml

5

800

1

160

0.5

80

0.25

40

% Viability

108.4%

46.1%

92.2%

80.3%

118.5%

84.2%

97.4%

94.24%

Values are the mean of three independent experiments, expressed as a percentage relative to untreated U937 cells.
Ery, erythromycin.
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Figure 4.15: PMA differentiation of U937 cells.
Differentiation of U937 monocytes into macrophages. (A) U937 cells without PMA before
removal of media; (B) U937 cells without PMA after replacement of media; (C) U937 cells
treated with 100 ng/ml PMA; (D) U937 cells treated with 50 ng/ml PMA; (E) U937 cells
treated with 20 ng/ml PMA; (F) U937 cells treated with 10 ng/ml PMA.
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Figure 4.16: Challenge of U937 cells with Group B Streptococcus in the presence/absence
of antimicrobials.
(A) U937 cells without antibiotics or GBS; (B) U937 cells challenged with LPS; (C) U937
cells challenged with GBS; (D) U937 cells challenged with GBS and erythromycin; (E) U937
cells challenged with GBS and nisin; (F) U937 cells challenged with GBS, erythromycin and
nisin.
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Figure 4.17: TNF-alpha secretion of differentiated U937 cells challenged with Group B
Streptococcus in the presence/absence of antimicrobials.
Data shows TNF-alpha secretion (pg/ml) of PMA treated U937 cells in response to 1 x 10 6
CFU/ml GBS alone (control), when treated with erythromycin (1 X MIC, 1 µg/ml), nisin (1
X MIC, 160 µg/ml) and when treated with erythromycin and nisin in combination at these
concentrations. Data represents the mean ± standard deviations of triplicate experiments. *
indicate statistically significant differences (P < 0.05).
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4.5. Discussion
Despite the global increase of antibiotic resistance, there remains a lack of
development of new antibiotics (Roca et al., 2015), therefore alternative approaches
are needed to conventional antibiotic therapy. Penicillin remains the first choice of
antibiotic in prophylaxis guidelines and beta-lactams are also used in treating GBS
infections, while second-line antibiotics include erythromycin and clindamycin.
Worryingly, there have been reports of reduced beta-lactam susceptibility amongst
GBS in certain countries (Dahesh et al., 2008; Kimura et al., 2008) and resistance to
previously used second-line antibiotics continues to rise (Lamagni et al., 2013; Hayes
et al., 2017). Alternative strategies would help prevent the development and/or spread
of further resistance among GBS. Combination therapy is an attractive option,
particularly if the approach involves improving the effectiveness of ‘old’ antibiotics
(Worthington and Melander, 2012; Wright, 2016). Some antibiotic combinations are
synergistic, such that the combined effect is more potent than when the antibiotics are
used on their own (Doern, 2014; Kumar et al., 2014; Skarp et al., 2019). Furthermore,
the use of combination therapy can help control further development of resistance to
individual antimicrobials when the compounds have distinct modes of action (Brooks
and Brooks, 2014; Tong et al., 2014). Combining conventional antibiotics with
alternative antimicrobials is also advantageous as it can reduce the likelihood of
bacteria developing resistance to either antimicrobial (Tyers and Wright, 2019).
Several reviews highlight the advantages of using bacteriocins in combination with
antibiotics (Cavera et al., 2015; Mathur et al., 2017) and in particular studies have
reported synergistic effects when nisin has been combined with antibiotics against
clinically relevant bacteria (Dosler and Gerceker, 2011; Okuda et al., 2013).
Lactoferrin has also exhibited improved antimicrobial activity when used in
conjunction with conventional antibiotics (Ciccaglione et al., 2019) as well as when
combined with nisin (Murdock et al., 2007).
In the current study various combinations of antibiotics (erythromycin, clindamycin
and tetracycline) and antimicrobials (nisin, nisin PV and lactoferrin) were initially
screened for enhanced antimicrobial activity using growth curve analysis with
antimicrobials combined at ½ X MIC. Of these combinations, only a selection elicited
improved activities against all six GBS isolates. Tetracycline combined with either
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erythromycin or clindamycin exerted favourable results with enhanced antimicrobial
activity; however, it is considered unsafe to use tetracycline for pregnant women thus
limiting its potential for use. The combination of erythromycin and clindamycin did
not elicit improved activity for four of the six isolates, which is not surprising, as
erythromycin and clindamycin share similar modes of action. The two isolates for
which complete inhibition was observed with this combination were susceptible to
clindamycin when used alone, which may explain the effect observed. Nisin combined
with either clindamycin, tetracycline or lactoferrin resulted in too varied a response to
warrant further investigation, while nisin and erythromycin exhibited improved
activity for all isolates tested, either by complete inhibition or delayed growth.
Similarly, nisin PV used in combination with antibiotics exerted a varied response
among GBS isolates. In the current study improved activity was not observed between
lactoferrin and any of the antibiotics, although there have been reports of lactoferrin
acting synergistically with other antimicrobials (Murdock et al., 2007; Desbois and
Coote, 2011). Proteolytic enzymes which act on lactoferrin in-vivo produce
antimicrobial peptides such as LF1-11, lactoferricin and lactoferrampin and these have
shown to elicit increased antimicrobial effects compared to native lactoferrin (Sinha
et al., 2013). Future studies investigating the effect of digested lactoferrin, alone or in
combination with other antimicrobials, against GBS strains would be of interest.
The combination of erythromycin and nisin exerted the most pronounced effect of all
combinations tested, with complete inhibition or delayed growth by 6-15 hours
observed for all six isolates. This was particularly interesting as each of the isolates
tested were previously determined to be resistant to erythromycin and therefore, we
sought to determine if the resistance could be circumvented when combined with nisin.
Furthermore, despite each of the genes harbouring the nisin resistance gene, several
factors may explain the antibacterial activity of nisin still observed such as a lack of/or
reduced expression of the nsr gene or systems involved in it’s regulation. Importantly,
the combination of erythromycin and nisin has the best likelihood for clinical use
owing to the fact that nisin has long been established as safe for use as a food
preservative and there are a plethora of studies highlighting the antimicrobial activity
of nisin against clinically relevant bacteria (Dosler and Gerceker, 2011; Okuda et al.,
2013; Field et al., 2016a, b). Taking all of these factors into consideration, the
combination of erythromycin and nisin was selected for further analysis.
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As purified nisin is expensive and laborious to produce, we investigated if a
commercially available preparation of nisin would still elicit improved activity when
used in combination with erythromycin. Improved activity was confirmed for all six
isolates using this nisin preparation and thus further analysis of interactions between
erythromycin and this commercial nisin were carried out with the commercial
preparation. When the checkerboard assay was used to assess the combination of
erythromycin and nisin, an additive effect was observed for five of the isolates tested,
while one isolate demonstrated an indifferent response. It is worth noting that this
isolate had the highest MIC for nisin (>640 µg/ml). MIC based investigations, such as
the checkerboard assay, are widely used for synergy testing, however, they do not
provide time-dependent information on the activity of antibiotics. Time-kill curves
overcome this limitation and are therefore useful in determining the rate of killing of
the antibiotic (Doern, 2014). When the antimicrobials were combined at 2 X MIC and
assessed by time-kill curve analysis, a synergistic effect was observed for three of the
six isolates (CIT 66, 67 and 85), with > 4-fold log reduction in growth, and an additive
effect was observed for CIT 223, 239 and 395. A review by Doern (2014) on the
methodologies used to assess synergy found a frequent lack of concordance between
the checkerboard and time-kill assays, as was observed in our study (Doern, 2014).
Interestingly, the three isolates for which the antimicrobial combination was most
effective (CIT 66, 67 and 85) were the invasive isolates obtained from neonatal and
adult blood culture samples. The remaining isolates (CIT 223, 239 and 395) were
colonising strains obtained from high vaginal swabs, and an additive effect was
observed with the combination for these strains. These three isolates displayed high
MICs for both erythromycin and nisin. The combination of erythromycin and nisin at
2 X MIC was most effective for CIT 66 and 67 with a complete bactericidal effect
and, of interest, these isolates both had the lowest MIC for erythromycin (0.5 and 1
µg/ml respectively). Furthermore, isolate CIT 67 was the only isolate that
demonstrated synergy at 1 X MIC (Figure 4.13 B) and it is worth noting that this was
the only isolate to harbour the mefA/E gene for erythromycin resistance. This may
suggest a possible connection between the combined effect of erythromycin and nisin
and the mechanism of resistance conferred by the mefA/E-encoded antibiotic efflux
pump. As strains were selected based on their levels of resistance to erythromycin, it
is interesting to note that for the three strains with lower MICs for erythromycin, a
synergistic effect was achieved. Conversely, an additive effect was observed for the
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isolates with extremely high MICs for erythromycin (> 256 µg/ml). It is therefore
important to note that for strains displaying low levels of erythromycin resistance, it
is likely that a synergistic effect would be achieved with the combination treatment.
Going forward, further investigations on larger sample populations will help clarify
this hypothesis.
For all of the GBS isolates, it is interesting to note that a bactericidal or bacteriostatic
effect was observed with nisin alone at 2 X MIC over 6-9 hours, before re-growth of
bacteria occurred (Table 4.5; Figure 4.14 A-F). This could be explained by the fact
that all isolates harbour the nisin resistance gene and thus, exposure to nisin in the
external environment possibly induced its expression and subsequent production of
the nisin resistance protein, which causes proteolytic cleavage of nisin thereby
rendering its antimicrobial activity redundant (Sun et al., 2009). However, for three of
the isolates (CIT 66, 67 and 85) bacterial re-growth was prevented when nisin was
used in combination with erythromycin. This could suggest that the mode of action of
the antimicrobials may complement one another and facilitate better killing of the
bacteria, while simultaneously subverting resistance mechanisms. An additive effect
was observed for isolates CIT 223, 239 and 395, however the combination of
erythromycin and nisin did cause a reduction in bacterial growth. A bactericidal effect
could possibly be achieved for these isolates if the antimicrobials were used at higher
concentrations, however, the MICs for these strains were high, and thus we would
speculate that the required concentrations may possibly exceed therapeutic dosage. A
possible solution may be to investigate bioengineered derivatives of nisin. The ability
to enhance the bioactivity of nisin through bioengineering (Field et al., 2012) provides
further scope to investigate synergy between bioengineered nisin derivatives and
antibiotics. The preliminary screen described herein demonstrated improved activity
when nisin PV was used combination with erythromycin at ½ X MIC, resulting in an
extended lag phase for four isolates and complete inhibition of one isolate. Moreover,
our previous research demonstrated that nisin and a novel derivative, nisin PV, have
potential for treating GBS infections (Hayes et al., 2019) and therefore is encouraging
for future studies.
The purpose of antimicrobial therapy is to reduce infection, but the ideal treatment
option eradicates the causative bacteria, while producing an effective but limited
immune response. TNF-alpha is a major activator of the inflammatory response in vivo
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and is elevated in response to bacterial infection, however, increased TNF-alpha
production is thought to play a major role in the severity of infection (Upadhyay et al.,
2017b; Sutton et al., 2019). Antibiotics can differ in their ability to induce an immune
response, with studies demonstrating that macrolides induce less of an inflammatory
response compared to beta-lactam antibiotics (Brinkmann et al., 2005; Upadhyay et
al., 2017a). A reduced TNF-alpha response was also observed when human PBMC
cells, challenged with LPS, were treated with nisin Z (Kindrachuk et al., 2013). The
results presented here demonstrate that nisin has immunomodulatory effects and can
reduce harmful GBS-induced inflammatory cytokines and further examination of the
potential for nisin to induce the secretion of anti-inflammatory chemokines would be
beneficial. Exploration of the mechanisms involved in the ability of nisin to modulate
the immune response would involve the elucidation of the signalling pathways
involved. Encouragingly, results presented herein demonstrate the potential for nisin
as a positive immune modulator. Moreover, in the current study, we found that the
combination of erythromycin and nisin resulted in a significantly decreased TNFalpha response in U937 cells challenged with GBS, compared to the control without
antibiotics (P < 0.05; Figure 4.17). Our data suggests that combining nisin with
erythromycin could potentially limit the inflammatory response to GBS infection,
which would be beneficial in-vivo for patient outcomes (Upadhyay et al., 2017a).
It is important to note that bacteriocins such as nisin are not currently licensed for use
as antimicrobials in a clinical setting (Healy et al., 2013; Shin et al., 2016). However,
nisin has long been approved for use in food preservation and regarded as safe for use
by the FDA (Hansen and Sandine, 1994), and it has proven to exert antimicrobial
activity against a variety of clinically relevant pathogens (Severina et al., 1998; Okuda
et al., 2013; Field et al., 2016b). Furthermore, studies examining the toxicity of nisin
to human cell lines reported that similar levels of nisin used in this study (160 µg/ml)
was non-toxic to gastrointestinal and blood cells (Dreyer et al., 2019; Mouritzen et al.,
2019). Moreover, this level of nisin is below the concentration considered safe for use
by the FDA (83.25 mg/kg), indicating the strong likelihood of nisin at the
concentrations tested in thus study being acceptable for clinical use. In this study the
combination of erythromycin and nisin demonstrated a synergistic antimicrobial effect
for some of the GBS isolates investigated, as well as a limited inflammatory response.
There were no antagonistic effects observed for the erythromycin/nisin combination
194

used against the GBS isolates in this study. The data suggests that antibioticbacteriocin combination therapy has potential as an effective antimicrobial treatment
option for GBS infections. Our results highlight the need for larger clinical studies that
investigate the use of nisin in combination with other conventionally used antibiotics,
or indeed other naturally occurring antimicrobials. Investigating these alternative
antimicrobials may prove useful, as reduced susceptibility to conventionally used
antibiotics has been observed for GBS (Kimura et al., 2008; Bergal et al., 2015; Lu et
al., 2016; Hayes et al., 2017) and combination therapy would help limit the spread of
antimicrobial resistance.
In conclusion, as the global threat of antimicrobial resistance continues to rise, and as
there is currently a lack of novel antibiotics being developed, there is an urgent need
for alternative treatment options for bacterial infections. Reports of reduced betalactam susceptibility amongst GBS is worrying, as this was the initial warning sign in
the now fully-resistant phenotype observed in other Streptococci. Moreover,
resistance to antibiotics previously used as an alternatives to penicillin, including
erythromycin and clindamycin, continues to rise amongst GBS, resulting in the use of
last resort antibiotics such as vancomycin in the case of severe penicillin allergies.
Approaches to help limit and/or reduce antibiotic resistance amongst Group B Strep
would therefore be highly beneficial. Our study demonstrates the in-vitro synergy
between erythromycin and the lantibiotic nisin against clinical GBS strains and
highlights the potential of antimicrobial combination therapy for use in treating
clinical GBS infections.
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____________________________________________________________________

Chapter V

Biofilm formation in Group B Streptococcus and the
anti-biofilm properties of food products.
_____________________________________________
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5.1. Abstract
Group B Streptococcus (GBS) is a leading cause of neonatal disease worldwide. It
frequently colonises the gastrointestinal and genital tracts of healthy adults and is the
primary coloniser of the genital tract in 35% of pregnant women. GBS can also form
biofilms, which promotes persistent colonisation and contributes to the pathogenic
nature of this organism. The initial aim of this study was to determine the biofilm
forming capacity of clinical GBS strains (n = 44). The frequency of genes associated
with biofilm formation, including pilus-encoding genes and the prophage A clpP gene,
was also investigated. Furthermore, the anti-biofilm potential of selected food
products including garlic, honey, fruits (strawberry, blackberry, goji berry, red pepper)
and cheese (feta, goats, halloumi, Roquefort, Wensleydale) was investigated. An
OD540nm of >0.2 corresponded to biofilm production. The majority of strains (n =
28; 63.6%) had the capacity to form biofilms, varying from moderate to strong
biofilms, with n = 11 (25%) of strains identified as strong biofilm producers. At least
one pilus island gene was detected in each GBS isolate, with PI-1 detected in
combination with other pilus genes including PI-2a (n = 21; 47.7%) and PI-2b (n =
20.5%). Within this GBS collection, there was no significant association between pilus
profiles and biofilm formation, but a significant association between serotype and
pilus island profiles (P < 0.05). While the clpP gene was detected in n = 26 (59.1%)
of strains, there was no significant association with biofilm formation. Honey, feta and
goats cheese significantly inhibited GBS biofilm formation at 1/2 X MIC, while garlic
significantly inhibited biofilm formation at 1/8X MIC. These foods also significantly
reduced biofilm mass and viability in strong biofilm producers at 1/2 X MIC. Data
from this study confirms that most clinical GBS strains can form biofilms and whole
food products, including garlic, honey and cheese, can inhibit formation of these
biofilms and reduce biofilm mass and viability.
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5.2. Introduction
Group B Streptococcus are frequent colonisers of the gastrointestinal and genital tracts
of healthy adults. Geographically colonisation rates vary with the most current,
comprehensive analysis estimating global vaginal colonisation rates of 18%, with the
lowest incidence in Asia (11-13%) and the highest prevalence in the Caribbean (34%)
(Russell et al., 2017a). GBS colonisation is transient and is influenced by strain
dependent expression of GBS virulence factors, adaption to different host
environments and competition with commensal flora (Park et al., 2012; D’Urzo et al.,
2014; Patras and Nizet, 2018).
Attachment and adherence to host cells is one of the most critical steps in infection,
and persistent colonisation by bacteria often involves biofilm formation. Biofilms are
microbial communities, where bacteria are enclosed in a self-produced extracellular
polymer substance matrix (EPS); a complex mix of proteins, polysaccharides, nucleic
acids and lipids (Donlan, 2002). Biofilm formation involves many stages including
the initial loose attachment of bacterial cells to the host, followed by stronger adhesion
through recruitment of additional adherent cells and the subsequent production of an
EPS. The biofilm then continues to mature and develop before finally dispersing,
facilitating the spread of planktonic bacteria (Costerton, 1999; Hall-Stoodley and
Stoodley, 2009). Bacterial biofilms are associated with increased survival in stressful
conditions, such as nutrient deprivation, pH change and increased levels of oxygen
radicals, and thus promote persistent colonisation and infection (Donlan and
Costerton, 2002). From a clinical perspective, bacterial biofilms are of interest because
they can cause chronic infections due to the ability to resist phagocytosis and other
immune components, as well as confer increased resistance to antibiotics (Høiby et
al., 2011).
Biofilm formation by GBS has been reported in many studies (Kaur et al., 2009;
Konto-Ghiorghi et al., 2009; Rinaudo et al., 2010; Borges et al., 2012; D’Urzo et al.,
2014). The formation of biofilms promotes GBS colonisation of the gastrointestinal
and genital tracts as it enables the bacteria to withstand harsh pH environments and
host defence systems (D’Urzo et al., 2014; Rosini and Margarit, 2015). Furthermore,
invasive GBS disease in adults often presents as prosthetic joint infections which are
strongly associated with biofilm formation (Barrett and Atkins, 2014). Infective
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carditis, which is linked to biofilm formation, has also been implicated in GBS
invasive disease (Ivánova-Georgiva et al., 2010;2018). Therefore, it is likely that
biofilm production plays a role in invasive adult GBS disease, although no studies
have explored this avenue presently. Current evidence regarding the optimal
conditions for testing GBS biofilm formation in-vitro remain contradictory, with some
studies recommending the use of media at an acidic pH (D’Urzo et al., 2014; Nie et
al., 2018), while others suggest the use of media at a neutral pH supplemented with
glucose (Rinaudo et al., 2010). Investigations that identify the conditions which trigger
GBS biofilm formation in different environments are therefore beneficial.
GBS possess an array of surface proteins that facilitate adherence to host cells,
including pilus proteins, fibrinogen binding proteins (Fbs), serine rich repeat proteins
(Srrs) and plasminogen-binding protein B (PbsP) (Schubert et al., 2004; Seifert et al.,
2006; Rinaudo et al., 2010; Seo et al., 2012; Buscetta et al., 2014, 2016). In particular,
pilus proteins are associated with biofilm formation in GBS. Pili are cell-wall anchored
proteins that protrude from the surface of the bacterial cell wall (Lauer et al., 2005;
Rosini et al., 2006; Margarit et al., 2009). Two pilus islands have been identified in
GBS, namely PI-1 and PI-2, the latter of which has two alleles, designated PI-2a and
PI-2b (Lauer et al., 2005; Rosini et al., 2006). Studies have demonstrated that GBS
strains harbour either PI-2a or PI-2b, and some strains may also possess the PI-1 pilus
island (Margarit et al., 2009; Springman et al., 2014). Pili allow attachment to
epithelial cells (Dramsi et al., 2006; Konto-Ghiorghi et al., 2009; Maisey et al., 2007),
as well as translocation across epithelial cells (Pezzicoli et al., 2008). Pilus proteins
are required at different stages of GBS pathogenesis and have a dual role in adherence
to host cells and biofilm formation (Konto-Ghiorghi et al., 2009). Specifically, PI-2a
plays a pivotal role in adherence and invasion (Maisey et al., 2007; Konto-Ghiorghi
et al., 2009) and is significantly correlated with GBS biofilm formation capacity
(Rinaudo et al., 2010). PI-2b mediates adherence and invasion of pulmonary epithelial
and brain endothelial cells (Lazzarin et al., 2017), while it’s specific role in biofilm
formation is currently less clear.
Prophages are bacteriophage genomes inserted and integrated into host genomes and
are thought to drive epidemiological changes within bacterial species (Fortier and
Sekulovic, 2013; Ramisetty and Sudhakari, 2019). A recent study characterised the
prophage elements present in a collection of GBS strains, finding at least one prophage
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in 72.4% of the 275 strains tested (van der Mee-Marquet et al., 2018). Six prophage
groups were identified in GBS (groups A-F), with group A prophage associated with
a clpP gene that is linked to stress tolerance, adaption and biofilm formation.
Interestingly, a recent study found an increased prevalence of group A prophage
among GBS strains implicated in neonatal infections (Renard et al., 2019); however,
no definitive studies have examined the association between clpP gene and biofilm
formation in GBS.
Biofilm production is advantageous for GBS virulence and encourages persistent
infection as bacterial cells within the biofilm are more resistant to antimicrobial
treatments (Ito et al., 2009; Høiby et al., 2010). Innovative alternative strategies to
combat biofilm formation are therefore needed, owing to their significant impact on
clinical infections (Høiby et al., 2011). Preventing biofilm formation by GBS could
help inhibit maternal colonisation, a major risk factor for neonatal disease (Russell et
al., 2017b). Furthermore, gastrointestinal colonisation by GBS is implicated in adult
infections. Moreover, while currently there are no studies that definitely associate
biofilms with invasive GBS disease in adults, many of the clinical presentations of
invasive GBS disease, such as skin and soft tissue infections and endocarditis, have
been linked with biofilm formation in other bacteria (Kwiecinski et al., 2015; Lynch
et al., 2019). A potentially interesting approach to reducing biofilm formation in-vivo
is through the consumption of plant and food products that have inherent antimicrobial
and anti-biofilm properties (Fletcher et al., 2014; Rabin et al., 2015; Aziz and
Karboune, 2016; Lima et al., 2019). These products contain natural bioactive
compounds that can prevent the formation of biofilms and/or eradicate established
biofilms (Fletcher et al., 2014; Rabin et al., 2015). Furthermore, as anti-biofilm agents
often prevent adherence without affecting bacterial viability, the bacteria are less
likely to develop resistance mechanisms to these agents (Rabin et al., 2015). There are
a plethora of foods that have been reported to have natural antimicrobial properties
including dairy products (Rizzello et al., 2005), honey (Grecka et al., 2018), fruits
(Sanhueza et al., 2017) and spices (Nassan et al., 2015). Furthermore, anti-biofilm
properties have been attributed to certain foods including garlic (Bjarnsholt et al.,
2005), ginger (Kim and Park, 2013), apples (Lee et al., 2011) and honey (Majtan et
al., 2014).
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Garlic has been shown to exhibit potent antimicrobial activity against a range of Gram
positive and Gram negative bacteria (Cutler and Wilson, 2004; Bachrach et al., 2011;
Wallock-Richards et al., 2014; Wu et al., 2015). Studies have also specifically
reported on its antibiofilm effects through inhibition of quorum-sensing or through
destruction of biofilms by garlic extract (Bjarnsholt et al., 2005; Jakobsen et al., 2012;
Birring et al., 2015; Roshan et al., 2017). Biofilm density was also significantly
reduced with 0.78 µg/ml allicin (Wu et al., 2015). The compound primarily
responsible for the bioactive properties of garlic, allicin, was isolated and identified in
1944 (Cavallito and Bailey, 1944). Allicin is produced when garlic is crushed, which
causes the release of alliin lyase which in turn converts alliin to the bioactive allicin
(Stoll and Seebeck, 2006). The exact mechanism of action of allicin is not clear but it
has been suggested to be via the inhibition of RNA synthesis, reacting covalently with
L-cysteine or the inhibition of acetyl-CoA synthetases (Borlinghaus et al., 2014). Both
purified allicin and fresh garlic extracts have demonstrated antimicrobial activity. A
commercial aqueous solution of allicin, AEAllicin, exerted bactericidal activity
against GBS strains with MICs ranging from 35-95 mg/L (Cutler et al., 2009).
Honey has long been used as a natural remedy for infections, particularly wound
infections (Yaghoobi et al., 2013; Sojka et al., 2016), and is an attractive antimicrobial
as it is non-toxic with few side effects and is generally inexpensive. It’s antimicrobial
properties are linked to its low pH, high sugar content, H2O2 production and inherent
bioactive compounds, specifically bee defensin-1 and methylglyoxal (MGO)
(Kwakman et al., 2010; Brudzynski and Lannigan, 2012). Studies have demonstrated
that honey can inhibit the biofilms of Streptococcus mutans, Staphylococcus aureus,
Streptococcus pyogenes and Pseudomonas aeruginosa (Nassar et al., 2012; Maddocks
and Jenkins, 2013; Grecka et al., 2018). In addition, C. difficile biofilms were shown
to be both inhibited and reduced by honey at concentrations higher than the MIC
(Piotrowski et al., 2017). Manuka honey was shown to inhibit and reduce biofilm
formation in Proteus mirabilis and Enterobacter cloacae, with MGO identified as the
active compound (Majtan et al., 2014). Interestingly, in an assessment of different
types of honey (including Manuka and honeydew honey) and recombinant bee
defensin-1, a significant reduction of S. aureus, S. agalactiae and P. aeruginosa
biofilms was observed (Sojka et al., 2016).
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Dairy foods, including milk, cheese and yoghurts, are associated with a range of health
benefits, including antimicrobial properties (Hernández-Ledesma et al., 2007). These
health benefits are largely linked to the bioactive compounds that are released from
the food matrices, which can occur in vitro during the production process (Losito et
al., 2006) and/or in vivo during the digestion process (Korhonen, 2009). In particular,
antimicrobial peptides (AMPs) are frequently released from milk proteins such as
casein and whey (Rizzello et al., 2005; López-Expósito et al., 2017). There has been
extensive research on the antimicrobial properties of milk (Pellegrini et al., 2001;
McCann et al., 2006; Hernández-Ledesma et al., 2007; Liu et al., 2015), but fewer
studies on the antimicrobial activities of whole cheese. A study by Rizzello et al.,
(2005) identified five Italian cheeses that had antimicrobial activity against
Lactobacillus sakei with MICs ranging from 20-200 µg/ml. Lignitto et al., (2012) and
Nguyen Thi et al., (2014) reported that Asiago d’ Allevo cheese significantly inhibited
Listeria species with MICs between 5-40 mg/ml, while Théolier et al., (2014)
demonstrated that mozzarella and gouda cheese also inhibited Listeria monocytogenes
at concentrations between 8.5 and 34 mg/ml. Pritchard et al., (2010) compared four
Australian cheddar cheeses for their ability to inhibit the growth of Bacillus cereus but
only one cheese demonstrated an antimicrobial effect with an MIC of approximately
1 mg/ml. More recently, peptides isolated from Canastra artisanal minas cheese
displayed bactericidal activity against E. coli, displaying MICs between 11 and 17
mg/ml (Fialho et al., 2018). These studies highlight antimicrobial potential of cheese
but to date, studies on its inhibitory activity against GBS biofilms are limited.
In this study, the biofilm-forming potential of a clinical collection of GBS isolates,
including invasive and colonising isolates, was determined. Association between
biofilm formation, pilus island profiles and prophage content within the population
was examined. Furthermore, the potential of whole foods, including garlic, honey,
selected fruit and cheese, to inhibit and/or eradicate biofilms in GBS was investigated.
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5.3. Materials and methods
5.3.1. Bacterial strains and growth conditions
A total of 44 clinical GBS isolates were tested for their ability to form biofilms. All
isolates had been previously assigned serotypes and antimicrobial resistance
phenotypes (Hayes et al., 2017). Invasive isolates (n = 24) and colonising isolates (n
= 20) were included in the study. All strains were cultured on Columbia Blood Agar
(CBA) plates (Fannin, Ireland) or in Todd Hewitt Broth (THB, Sigma-Aldrich,
Ireland), depending on growth requirements, and incubated at 370C overnight.
5.3.2. Preparation of antimicrobials
All foods investigated in this study were purchased from local supermarkets. All fruit
samples were cultivars. Garlic extracts were prepared as described Fujisawa et al.,
(2009). Ten grams of fresh garlic bulbs were crushed and mixed with 10 ml 50%
methanol. Samples were left to stand at room temperature for 10 minutes before
centrifuging at 5500 rpm for 10 minutes. The supernatant was collected, filter
sterilized (0.2µm) and aliquots stored at -20°C until required for analysis. Boyne
Valley Manuka Honey was prepared as previously described (Nassar et al., 2011).
Briefly, equal amounts of honey were dissolved in equal amounts of THB (1:1). All
fruit samples (strawberry, blackberry, goji berry and red pepper) were prepared by
mixing 25 grams of fruit with 50 ml 80% ethanol for 15 minutes before centrifuging
at 6,500 rpm for fifteen minutes. Supernatants were collected, filter sterilised (0.2µm)
and aliquots stored at -20°C until required for analysis (Venkatachalam et al., 2014).
Cheese samples were prepared as per Apostolidis et al., (2007). Briefly, 10 grams of
cheese (feta, goats, Wensleydale, halloumi and Roquefort cheese) was homogenised
in a blender with 10 ml deionised H20. Samples were then centrifuged at 6500 rpm for
20 minutes. Supernatants were collected and centrifuged for a further 10 minutes at
6500 rpm until a clear fluid was achieved (Apostolidis et al., 2007). Water soluble
extracts (WSE) were filter sterilised (0.22 µm) and stored at -20oC until use.
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5.3.3. Minimum inhibitory concentrations (MIC) of test substances
MICs were established according to CLSI guidelines (CLSI, 2012). Briefly, 200 µl of
test substance was added to the first well in each row of a microtitre plate (Sarstedt,
Germany) and serially diluted two-fold in THB to achieve concentrations ranging
from 100-0.5% (w/v) for fruits, garlic and cheese samples and 50-0.25% for honey.
GBS strains grown overnight on CBA plates were inoculated into 0.85% saline to a
density of 0.5 McFarland before diluting 1:100 in fresh THB to achieve a
concentration of 1 X 106 CFU/ml. When 100 µl of this cell suspension was added to
the microtitre plate containing test substances, the final concentration of cells was 5 X
105 CFU/ml and test substance concentrations ranged from 50-0.25%, or 25-0.125%
for honey. Wells with only THB and bacteria were included as positive growth
controls while THB without bacteria was used as a negative control. Plates were
incubated under static conditions at 37oC for 18-20 hours. The MIC was defined as
lowest concentration of test substance that visibly inhibited the growth of bacteria.
Test substances showing no inhibition at 50% were subsequently analysed at 100%.
Three independent experiments were performed in triplicate.
5.3.4. Biofilm protocol optimization
Biofilm production was assessed by the protocol described by D’ Urzo et al., (2014).
This method was used to investigate biofilm formation under different conditions
including the effect of sugar concentration (tested using THB supplemented with 1%
glucose, THBG) and pH (tested at pH3, pH5 and neutral pH) in order to determine
optimal conditions for biofilm formation. Briefly, GBS strains were grown overnight
in THB. Thereafter inoculums were prepared by diluting cultures to an OD600nm of
0.05 in fresh media (either THB, THBG, THB pH3 or THB pH5) and subsequently
200 µl was added to the appropriate wells in a microtitre plate (Sarstedt, Germany).
Plates were sealed and incubated shaking at 60 rpm at 370C for 8 hours. Following
this, the supernatant was removed and replaced with 200 µl fresh media before
incubation at 370C for 15 hours under static conditions (D’Urzo et al., 2014). Each
GBS strain was analysed in triplicate in three independent experiments. Biofilms were
quantified as outlined below by both CV and XTT assays.
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5.3.5. Crystal violet (CV) assay
Following biofilm formation, medium was removed, and the wells were washed 3
times with 200 µl PBS to remove any unattached cells. The wells were air dried and
stained with 200 µl of 0.5% Crystal Violet (Sigma-Aldrich, Ireland) for 1 hour before
rinsing with dH20. Bound dye was released from the cells by adding 200 µl 30%
glacial acetic acid. Biofilm quantification was performed by measuring the OD 540
nm of the wells using a microtitre plate reader (SpectraMAX). Each assay was
performed in triplicate and experiments repeated three times. Interpretation of results
was performed as previously described (Stepanović et al., 2007). Isolates were
characterised as non-biofilm forming (NF), weak, moderate or strong biofilm formers
based on the OD540 nm values.
5.3.6.

2,3-Bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide

(XTT) assay
Biofilms were also quantified using an XTT reduction assay to examine cell viability
(D’Urzo et al., 2014). Briefly, following overnight incubation to allow biofilm
formation, medium was removed and cells were washed with PBS. An XTT solution
was prepared by dissolving 0.5 mg XTT reagent (Sigma-Aldrich, Ireland) in 1ml PBS
and adding 2.5 µl menadione (Sigma-Aldrich, Ireland). To each well, 150 µl of XTT
solution was added and samples were left to incubate at 37oC in the dark for 4 hours.
Plates were then centrifuged for 20 minutes at 4000 rpm and 100 µl of each sample
was added to a new 96 well plate and the absorbance at 490nm was measured
(Varioskan LUX, ThermoFisher). Each assay was performed in triplicate and repeated
three times.
5.3.7. Inhibition and eradication of biofilms
The ability of test substances to inhibit and/or eradicate biofilms was investigated
using three GBS isolates identified as strong biofilm formers. For the inhibition assay,
all antimicrobial substances were tested at 1, 1/2, 1/4 and 1/8X MIC (Grecka et al.,
2018). Briefly, overnight GBS cultures were added at an OD600nm of 0.5 to wells
containing antimicrobial substances at the specified concentrations and biofilms were

205

developed using conditions described in section 5.3.4 above. Biofilms were quantified
using both the CV and XTT methods described in section 5.3.5 and 5.3.6 respectively.
For the biofilm eradication assay, selected food products (honey, garlic, feta and goats
cheese) were added to pre-formed biofilms, which were established in 96 well plates
under optimal conditions. After 24-hours the medium was removed, and antimicrobial
substances were added at 1 and 1/2 X MIC for honey and cheese samples, and at 8, 4,
2 and 1X MIC for garlic extract (Nassar et al., 2012). Plates were incubated for a
further 24 hours after which biofilms were quantified using the CV and XTT assay
described previously.
5.3.8. Pilus island and prophage detection by PCR
Detection of pilus island genes, PI-1, PI-2a and PI-2b, was carried out as described
previously (Martins et al., 2010). Amplification of the clpP gene, associated with
group A prophage, was performed using the primers outlined by van der Mee-Marquet
et al., (2018) with the inclusion of the cfb gene as an internal control. PCR conditions
for detection of the clpP gene were as follows: initial denaturation at 95oC for 4
minutes followed by 35 cycles of denaturation at 95oC for 30 seconds, annealing at
53oC for 1 minute and elongation at 72oC for 1 minute followed by a final extension
at 72oC for 10 minutes. Details of primers used in this study are outlined in
supplementary Table S5.1.
5.3.9. Statistical analysis
Statistical analysis was carried out using SPSS software (IBM v. 25). The χ2 test and
Fisher’s exact test were used to analyse associations. A one-way ANOVA with
Dunnett’s post-hoc testing was used to determine differences in biofilm production for
test substances compared to the untreated control. A P-value of < 0.05 was considered
statistically significant.
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5.4. Results
5.4.1. Optimisation of biofilm protocol and screen for biofilm production by GBS
isolates
Initially, a subset of isolates were tested for their ability to form biofilms in THB at
neutral pH, pH3, pH5 and neutral pH supplemented with 1% glucose. Strongest
biofilm formation was observed using THB supplemented with 1% glucose (THBG)
and representative samples are presented in Figure 5.1.
Following optimization, a selection of clinical GBS isolates (n = 44) were screened
for biofilm forming capabilities using THBG according to the method described by
D’Urzo et al., (2014). Isolates from a previously characterised collection were selected
to reflect the main serotypes (Ia-VI) identified (Hayes et al., 2017) and representatives
of both invasive (n = 24) and colonising (n = 20) populations were included (Table
5.1). Overall, no significant association was found between biofilm formation and
serotype (P = 0.709) or sample type (P = 0.136). Eight isolates were classified as nonbiofilm formers (NF), eight as weak biofilm formers, 17 as moderate biofilm formers
and 11 as strong biofilm formers (Table 5.1). Overall, 63.4% (n = 28) of strains were
classified as moderate and strong biofilm producers. Four of the 11 strong biofilmformers were invasive isolates, seven were colonising isolates and serotype
distribution varied, including Ia (n = 2), II (n = 1), III (n = 5), IV (n = 1), V (n = 1)
and VI (n = 1). Similar numbers of invasive or colonising isolates were identified as
moderate biofilm producers (n = 8 and n = 9, respectively), and of these 17 isolates,
nine (53%) were serotype III; eight of which belonged to ST-17.
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Figure 5.1: Optimisation of biofilm formation in Group B Streptococcus.
Biofilm formation of representative Group B Streptococcus strains under different
environmental conditions using the modified method described by D’Urzo et al., (2014).
Isolates were tested for their ability to form biofilms in Todd Hewitt Broth (THB) under four
different conditions. Strongest biofilm formation was observed with THBG media. Data
represent the mean ± SD of three independent experiments performed in triplicate.
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5.4.2. Pilus island profile and prophage A clpP gene detection
At least one pilus island was detected in each of the 44 isolates (Figure 5.2; Table 5.1).
PI-1 was only found in combination with other pilus islands; with PI-1+PI-2a profile
identified in 21 strains (47.7%) and PI-1+PI-2b profile detected in nine isolates
(20.5%). Six isolates (13.6%) harboured PI-2a only and eight isolates (18.2%)
harboured PI-2b only. No significant association was found between a specific pilus
island and biofilm formation (P = 0.796) or between pilus island profiles and invasive
or colonising sample type (P = 0.288). A statistically significant association was
observed between serotype III and the PI-2b pilus island profile (P = 0.00033), as well
as between serotype III and the PI-1+PI-2a pilus profile (P = 0.00022). Furthermore,
ST-17 strains were significantly associated with PI-2b and PI-1+PI-2b profiles (P <
0.0005).
The clpP gene, linked to the prophage A group, was detected in 26 (59.1%) isolates
(Table 5.1; Figure 5.3). However, in this study the clpP gene was not associated with
biofilm formation (P = 0.751) or pilus island profile (P = 0.795).

Figure 5.2: PCR detection of pilus island genes.
Lane M, 100bp Hyperladder (Bioline, MSC); Lanes 1-20, representative PCR data of pilus
island profiles in GBS strains. Pilus profile PI-1 + PI-2a identified by amplification of 881bp
and 575bp products respectively are shown in lanes 2-4, 6, 8, 10, 13, 15 and 17. Pilus profile
PI-1 + PI-2b identified by amplification of 881 bp and 721bp products respectively are shown
in lanes 1, 11, 18 and 20. Pilus profile PI-2a identified by the amplification of the 575bp
product are shown in lanes 5, 7, 9, 12, 16 and 19.
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Figure 5.3: PCR screen for detection of the clpP gene associated with the prophage A
group.
Lane M, 100bp Hyperladder (Bioline, MSC); lanes 1-3, detection of the 460bp clpP gene and
153bp internal control; lane 4 negative assay control for the clpP gene but still containing the
internal control; lane 5, negative PCR control.

5.4.3. Minimum inhibitory concentration (MIC) of test substances
Subsequent to assessing biofilm production, three strong biofilm formers (CIT 87, 223
and 273) were selected for anti-biofilm investigations (Table 5.2). Initially, MIC data
for honey, garlic and fruit extracts (strawberry, blackberry, goji berry and red pepper)
against these three isolates was generated (Table 5.3). MICs for each test substance
against all three isolates were similar and ranged from 3.125% (w/v) for goji berry
extract to 25% (w/v) for honey. MICs for water-soluble extracts of cheese (feta, goat,
Wensleydale, halloumi and Roquefort) were also determined with no inhibitory
activity observed for any of the cheese samples (Table 5.3). Therefore, an MIC of
100% (w/v) was assigned for each of the cheese samples.
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Table 5.1: Correlation of Group B Streptococcus biofilm production, serotype, pilus island profile and prophage A clpP screen.
Biofilm quantification
Non-former
(n = 8)

Weak
(n = 8)

Moderate
(n = 17)

Strong
(n = 11)

Total
(n = 44)

Invasive
Colonising
Serotype

7
1

5
3

8
9

4
7

24
20

Ia
Ib
II
III
IV
V
VI
Pilus island profile

1
2
0
3 (all ST-17)
0
2
0

4
0
1
2 (1 ST-17)
0
1
0

2
2
1
9 (8 ST-17)
1
2
0

2
0
1
5 (3 ST-17)
1 (1 ST-17)
1
1

9
4
3
19 (15 ST-17)
2
6
1

PI-1
PI-2a
PI-2b
PI-1 + PI- 2a
PI-1 + PI-2b
PI-2a + PI-2b
None
Prophage A content
clpP gene positive

0
0
1
5
2
0
0

0
2
0
5
1
0
0

0
2
4
7
4
0
0

0
2
3
4
2
0
0

0
6
8
21
9
0
0

6

4

9

7

26

Sample type
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Table 5.2: Characteristics of Group B Streptococcus isolates chosen for anti-biofilm
testing.
Isolate

Sample

Biofilm

type

production

Serotype

Pilus

clpP

Resistance

island

gene

profile

-

Ery, Da

profile
CIT 87

Invasive

Strong

III, ST-17

PI-2b

BC

and Tet
resistant

CIT 223

Colonising,

Strong

III

PI-2b

+

HVS

Ery, Da
and Tet
resistant

CIT 273

Colonising,

Strong

III, ST-17

HVS

PI-1 +
PI-2b

+

Ery, Da
and Tet
resistant

BC, blood culture; HVS, high vaginal swab; ST-17, hypervirulent clone; Ery, erythromycin;
Da, clindamycin; Tet, tetracycline. Resistance profiles were determined from disk diffusion
testing as per EUCAST guidelines.

212

Table 5.3: Minimum inhibitory concentrations (MICs) of honey, garlic extract, fruit extracts and water-soluble cheese extracts (WSEs) against
Group B Streptococcus isolates.
MIC (% w/v )
Fruit extracts
Isolate

Garlic

Honey

Black-

Goji

berry

berry

Strawberry

Water-soluble extracts (WSEs) of cheese samples
Red

Feta

Goat

Halloumi

Roquefort

Wensleydale

pepper

CIT 87

12.5

25

6.25

3.125

12.5

6.25

100

100

100

100

100

CIT 223

12.5

25

6.25

3.125

12.5

6.25

100

100

100

100

100

CIT 273

12.5

25

6.25

3.125

12.5

6.25

100

100

100

100

100

Values are the equal mean of three independent experiments, performed in triplicate.
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5.4.4. Initial screen of biofilm inhibition by natural food products
An initial screen of the biofilm-inhibitory effects of garlic, honey, fruit extracts and
cheese extracts was performed using the CV assay to identify potential anti-biofilm
properties. Test substances were investigated at 1X, 1/2X, 1/4X and 1/8X the MIC.
Garlic significantly inhibited biofilm formation in all isolates tested and at all
concentrations tested (Figure 5.4A). Honey significantly inhibited biofilm formation
in all three isolates at 1X and 1/2X MIC (Figure 5.4B). For the fruit and some of the
cheese extracts biofilm inhibition was strain-specific. For the fruit extracts, significant
inhibition was observed for only one isolates (CIT 273) with strawberry (1X MIC),
goji berry (1X and 1/2X MIC) and red pepper (1X MIC) (Figure 5.4C, 5E, 5F).
Blackberry did not significantly inhibit biofilm formation in any isolate (Figure 5.4D).
Interestingly, a proliferative effect was observed fruit extracts at sub-MIC
concentrations and this effect was variable across the strains tested (Figure 5.4). For
the cheese WSEs, significant inhibition was observed with feta cheese for two of the
isolates (CIT 223 and 273) and at 1X and 1/2X MIC (Figure 5.5A), while goats cheese
significantly inhibited biofilm formation in all isolates at 1X MIC (Figure 5.5B).
Significant inhibition was observed with halloumi for CIT 87 and 273 (1X MIC), with
Roquefort for isolates CIT 87 and 223 (1, 1/2 and 1/4X MIC) and with Wensleydale
for CIT 87 (1 and 1/2X MIC) (Figure 5.5C-E). Garlic and honey demonstrated greatest
biofilm inhibitory action at a variety of concentrations and were selected for further
anti-biofilm investigations, specifically the XTT viability assay and the biofilm
eradication assay. As feta and goats cheese also inhibited biofilm formation at 1X MIC
for more than one isolate, these WSEs were also selected for further antibiofilm
investigations.
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Figure 5.4: Group B Streptococcus biofilm inhibition by garlic, honey and fruit extracts.
Inhibition of Group B Streptococcus biofilm formation by (A) garlic extract, (B) honey, (C)
strawberry extract, (D) blackberry extract, (E) goji berry extract and (F) red pepper extract.
Biofilm formation was quantified using the CV assay. Data represents the mean ±SD of
triplicate independent experiments. * indicates a statistically significant difference compared
to the control.
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Figure 5.5: Biofilm inhibition by water-soluble cheese extracts.
Inhibition of Group B Streptococcus biofilm formation by (A) feta, (B) goats, (C) halloumi,
(D) Roquefort and (E) Wensleydale cheese extracts. Biofilm formation was quantified using
the CV assay. Data represents the mean ± SD of triplicate independent experiments. *
indicates a statistically significant difference compared to the control.
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5.4.5. Quantifying inhibition and eradication of biofilm biomass and viability by food
products
Based on the initial screening data garlic, honey, feta and goats cheese were selected
for further anti-biofilm investigations. Garlic extract exerted a significant (P < 0.05)
inhibitory effect on the formation of biofilms, reducing biofilm biomass (Figure 5.6A)
and biofilm viability (Figure 5.6B) for all three isolates and at all concentrations tested.
In the eradication assays garlic extract at 1X, 2X and 4X MIC significantly (P < 0.05)
reduced biomass in preformed biofilms in isolates CIT 87 and CIT 273 (Figure 5.6C).
A similar effect was observed for isolate CIT 223, although it did not reach statistical
significance (Figure 5.6C). Garlic also significantly (P < 0.05) reduced the viability of
preformed biofilms at 1X, 2X and 4X MIC for all isolates (Figure 5.6D).
Honey exerted a significant inhibitory effect on the growth of biofilms at 1X and 1/2X
MIC for all three isolates, with a reduction also observed at 1/4X MIC, although this
only reached significance for CIT 87 (Figure 5.7A). Interestingly, when honey was
used at 1/8X MIC, a proliferative effect on biofilm formation was observed (Figure
5.7A). Subsequently it was established using the XTT assay for viability that honey
significantly inhibited the growth of biofilms at 1 and 1/2X MIC, whereas it
significantly promoted the formation of biofilms at 1/4X and 1/8X MIC (Figure 5.7B).
Furthermore, honey caused significant reduction in both the biomass and
bioavailability of pre-established biofilms at 1X and 1/2X MIC (Figure 5.7C and D).
Feta cheese significantly inhibited development of biofilm biomass (P < 0.05) for CIT
223 (1 and 1/2X MIC) and CIT 273 (1, 1/2 and 1/4X MIC), with the inhibition for CIT
87 not reaching significance (Figure 5.8A). Interestingly a significant increase in
biofilm was observed at 1/8X MIC for all three isolates (Figure 5.8A). Furthermore,
feta cheese significantly inhibited the viability of biofilm cells at 1X MIC for all three
isolates, (Figure 5.8B). Proliferation of viable biofilm occurred when feta cheese was
used at 1/8X MIC, although this did not reach significance (Figure 5.8B). In the
eradication assays feta cheese significantly reduced biofilm mass and biofilm viability
in preformed biofilms at 1X for all three isolates (Figure 5.8C and 5.8D respectively).
When used at 1X MIC, goats cheese inhibited biofilm mass, but promoted biofilm
formation at all other concentrations tested (Figure 5.9A). Similarly, goats cheese
exerted an inhibitory effect on viable biofilm cells when used at 1 and 1/2X MIC,
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although proliferation occurred when used at 1/8X MIC (Figure 5.9B). Goats cheese
reduced biofilm mass in preformed biofilms at 1X MIC for all three isolates, although
this effect only reached significance for CIT 273 (Figure 5.9C). However, a significant
reduction in the viability of the preformed biofilms was observed at 1X MIC for all
three isolates (Figure 5.9D).
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Figure 5.6: Inhibition and eradication of Group B Streptococcus biofilms by garlic
extract.
Inhibition of Group B Streptococcus biofilms by garlic extracts at sub-lethal concentrations
quantified by the CV biomass assay (A) and XTT viability assay (B). Reduction of
established biofilms by garlic extract as assessed by the CV assay (C) and XTT assay (D). *
indicates a statistically significant difference compared to the untreated control.
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Figure 5.7: Inhibition and eradication of Group B Streptococcus biofilms by honey.
Inhibition of Group B Streptococcus biofilms by honey at sub-lethal concentrations quantified
by the CV biomass assay (A) and XTT viability assay (B). Reduction of established biofilms
by garlic extract as assessed by the CV assay (C) and XTT assay (D). * indicates a statistically
significant difference compared to the untreated control.

220

Figure 5.8: Inhibition and eradication of Group B Streptococcus biofilms by feta cheese
water-soluble extracts.
Inhibition of Group B Streptococcus biofilms by feta cheese WSEs at sub-lethal
concentrations quantified by the CV biomass assay (A) and XTT viability assay (B).
Reduction of established biofilms by garlic extract as assessed by the CV assay (C) and XTT
assay (D). * indicates a statistically significant difference compared to the untreated control.
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Figure 5.9: Inhibition and eradication of Group B Streptococcus biofilms by goats
cheese water-soluble extracts.
Inhibition of Group B Streptococcus biofilms by feta cheese WSEs at sub-lethal
concentrations quantified by the CV biomass assay (A) and XTT viability assay (B).
Reduction of established biofilms by garlic extract as assessed by the CV assay (C) and XTT
assay (D). * indicates a statistically significant difference compared to the untreated control.
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5.5. Discussion
Adapting to and persisting in different host environments is critical for GBS
pathogenesis. Biofilm production can aid persistent colonisation of GBS by helping
the bacteria to withstand harsh conditions, such as low pH, and helping to evade host
immune defence mechanisms (Kaur et al., 2009; D’Urzo et al., 2014). In this study,
we observed that the majority of the clinical GBS strains (81.8%) were capable of
forming biofilms in vitro, highlighting the biofilm-forming capacity of GBS. Reports
vary with regards to what constitutes the most favourable conditions for biofilm
formation in GBS, with the pH and sugar content of media cited as influencing factors
(Kaur et al., 2009; Borges et al. 2012; D’Urzo et al., 2014). In the current study, the
optimal method for biofilm formation in vitro utilised THB media at a neutral pH
supplemented with 1% glucose. Assessment of our isolate collection (n = 44)
identified that 25% (n = 11) of the GBS population were strong biofilm producers and
38.6% (n = 17) were moderate biofilm producers. This is slightly lower than other
studies where strong biofilm formation was reported in 43-56% GBS isolates.
However, it is important to note that these studies did not discriminate between
moderate and strong biofilms and variations in the biofilm growth conditions makes a
direct comparison difficult (Rinaudo et al., 2010; Parker et al., 2016).
Biofilm production has been linked to various factors including sample type and
serotype. Parker et al., (2016) reported that biofilm formation was associated with
colonising isolates; however, in the current study there was no association between
biofilm production and sample type (invasive or colonising) (P = 0.136). Kaur et al.,
(2009) examined serotype distribution with respect to biofilm formation and found
serotypes Ia and Ib to be the most common among biofilm producers. Again, in this
study there was no association between serotype and biofilm formation (P = 0.709).
D’Urzo et al., (2014) observed a strong association between biofilm formation and
ST-17 strains; however, no such association was found among our collection (P =
0.474). The small number of isolates used in this study may have contributed to the
lack of association between biofilm formation, sample type and serotype. Furthermore
most studies reporting on GBs biofilm formation applied less stringent discrimination
methods and classified isolates as either non-forming or strong biofilm formers. In the
present study, over half (63.4%) of strains together produced either moderate or strong
biofilms. When grouped together moderate and strong biofilm producers comprised
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80% of the total colonising strains tested, indicating an association between biofilm
formation and colonising isolates (P < 0.05).
Pilus proteins have a role in biofilm formation, with PI-2a being significantly
associated with strong biofilm formation (Rinaudo et al., 2010). In this study, at least
one pilus island was present in each GBS strain. The most common pilus profile was
PI-1+PI-2a, which was detected in n = 21 isolates (47.7%) and this profile was most
frequently observed in moderate biofilm producers. This concurs with studies by
Martins et al., (2013) and Springman et al., (2014), but conflicts with Madzivhandila
et al., (2011) who found that the PI-1+PI-2b profile was the most frequent profile in
GBS isolates. Of interest, there was a significant association observed between ST-17,
hypervirulent strains and the P1-2b and PI-1+PI-2b profiles (P < 0.0005). The PI-1
pilus island was detected in n = 30 strains (68.2%); however, it was always found in
combination with either P1-2a or PI-2b. Previous studies have reported a significant
association between the PI-1+PI-2a profile and maternal colonisation, and between
the PI-1+PI-2b profile and neonatal invasive isolates (Kaur et al., 2009;
Madzivhandila et al., 2011; Martins et al., 2013; Springman et al., 2014; Parker et al.,
2016) but no such associations were observed in the current study.
A recent study by van der Mee-Marquet et al., (2018) focused on the prophage content
in GBS strains and reported that at least one prophage was detected in 72.4% of GBS
strains tested. Furthermore, Renard et al., (2019) highlighted the increased prevalence
of group A prophage within GBS strains, which carry genes associated with bacterial
persistence and biofilm formation. In addition, it is suggested that type A prophage
increase the ability of ST-17 hypervirulent strains to withstand acidic environments
and thus aid in the progression of GBS from colonisation to invasive disease state
(Renard et al., 2019). We screened our collection for the presence of the clpP gene,
associated with group A prophage, and detected it in over half of our isolates (n = 26;
59.1%), confirming that at least 59.1% of isolates contained group A prophage. There
are other genes associated with group A prophage, but to date only clpP has been
linked to stress adaptation and biofilm formation (Nair et al., 2003; Xie et al., 2013;
Zhang et al., 2015). While no significant association was observed in our study (P =
0.751) between clpP and biofilm formation, information regarding the specific role of
prophage in biofilm production in GBS is still unclear. Therefore, there would be value
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in identifying other genes associated with group A phage and examining their role in
relation to biofilm formation.
As antibiotic resistance levels continue to rise and with a lack of new antibiotics being
developed (World Health Organization, 2017), the use of natural compounds as
antimicrobial or anti-biofilm agents is gaining attention (Lima et al., 2019). Three
strong biofilm producing GBS strains, confirmed as resistant to conventional
antibiotics, were selected to investigate the antibiofilm properties of garlic, honey,
selected fruit and cheese products. An MIC of 12.5% for garlic was established for all
three isolates, which is higher than reported ranges of 0.5 – 3% for other microorganisms (Roshan et al., 2017; Wallock-Richards et al., 2014). Garlic significantly
inhibited biofilm mass and viability for all isolates at concentrations as low as 1/8X
MIC, which is comparable to other studies (Wu et al., 2015). Interestingly, biofilm
mass was significantly increased at 8X MIC for one isolate; however, cell viability
within the biofilm was significantly reduced, which possibly suggests non-specific
binding during the CV assay. A significant reduction in biofilm mass was observed at
4, 2 and 1X MIC garlic for CIT 87 and CIT 273, and while the same effect was
observed for CIT 223, it did not reach significance.
For all three GBS isolates, an MIC of 25% (w/v) was observed for honey. This is
higher than studies on other bacterial species where MICs of 12.5% for S. mutans
(Nassar et al., 2012), 6.25% for C. difficile (Piotrowski et al., 2017) and 1.56% for S.
aureus (Grecka et al., 2018) were observed. Inhibition of biofilm mass and viability
by honey was observed at 1X and 1/2X MIC for all three isolates, however, at
concentrations lower than this, increased biofilm formation was observed. This has
been noted in other studies, where sub-MIC concentrations of honey promoted biofilm
production (Nassar et al., 2012; Piotrowski et al., 2017; Grecka et al., 2018). A
significant reduction in biofilm formation at 1X and 1/2X MIC is of interest, as other
studies have only reported biofilm reduction by honey, at concentrations of 1 – 16fold higher than the MIC (Piotrowski et al., 2017; Grecka et al., 2018). However, this
may be due to different types of honey used, which has been reported to impact antibiofilm activity (Sojka et al., 2016; Grecka et al., 2018).
Despite the wealth of knowledge about antimicrobial peptides isolated from milk,
there are limited studies examining the antimicrobial properties of cheese. All WSE
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of cheese samples in this study were assigned MICs of 100% (w/v). However, feta and
goats cheese WSEs showed greater biofilm inhibitory potential and thus were further
investigated for anti-biofilm properties. Feta cheese WSE was observed to inhibit
biofilm production at 1, 1/2 and sometimes 1/4 XMIC while goats’ cheese inhibited
biofilm formation at 1 and 1/2 XMIC. This is interesting as although the cheese
samples did not affect the growth of planktonic cells, they still inhibited biofilm
formation. This suggests that the mechanism of biofilm prevention is caused by some
factor other than inhibition of microbial growth and is most likely caused by
preventing adherence as reported by Lee et al., (2011). Similar to honey, when tested
at lower concentrations, both cheese samples promoted biofilm production. Feta
cheese significantly reduced biofilm formation at 1 and 1/2X MIC, whereas the
reduction by goats cheese was most effective at 1X MIC. To the best of our
knowledge, there have been no studies examining the antimicrobial properties of
cheese against GBS and furthermore, there have been no previous studies investigating
the anti-biofilm properties of cheese extracts. These preliminary data suggest that
cheese has the potential to inhibit biofilm formation in GBS but further studies are
required to characterise the bioactive compounds. Furthermore, in order to assess the
potential effect of these products in-vivo, it would be necessary to evaluate their
activity after digestion in models that accurately reflect the host.
The current study confirms that most clinical GBS strains are capable of producing
biofilms. Moreover, all isolates harboured pilus island proteins and 59.1% of isolates
harboured the clpP gene, which are associated with biofilm formation. However, these
biofilm studies were based on in vitro investigations, future studies should include
models that more accurately represent the host and in vivo conditions (Kim et al.,
2010; Guggenheim et al., 2011). Furthermore, the limitations of the method used in
this study such as the crystal violet and XTT assay are that they are crude estimations
of biofilms formation. Future studies should include closed system and flow cell
models as well as visually examining anti-biofilm effects using techniques such as
confocal laser microscopy. Moreover, while the main bioactive components of garlic
and honey have been identified, further studies to identify the antibiofilm compounds
in the cheese samples are required.
The continued increase of antimicrobial resistance coupled with the lack of new
antibiotics remains a concern for the treatment of GBS infections. Moreover, biofilm
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formation, which is well documented in GBS, leads to increased resistance to
antibiotic treatment and also promotes persistent colonisation. Natural products as
alternative antimicrobials have received a reinvigoration in terms of research and
development in recent years (Moloney, 2016). Importantly, natural food products
specifically aimed at inhibiting or reducing biofilm formation in GBS could prevent
persistent colonisation and therefore limit infections. The natural food products
reported herein display potential as anti-biofilm agents. Indeed, each of the food
products successfully inhibited and reduced GBS biofilm formation, despite the
isolates being highly resistant to conventional antibiotics. An interesting approach to
help limit gastrointestinal GBS colonisation is through the consumption of these food
products, which in turn could also help reduce gut colonisation by other clinically
relevant pathogens such as vancomycin-resistant enterococci. Results from this
investigation are encouraging and highlight the need for more extensive research in
this area, through in-vitro and in-vivo anti-adherence studies. Furthermore, there is
scope to explore the potential for synergistic combinations as therapeutics for biofilms,
which has demonstrated promising results previously (Dosler and Gerceker, 2011;
Field et al., 2016a, b; Idris and Afegbua, 2017). This study has generated promising
candidates for anti-biofilm agents against GBS strains and building on these platforms
will continue to aid in the discovery and development of new antimicrobials.
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5.7. Supplementary information

Table S5.1: Primer sequences used in this study.
Target

Sequence (5’ – 3’)

Amplicon size
(bp)

Reference

PI-1
(gbs80)
PI-2a
(gbs67)
PI-2b
(san_1519)
clpP

F: GGTCGTCGATGCTCTGGATTC
R: GTTGCCCAGTAACAGCTTCTCC
F: CTATGACACTAATGGTAGAAC
R: CACCTGCAATAGACATCATAG
F: ACACGACTATGCCTCCTCATG
R: TCTCCTACTGGAATAATGACAG
F: CAGATTGCGGACGAGACTTG
R: TATCCGCAAAACCAAGCTCC
F: TTT CAC CAG CTG TAT TAG AAG TA
R: GTT CCC TGA ACA TTA TCT TTG AT

881

Martins et al., (2010)

575

Martins et al., (2010)

721

Martins et al., (2010)

460

van der Mee-Marquet et al., (2018)

153

(Ke et al., 2000)

cfb
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Chapter VI

Thesis summary
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Group B Streptococcus (GBS) are frequent colonisers of healthy adults, commonly
found in the gastrointestinal tract. GBS is particularly prevalent among pregnant
women and is present in the genitourinary tract of up to 30% of healthy pregnant
women worldwide. GBS are opportunistic pathogens that can progress to invasive
disease, and are the leading cause of neonatal disease worldwide. Moreover, the
prevalence of invasive GBS disease in adults continues to rise, particularly in
immunocompromised patients and those with underlying conditions. There is no
licensed vaccine for GBS at present; however, there are promising candidates at the
clinical trial stage, mostly targeting the capsular polysaccharide of GBS. In the interim,
efforts to reduce the incidence of GBS disease in infants include intrapartum antibiotic
prophylaxis for pregnant women, administered based on microbiological screening or
risk factors. Penicillin remains the first choice for this regimen; however, there are
growing reports of GBS isolates with reduced beta-lactam susceptibility. Resistance
to previously second line antibiotics such as erythromycin and clindamycin continues
to rise among GBS populations such that vancomycin is now offered as a second-line
treatment. There is a need to look for alternative treatment options, to limit the
development of further resistance or indeed prevent resistance to antibiotics which are
currently effective.
This thesis investigates the predominant serotypes and examined the current status of
antibiotic susceptibilities within a clinical collection of GBS strains from the Irish
population. The pathogenic traits of GBS strains were examined, through detection of
the hypervirulent clone, ST-17, antimicrobial resistance determinants and the ability
to form biofilms. Moreover, the work explored novel antimicrobial strategies against
GBS, including the bacteriocin nisin and a bioengineered nisin derivative, nisin PV,
combination therapies and natural anti-biofilm agents.
Chapter I

Group B Streptococcus: infection, antimicrobial resistance and

control strategies.
Chapter I reviews the current literature regarding Group B Streptococcus disease,
antimicrobial resistance and potential alternative antimicrobials. Initially, an overview
of GBS disease, in both infants and adults, was provided with an epidemiological
analysis of GBS carriage rates and serotype distributions worldwide. Importantly, an
in-depth review of the current status of antibiotic resistance among GBS strains
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worldwide was conducted, detailing the prevalence rates and mechanisms of action.
Moreover, a comprehensive examination of alternative approaches to combat
antimicrobial resistance was presented, offering an insight into alternative
antimicrobials with potential activity against GBS.

Chapter II

Molecular epidemiological analysis of Group B Streptococcus in

the South of Ireland.
In total, 253 clinical GBS isolates (both invasive and colonizing) were analysed to
determine the serotype frequencies of circulating GBS strains within the Irish
population. Identifying the predominant serotypes is particularly important for vaccine
development, as current vaccine efforts focus largely on serotype targets. The
susceptibility of the GBS collection to conventional antibiotics was also presented in
this chapter. Surveillance of antibiotic resistance rates is important in order to elucidate
if current treatment regimens are likely to remain effective. The work presented in this
chapter highlighted the stability of penicillin susceptibility within the Irish population
(100%) and observed high levels of erythromycin resistance (22.5%) and clindamycin
resistance (21.3%). Both erythromycin and clindamycin resistance were significantly
associated with invasive isolates (P < 0.05). Clindamycin resistance was observed at
a higher rate in the current study compared to a previous Irish report (MIC50 1 µg/ml,
MIC90 >256 µg/ml) and the emergence of an unusual resistance phenotype (L
phenotype), of isolated clindamycin resistance was observed. Interestingly, this
phenotype appeared to emerge during the latter part of the study, emphasising that
continued surveillance of this rare phenotype is warranted and highlighting the merit
of antibiotic resistance monitoring in GBS strains.
Serotype distribution reflected stability within the Irish population, with serotypes Ia
(28.1%), III (26.88%), II (13.44%), V (11.86%) and Ib (11.46%) being the most
frequently detected. Among the invasive isolates, serotype III (31.37%) was the most
common, while serotype Ia (29.7%) was the most common detected among colonising
strains. Overall, the serotype distribution amongst the GBS strains within this study
were in line with worldwide estimates. These data indicate that a vaccine aimed at
targeting the most common serotypes would likely be effective for the Irish population
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and highlights the importance of monitoring serotype distributions within GBS
populations.

Chapter III

Investigation of nisin and bioengineered nisin derivatives for use

against clinical GBS strains.
The study in chapter III examined the susceptibility amongst a clinical collection of
GBS strains to nisin. Nisin can be easily bioengineered to produce derivatives with
potentially enhanced antimicrobial activity and therefore bioengineered derivatives of
nisin were examined for activity against GBS strains. As a preliminary screen, 17 GBS
isolates were chosen at random to investigate their susceptibility to nisin A and 26
bioengineered derivatives of nisin. One such derivative, nisin PGA, demonstrated
superior activity based on the deferred antagonism assay (DAA) screen and was
subsequently assessed for microbial activity using the MIC assay. MIC results
indicated a decrease in specific activity of nisin PGA compared to nisin A and
therefore no further testing of this derivative was performed. Strategic design of a
bioengineered nisin derivative, nisin PV, with amino acid substitutions Ser-29-Pro and
Ile-30-Valine was performed to prevent proteolytic cleavage of nisin by nisin
resistance proteins produced by many GBS. A bank of 122 clinical GBS strains were
examined for their susceptibility to both nisin and nisin PV, to determine if the
derivative demonstrated enhanced antimicrobial activity compared to nisin A. Nisin
PV exhibited greater antimicrobial activity for 68.4% of strains according to the DAA
screen through production of larger zones of inhibition. Furthermore, the evaluation
of the specific activities of both peptides deduced that nisin PV displayed significantly
greater antimicrobial activity against strains tested, with an MIC50 of 20.1 µg/ml for
nisin A compared to 6.3 µg/ml for nisin PV. A novel PCR was designed to detect the
nsr gene in GBS strains, which was detected in 98.4% of strains in this study. The
GBS collection was also screened for another nisin resistance determinant the nsrFP
gene and 84.4% of strains were positive for this determinant. Due to the varied
susceptibility phenotypes observed for strains, the nsr gene of representative isolates
was sequenced. Sequence analysis deduced that the catalytically important residues
Ser236 and His98 of NSR for each clinical strain tested showed no differences when
compared to the reference strain.
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This chapter highlights the potential for nisin and its derivatives to be used as
antimicrobial agents against GBS strains.

Chapter IV

Investigating the effects of combining conventional antibiotics and

alternative antimicrobial agents against Group B Streptococcus isolates.
In Chapter IV, the effect of combining antibiotics and alternative antimicrobials was
investigated to identify combinations with improved antimicrobial activity against
GBS strains. An initial screen using growth curve analysis identified combinations
with potential synergistic activity. From these data the combination of erythromycin
and nisin was selected for further analysis due to the improved antimicrobial activity
observed. Moreover, as erythromycin resistance in GBS remains high (22.5% in the
present study), we sought to examine if this resistance could be overcome when
erythromycin and nisin were used in combination. Checkerboard assays revealed an
additive effect for five isolates and an indifferent effect for one isolate. A synergistic
effect was observed by the combination of erythromycin and nisin at 2XMIC in timekill assays for three isolates, while an additive effect was observed for the remaining
three isolates tested. The effect on the inflammatory response in U937 cells challenged
with GBS was investigated in response to erythromycin, nisin and a combination of
both. When antimicrobials were combined, significantly lower TNF-alpha secretion
was observed compared to the untreated control group (P < 0.05). This in vitro data
could be beneficial in-vivo for patient outcomes, as an exaggerated, uncontrolled
immune response can lead to sepsis caused by GBS infection. Data from this chapter
highlights the potential of combination therapy for GBS infections, particularly the
combination of erythromycin and nisin, and encourages larger clinical studies to be
performed. Furthermore, the initial screen provides scope for different combinations
of antibiotics and nisin derivatives to be further investigated.

Chapter V

Biofilm formation in Group B Streptococcus and the anti-biofilm

properties of food products.
Chapter V aimed to characterize the biofilm forming capacity of a collection of 44
GBS strains and determine the prevalence of genes associated with biofilm production.
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Subsequently, natural food products were examined for their anti-biofilm activity
against GBS. For biofilm formation assays, an OD540nm >0.2 was considered to
correspond with biofilm production. Overall, 81.8% of strains tested formed biofilms
to some capacity (weak, medium or strong). Pilus islands associated with biofilm
production were detected in all isolates examined, with the combination of PI-1+PI2a pilus islands being the most common pilus profile found. The clpP gene linked to
stress adaptation and biofilm formation was also detected in 59.1% of strains.
Following characterisation of the biofilm forming properties of these strains, three
strong biofilm producers were selected for anti-biofilm investigations. Natural food
products, including garlic, honey, and cheese samples were examined for their ability
to inhibit and reduce biofilm formation in GBS. Garlic significantly inhibited and
reduced biofilm formation in the GBS strains. Honey also showed anti-biofilm
potential, with inhibition and reduction of biofilms observed at 1/2X and 1X MIC.
While feta and goat’s cheese did not affect the viability of GBS growth, they both
inhibited and prevented biofilm formation at 1/2X and 1 X MIC. These results
highlight the potential of natural food products to prevent biofilm formation, which
could prevent colonisation and thus limit persistent GBS infections. The results
generated in Chapter V reaffirm the ability of GBS to form biofilms, highlighting the
role of biofilm in GBS infections. Interestingly, we identified anti-biofilm properties
of natural food products, indicating the merit in further characterisation of these
products in future studies.

Conclusion
The work presented in this thesis provide a current epidemiological study of the
serotype prevalence and antimicrobial resistance rates of circulating GBS strains in
Ireland. Antimicrobial susceptibility testing reinforced the appropriateness of
penicillin as a first line antibiotic, as all strains were susceptible to penicillin.
Resistance to erythromycin (22.5%) and clindamycin (21.3%) was high in the
collection, and 2.8% of strains displayed an unusual phenotype of isolated
clindamycin resistance, which is the first report of this phenotype among GBS strains
in Ireland. Identification of this phenotype prompted continued surveillance of GBS
strains in the Irish population, whereby an additional five strains of this phenotype
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were identified. These results highlight the importance of continuous monitoring of
antimicrobial susceptibilities in GBS populations and in particular, surveillance of this
phenotype is warranted.
Novel antimicrobial strategies for GBS were investigated. Nisin, and indeed its
bioengineered derivatives, could prove useful alternatives to current antibiotics for
GBS infections. Nisin PV exhibited enhanced antimicrobial activity against over half
the strains tested in this study. This nisin derivative was designed to evade proteolytic
cleavage by NSR at the C-terminus of nisin. This was achieved by creating amino acid
substitutions in nisin at the site of cleavage. However, another protein involved in nisin
resistance, NsrFP, acts on the N-terminus of nisin and thus could still exert resistance
to nisin. Continued research within this area is focused on designing a derivative of
nisin with mutations at both the N-terminus and C-terminus of nisin to prevent action
by both the NsrFP and NSR proteins, respectively. Furthermore, continued
collaborations with the APC group in UCC involves whole genome sequencing on a
selection of GBS strains from our collection in order to further examine the role of
genetic components in relation to nisin resistance.
Continued exploration for alternative antimicrobial therapies for GBS highlighted the
synergistic potential between conventional antibiotics and alternative antimicrobial
agents. Results presented in Chapter IV, although preliminary, are positive and
warrant the need for larger clinical studies examining the combination of erythromycin
and nisin. Moreover, results from Chapter III provide scope to further explore the use
of nisin PV in combination with conventional antibiotics. The high levels of biofilm
production amongst the clinical GBS strains is worrying as biofilm formation is
associated with persistent infection and increased antimicrobial resistance. The
consumption of functional foods with antimicrobial properties that could limit
gastrointestinal GBS colonisation would be clinically significant as it could have the
potential to help limit GBS infections. Moreover, exploring how natural food products
could limit biofilm formation, or indeed eradicate biofilms in-vivo is an interesting
avenue and data from this study provides scope to further investigate food derived
bioactive

compounds

with

anti-biofilm

properties.

This

would

involve

characterisation through isolation, separation and identification of antimicrobial
compounds from each food source and is beyond the scope of the present thesis.
However, the results generated provide a platform on which to build and potentially
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identify novel anti-biofilm agents, particularly from the cheese samples examined in
this thesis.
Overall, the work encompassed in this thesis highlights the high resistance rates to
certain antibiotics in GBS strains. In the era of increased antibiotic resistance coupled
with the lack of new antibiotics, the identification of novel antimicrobial therapies
could help prevent the development and spread of further resistance. This thesis
showcases possible alternative therapies and potential solutions to antimicrobial
resistance for GBS strains.
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